P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
6.200e-09 | -18.90 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 45 | 16828 | 49 |
TRPS1,PREX2,DTNA,ABLIM1,NTM,HIF3A,NPAS3,PARD3,ZBTB20,PITPNC1,SFXN5,MAML2,LSAMP,NHSL1,SLC1A3,RFX4,PRKG1,SOX5,CTNND2,NKAIN3,FGFR3,ATP13A4,PTPRZ1,ERBB4,GPC5,GLIS3,TNIK,RORA,LRIG1,GPM6A,PARD3B,SPARCL1,NFIA,MACF1,CDH20,RYR3,MSI2,FBXL7,TRPM3,SLC4A4,SORBS1,BMPR1B,ZNRF3,CLU,SLC1A2 |
9.808e-09 | -18.44 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 16 | 19454 | 50 |
SPARCL1,TRPM3,NHSL1,CLU,MACF1,SLC4A4,MAML2,ATP1A2,ABLIM1,TRPS1,PTPRZ1,GPM6A,MSI2,LSAMP,SLC1A3,SORBS1 |
1.540e-08 | -17.99 | nervous system development | biological process | GO:0007399 | 2185 | 22 | 18204 | 50 |
PTPRZ1,CLU,TNIK,BMPR1B,GPM6A,SLC1A2,CTNNA2,PREX2,SLC1A3,NTM,PARD3,ERBB4,SOX5,PRKG1,ATP1A2,RORA,LSAMP,RFX4,CTNND2,LRIG1,MSI2,NFIA |
1.790e-08 | -17.84 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 20 | 16828 | 49 |
SLC1A3,TRPS1,PARD3B,GPM6A,ACSS1,ATP13A4,FGFR3,SOX5,CTNND2,TRPM3,PRKG1,ERBB4,PARD3,DTNA,RYR3,LSAMP,TNIK,MAML2,SFXN5,GPC5 |
2.751e-08 | -17.41 | cell morphogenesis | biological process | GO:0000902 | 687 | 13 | 18204 | 50 |
GPM6A,CTNND2,CTNNA2,NFIA,PTPRZ1,SLC1A3,PREX2,CDH20,CLU,TNIK,PARD3,BMPR1B,PRKG1 |
4.928e-08 | -16.83 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 39 | 16828 | 49 |
TNIK,SLC1A2,RORA,LRIG1,GPC5,ZNRF3,ERBB4,SORBS1,PTPRZ1,CST3,FGFR3,ATP13A4,SLC4A4,PRKG1,RFX4,TRPM3,CTNND2,SOX5,FBXL7,NHSL1,RYR3,LSAMP,PITPNC1,MAML2,SFXN5,PARD3,ZBTB20,DTNA,HIF3A,NTM,ABLIM1,MACF1,CDH20,PREX2,PARD3B,TRPS1,ACSS1,ATP1A2,GPM6A |
9.120e-08 | -16.21 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 11 | 16828 | 49 |
ATP13A4,PRKG1,TRPM3,CTNND2,GPM6A,RYR3,LSAMP,GPC5,MAML2,SFXN5,ERBB4 |
1.057e-07 | -16.06 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 16 | 16828 | 49 |
NPAS3,ERBB4,PARD3,BMPR1B,LSAMP,RYR3,SLC1A2,TNIK,ATP1A2,FBXL7,FGFR3,NKAIN3,SOX5,PRKG1,PREX2,NFIA |
1.057e-07 | -16.06 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 16 | 16828 | 49 |
FGFR3,NKAIN3,SOX5,PRKG1,NFIA,PREX2,ATP1A2,FBXL7,LSAMP,RYR3,SLC1A2,TNIK,ERBB4,BMPR1B,PARD3,NPAS3 |
1.314e-07 | -15.84 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 21 | 16828 | 49 |
FBXL7,NHSL1,GPM6A,SLC1A3,CTNND2,SOX5,PRKG1,PREX2,RFX4,ATP13A4,NKAIN3,BMPR1B,NPAS3,PARD3,ERBB4,MAML2,GPC5,RYR3,LSAMP,SLC1A2,LRIG1 |
1.314e-07 | -15.84 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 21 | 16828 | 49 |
NKAIN3,ATP13A4,RFX4,PRKG1,PREX2,SOX5,CTNND2,SLC1A3,GPM6A,NHSL1,FBXL7,SLC1A2,LRIG1,LSAMP,RYR3,GPC5,MAML2,BMPR1B,PARD3,NPAS3,ERBB4 |
2.237e-07 | -15.31 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 24 | 16828 | 49 |
MAML2,SFXN5,RYR3,LSAMP,HIF3A,PARD3,PREX2,GPM6A,TRPS1,PARD3B,GPC5,LRIG1,SLC1A2,ZNRF3,ERBB4,CTNND2,TRPM3,SOX5,PRKG1,RFX4,ATP13A4,NKAIN3,FBXL7,SLC1A3 |
2.486e-07 | -15.21 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 25 | 16828 | 49 |
PRKG1,CTNND2,SOX5,FGFR3,NKAIN3,ATP13A4,FBXL7,SLC1A3,GPC5,TNIK,SLC1A2,RORA,PTPRZ1,ZNRF3,ERBB4,PREX2,CDH20,GPM6A,MAML2,SFXN5,RYR3,LSAMP,PARD3,NPAS3,ZBTB20 |
2.687e-07 | -15.13 | cell periphery | cellular component | GO:0071944 | 6020 | 33 | 19108 | 49 |
BMPR1B,GPM6A,SLC4A4,FGFR3,TRPM3,GPC5,SLC1A3,SORBS1,CLU,PRKG1,ATP1A2,ERBB4,CDH20,ZNRF3,PARD3,TNIK,LRIG1,CTNNA2,DTNA,HIF3A,NKAIN3,LSAMP,SLC1A2,CTNND2,RYR3,PARD3B,CST3,MACF1,PTPRZ1,PREX2,NTM,SPARCL1,ATP13A4 |
2.811e-07 | -15.08 | generation of neurons | biological process | GO:0048699 | 1158 | 15 | 18204 | 50 |
NTM,PTPRZ1,SLC1A3,PREX2,SOX5,PARD3,ERBB4,BMPR1B,TNIK,PRKG1,RORA,GPM6A,CTNND2,CTNNA2,NFIA |
2.862e-07 | -15.07 | neurogenesis | biological process | GO:0022008 | 1334 | 16 | 18204 | 50 |
TNIK,BMPR1B,SOX5,PARD3,ERBB4,PRKG1,PREX2,SLC1A3,PTPRZ1,NTM,CLU,CTNNA2,NFIA,GPM6A,RORA,CTNND2 |
5.795e-07 | -14.36 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 22 | 16828 | 49 |
CDH20,PREX2,GPM6A,LSAMP,RYR3,SFXN5,MAML2,ZBTB20,PARD3,ATP13A4,NKAIN3,CTNND2,SOX5,PRKG1,SLC1A3,FBXL7,RORA,TNIK,GPC5,ZNRF3,ERBB4,PTPRZ1 |
6.051e-07 | -14.32 | multicellular organism development | biological process | GO:0007275 | 3957 | 27 | 18204 | 50 |
ZNRF3,RFX4,CTNND2,LSAMP,RORA,ATP1A2,TRPS1,NFIA,MSI2,FGFR3,LRIG1,CDH20,NTM,PREX2,SLC1A3,PRKG1,PARD3,ERBB4,SOX5,SLC1A2,GPM6A,CTNNA2,CLU,HIF3A,PTPRZ1,BMPR1B,TNIK |
6.193e-07 | -14.29 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 20 | 18204 | 50 |
GPM6A,RORA,CTNND2,ABLIM1,LRIG1,CTNNA2,FGFR3,NFIA,SLC1A3,PTPRZ1,PREX2,HIF3A,CDH20,CLU,TNIK,SOX5,PARD3,BMPR1B,ERBB4,PRKG1 |
6.436e-07 | -14.26 | plasma membrane | cellular component | GO:0005886 | 5538 | 31 | 19108 | 49 |
SORBS1,SLC1A3,LRIG1,TNIK,PARD3,ZNRF3,ERBB4,ATP1A2,CDH20,PRKG1,SLC4A4,FGFR3,GPM6A,BMPR1B,GPC5,TRPM3,PTPRZ1,PARD3B,MACF1,CST3,RYR3,CTNND2,ATP13A4,NTM,PREX2,NKAIN3,HIF3A,DTNA,CTNNA2,SLC1A2,LSAMP |
7.587e-07 | -14.09 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 38 | 16828 | 49 |
ERBB4,PTPRZ1,SORBS1,SLC1A2,RORA,LRIG1,GLIS3,TNIK,GPC5,SLC1A3,NHSL1,FBXL7,SLC4A4,ATP13A4,NKAIN3,FGFR3,SOX5,TRPM3,CTNND2,RFX4,PRKG1,ZBTB20,NPAS3,PARD3,NTM,ABLIM1,RYR3,LSAMP,SFXN5,MAML2,PITPNC1,TRPS1,PARD3B,GPM6A,ACSS1,MACF1,PREX2,NFIA |
7.801e-07 | -14.06 | neuron differentiation | biological process | GO:0030182 | 1081 | 14 | 18204 | 50 |
PRKG1,BMPR1B,ERBB4,PARD3,TNIK,NTM,PTPRZ1,SLC1A3,PREX2,NFIA,CTNNA2,CTNND2,RORA,GPM6A |
1.129e-06 | -13.69 | system development | biological process | GO:0048731 | 3533 | 25 | 18204 | 50 |
TNIK,BMPR1B,CLU,PTPRZ1,HIF3A,CTNNA2,SLC1A2,GPM6A,PRKG1,SOX5,ERBB4,PARD3,PREX2,SLC1A3,NTM,NFIA,LRIG1,MSI2,FGFR3,RFX4,CTNND2,ATP1A2,TRPS1,RORA,LSAMP |
1.377e-06 | -13.50 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 12 | 16828 | 49 |
SLC1A2,RYR3,LSAMP,GPC5,MAML2,PARD3,ERBB4,NKAIN3,PREX2,SOX5,ATP1A2,FBXL7 |
1.623e-06 | -13.33 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 8 | 19454 | 50 |
ABLIM1,NHSL1,CTNNA2,DTNA,PARD3,MACF1,TNIK,SORBS1 |
1.873e-06 | -13.19 | mouth | COSMIC cancer mutations | mouth | 9004 | 42 | 16828 | 49 |
TRPS1,PARD3B,ATP1A2,GPM6A,ACSS1,CDH20,MACF1,PREX2,ZBTB20,NPAS3,PARD3,HIF3A,NTM,ABLIM1,DTNA,RYR3,LSAMP,MAML2,SFXN5,PITPNC1,SLC1A3,FBXL7,NHSL1,SLC4A4,ATP13A4,FGFR3,TRPM3,CTNND2,SOX5,PRKG1,RFX4,ZNRF3,ERBB4,CST3,SORBS1,PTPRZ1,SLC1A2,RORA,LRIG1,TNIK,GPC5,CLU |
2.220e-06 | -13.02 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 28 | 16828 | 49 |
TNIK,LRIG1,PTPRZ1,SORBS1,RFX4,PRKG1,SOX5,CTNND2,TRPM3,FGFR3,ATP13A4,SLC4A4,NHSL1,FBXL7,PTGDS,RYR3,NTM,HIF3A,PARD3,ZBTB20,NFIA,PREX2,MACF1,CDH20,ACSS1,GPM6A,PARD3B,TRPS1 |
2.259e-06 | -13.00 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 22 | 16828 | 49 |
FBXL7,GPM6A,TRPS1,SLC1A3,PARD3B,CTNND2,SOX5,PREX2,PRKG1,RFX4,NKAIN3,HIF3A,ZNRF3,ERBB4,PARD3,MAML2,SFXN5,GPC5,LSAMP,RYR3,SLC1A2,LRIG1 |
2.341e-06 | -12.96 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 27 | 16828 | 49 |
HIF3A,PARD3,NPAS3,PITPNC1,MAML2,RYR3,ACSS1,GPM6A,ATP1A2,PARD3B,TRPS1,NFIA,PREX2,MACF1,PTPRZ1,ERBB4,ZNRF3,TNIK,GLIS3,SLC1A2,NHSL1,FBXL7,RFX4,PRKG1,CTNND2,FGFR3,SLC4A4 |
3.516e-06 | -12.56 | tibia | COSMIC cancer mutations | tibia | 836 | 12 | 16828 | 49 |
ABLIM1,TNIK,LSAMP,ACSS1,GPM6A,NKAIN3,MACF1,FGFR3,PRKG1,PREX2,TRPM3,CTNND2 |
3.650e-06 | -12.52 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 12 | 19454 | 50 |
NTM,CTNND2,CLU,SLC1A2,CTNNA2,TNIK,ATP1A2,ABLIM1,SLC1A3,GPM6A,LSAMP,SORBS1 |
3.755e-06 | -12.49 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 26 | 16828 | 49 |
RYR3,LSAMP,MAML2,PARD3,ZBTB20,NTM,HIF3A,PREX2,NFIA,GPM6A,TNIK,GLIS3,SLC1A2,RORA,GPC5,BMPR1B,ERBB4,PTPRZ1,NKAIN3,SLC4A4,ATP13A4,PRKG1,SOX5,CTNND2,SLC1A3,FBXL7 |
3.755e-06 | -12.49 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 26 | 16828 | 49 |
GPM6A,PREX2,NFIA,PARD3,ZBTB20,NTM,HIF3A,LSAMP,RYR3,MAML2,SLC1A3,FBXL7,NKAIN3,SLC4A4,ATP13A4,PRKG1,SOX5,CTNND2,BMPR1B,ERBB4,PTPRZ1,TNIK,GLIS3,SLC1A2,RORA,GPC5 |
4.679e-06 | -12.27 | cell junction | cellular component | GO:0030054 | 2224 | 18 | 19108 | 49 |
SLC1A2,GPM6A,FGFR3,CTNNA2,DTNA,SPARCL1,PARD3,TNIK,ERBB4,ATP1A2,CDH20,PARD3B,CLU,SORBS1,PTPRZ1,SLC1A3,CTNND2,NFIA |
4.871e-06 | -12.23 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 27 | 16828 | 49 |
MACF1,CDH20,PREX2,SPARCL1,TRPS1,ACSS1,ATP1A2,GPM6A,LSAMP,RYR3,MAML2,PARD3,DTNA,FGFR3,NKAIN3,ATP13A4,PRKG1,CTNND2,SOX5,SLC1A3,FBXL7,TNIK,RORA,SLC1A2,GPC5,CLU,ERBB4 |
6.057e-06 | -12.01 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 9 | 18204 | 50 |
CTNND2,PTPRZ1,PREX2,GPM6A,PRKG1,TNIK,CTNNA2,PARD3,BMPR1B |
6.578e-06 | -11.93 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 9 | 18204 | 50 |
PRKG1,TNIK,CTNNA2,BMPR1B,PARD3,CTNND2,GPM6A,PREX2,PTPRZ1 |
7.138e-06 | -11.85 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 9 | 18204 | 50 |
CTNND2,PREX2,GPM6A,PTPRZ1,PRKG1,PARD3,BMPR1B,TNIK,CTNNA2 |
7.143e-06 | -11.85 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 2 | 18521 | 50 |
PARD3B,PARD3 |
7.388e-06 | -11.82 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 21 | 16828 | 49 |
NPAS3,PTPRZ1,SORBS1,DTNA,SLC1A2,RYR3,CLU,PITPNC1,GPC5,SFXN5,PARD3B,NHSL1,ATP1A2,FGFR3,MACF1,SLC4A4,ATP13A4,RFX4,NFIA,PREX2,CTNND2 |
7.657e-06 | -11.78 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 26 | 16828 | 49 |
PTPRZ1,ERBB4,ZNRF3,SLC1A2,TNIK,GLIS3,FBXL7,CTNND2,RFX4,PRKG1,SLC4A4,FGFR3,HIF3A,PARD3,NPAS3,MAML2,PITPNC1,RYR3,GPM6A,ATP1A2,ACSS1,TRPS1,PARD3B,PREX2,NFIA,MACF1 |
7.694e-06 | -11.78 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 26 | 16828 | 49 |
TRPS1,PARD3B,GPM6A,ATP1A2,ACSS1,MACF1,NFIA,PREX2,PARD3,NPAS3,HIF3A,RYR3,MAML2,PITPNC1,FBXL7,SLC4A4,FGFR3,CTNND2,RFX4,PRKG1,ERBB4,ZNRF3,PTPRZ1,SLC1A2,GLIS3,TNIK |
7.737e-06 | -11.77 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 2 | 17795 | 50 |
PARD3,PARD3B |
8.240e-06 | -11.71 | adherens junction | cellular component | GO:0005912 | 188 | 6 | 19108 | 49 |
CTNND2,CTNNA2,CDH20,PARD3B,SORBS1,PARD3 |
1.002e-05 | -11.51 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 11 | 16828 | 49 |
RYR3,MAML2,GPC5,PARD3,ERBB4,NPAS3,ABLIM1,PTPRZ1,CTNND2,PRKG1,PARD3B |
1.311e-05 | -11.24 | anatomical structure development | biological process | GO:0048856 | 5207 | 29 | 18204 | 50 |
TNIK,BMPR1B,CLU,PTPRZ1,HIF3A,CTNNA2,SLC1A2,GPM6A,PRKG1,SOX5,ERBB4,PARD3,SLC1A3,PREX2,NTM,CDH20,NFIA,LRIG1,SPARCL1,FGFR3,MSI2,CTNND2,RFX4,ABLIM1,ZNRF3,TRPS1,ATP1A2,RORA,LSAMP |
1.324e-05 | -11.23 | multicellular organismal process | biological process | GO:0032501 | 6177 | 32 | 18204 | 50 |
BMPR1B,TNIK,HIF3A,PTPRZ1,CLU,CTNNA2,RYR3,GPM6A,SLC1A2,DTNA,SLC4A4,PARD3,ERBB4,SOX5,PRKG1,NTM,CDH20,PREX2,SLC1A3,MSI2,FGFR3,LRIG1,NFIA,PTGDS,RORA,LSAMP,ATP1A2,TRPS1,ZNRF3,RFX4,ABLIM1,CTNND2 |
1.509e-05 | -11.10 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 10 | 16828 | 49 |
ABLIM1,PTPRZ1,PARD3,ERBB4,PARD3B,NPAS3,CTNND2,MAML2,PRKG1,RYR3 |
1.529e-05 | -11.09 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 10 | 16828 | 49 |
RYR3,PRKG1,MAML2,CTNND2,PARD3,ERBB4,NPAS3,PARD3B,PTPRZ1,ABLIM1 |
1.598e-05 | -11.04 | nodular | COSMIC cancer mutations | nodular | 1515 | 15 | 16828 | 49 |
ERBB4,NPAS3,HIF3A,ABLIM1,PTPRZ1,GLIS3,SPARCL1,ATP1A2,ATP13A4,CDH20,SLC4A4,FGFR3,MACF1,CTNND2,PREX2 |
1.668e-05 | -11.00 | neuron development | biological process | GO:0048666 | 859 | 11 | 18204 | 50 |
PRKG1,TNIK,CTNNA2,BMPR1B,PARD3,CTNND2,SLC1A3,PTPRZ1,PREX2,GPM6A,NTM |
1.702e-05 | -10.98 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 15 | 16828 | 49 |
NKAIN3,SOX5,CTNND2,PRKG1,PREX2,SLC1A3,FBXL7,ACSS1,RORA,LSAMP,RYR3,MAML2,GPC5,ERBB4,PARD3 |
1.702e-05 | -10.98 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 15 | 16828 | 49 |
RORA,RYR3,LSAMP,GPC5,MAML2,PARD3,ERBB4,NKAIN3,PREX2,PRKG1,SOX5,CTNND2,SLC1A3,ACSS1,FBXL7 |
1.782e-05 | -10.94 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 24 | 16828 | 49 |
ERBB4,TNIK,SLC1A2,RORA,CLU,GPC5,FBXL7,NKAIN3,FGFR3,ATP13A4,PRKG1,SOX5,CTNND2,PARD3,RYR3,LSAMP,MAML2,SPARCL1,ACSS1,GPM6A,ATP1A2,MACF1,CDH20,PREX2 |
2.020e-05 | -10.81 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 9 | 16828 | 49 |
GPM6A,NKAIN3,LSAMP,RYR3,PRKG1,GPC5,CTNND2,SFXN5,SOX5 |
2.529e-05 | -10.59 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 8 | 18204 | 50 |
PRKG1,CTNNA2,BMPR1B,PARD3,CTNND2,SLC1A3,PTPRZ1,PREX2 |
2.544e-05 | -10.58 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 18 | 16828 | 49 |
MAML2,GPC5,LSAMP,RYR3,SLC1A2,PTPRZ1,PARD3,ERBB4,CTNND2,SOX5,PRKG1,PREX2,CDH20,FGFR3,NKAIN3,FBXL7,GPM6A,SLC1A3 |
2.773e-05 | -10.49 | developmental process | biological process | GO:0032502 | 5716 | 30 | 18204 | 50 |
ZNRF3,CTNND2,RFX4,ABLIM1,LSAMP,RORA,TRPS1,ATP1A2,NFIA,FGFR3,MSI2,LRIG1,SPARCL1,CDH20,NTM,SLC1A3,PREX2,PRKG1,SOX5,PARD3,ERBB4,SLC1A2,NHSL1,GPM6A,CTNNA2,CLU,HIF3A,PTPRZ1,BMPR1B,TNIK |
2.973e-05 | -10.42 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 47 | 16828 | 49 |
RYR3,MSI2,NFIA,MACF1,CDH20,ACSS1,ATP1A2,GPM6A,SPARCL1,PARD3B,CLU,SLC1A2,SORBS1,ZNRF3,BMPR1B,TRPM3,SLC4A4,FBXL7,PITPNC1,SFXN5,MAML2,LSAMP,DTNA,HIF3A,ABLIM1,NTM,NPAS3,PARD3,ZBTB20,PREX2,TRPS1,GPC5,TNIK,GLIS3,RORA,LRIG1,PTPRZ1,ERBB4,PRKG1,RFX4,CTNND2,SOX5,FGFR3,NKAIN3,ATP13A4,NHSL1,SLC1A3 |
3.292e-05 | -10.32 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 33 | 16828 | 49 |
NPAS3,PARD3,ZBTB20,HIF3A,NTM,ABLIM1,RYR3,PITPNC1,MAML2,SFXN5,PARD3B,TRPS1,ACSS1,GPM6A,MACF1,CDH20,PREX2,ERBB4,SORBS1,SLC1A2,RORA,GPC5,CLU,SLC1A3,FBXL7,NHSL1,FGFR3,SLC4A4,PRKG1,RFX4,CTNND2,TRPM3,SOX5 |
3.970e-05 | -10.13 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 23 | 16828 | 49 |
BMPR1B,ERBB4,ZNRF3,PTPRZ1,TNIK,CLU,GPC5,SLC1A3,FBXL7,SLC4A4,PRKG1,TRPM3,CTNND2,PARD3,NPAS3,DTNA,MSI2,LSAMP,RYR3,PITPNC1,PARD3B,MACF1,PREX2 |
3.970e-05 | -10.13 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 23 | 16828 | 49 |
GPC5,CLU,TNIK,PTPRZ1,ZNRF3,BMPR1B,ERBB4,PRKG1,CTNND2,TRPM3,SLC4A4,FBXL7,SLC1A3,PITPNC1,MSI2,LSAMP,RYR3,DTNA,PARD3,NPAS3,PREX2,MACF1,PARD3B |
3.982e-05 | -10.13 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 31 | 16828 | 49 |
GLIS3,RORA,SLC1A2,GPC5,CLU,ZNRF3,ERBB4,SORBS1,PTPRZ1,FGFR3,NKAIN3,PRKG1,TRPM3,CTNND2,SOX5,SLC1A3,FBXL7,NHSL1,RYR3,LSAMP,MAML2,PARD3,NPAS3,MACF1,CDH20,PREX2,NFIA,SPARCL1,PARD3B,TRPS1,GPM6A |
5.020e-05 | -9.90 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 35 | 16828 | 49 |
CLU,RORA,LRIG1,SLC1A2,PTPRZ1,CST3,ZNRF3,ERBB4,PRKG1,RFX4,CTNND2,TRPM3,SOX5,FGFR3,SLC4A4,ATP13A4,FBXL7,NHSL1,PITPNC1,SFXN5,MAML2,RYR3,LSAMP,NTM,PARD3,NPAS3,ZBTB20,NFIA,PREX2,MACF1,CDH20,ACSS1,ATP1A2,PARD3B,TRPS1 |
5.020e-05 | -9.90 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 35 | 16828 | 49 |
NHSL1,FBXL7,ATP13A4,SLC4A4,FGFR3,SOX5,TRPM3,CTNND2,RFX4,PRKG1,ERBB4,ZNRF3,CST3,PTPRZ1,LRIG1,SLC1A2,RORA,CLU,TRPS1,PARD3B,ATP1A2,ACSS1,CDH20,MACF1,NFIA,PREX2,ZBTB20,PARD3,NPAS3,NTM,RYR3,LSAMP,MAML2,SFXN5,PITPNC1 |
5.256e-05 | -9.85 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 31 |
SLC1A3,SLC1A2 |
5.256e-05 | -9.85 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 31 |
SLC1A2,SLC1A3 |
5.396e-05 | -9.83 | scalp | COSMIC cancer mutations | scalp | 2110 | 17 | 16828 | 49 |
TRPS1,ATP1A2,FGFR3,MACF1,ATP13A4,SLC4A4,NFIA,PREX2,PRKG1,SOX5,ERBB4,SORBS1,PTPRZ1,NTM,LSAMP,RORA,GPC5 |
5.657e-05 | -9.78 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 20 | 16828 | 49 |
MACF1,FGFR3,NKAIN3,SLC4A4,PRKG1,PREX2,TRPM3,CTNND2,SPARCL1,TRPS1,NHSL1,TNIK,RYR3,LRIG1,CLU,PITPNC1,ZNRF3,PARD3,ERBB4,PTPRZ1 |
5.657e-05 | -9.78 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 20 | 16828 | 49 |
SPARCL1,TRPS1,NHSL1,MACF1,FGFR3,NKAIN3,SLC4A4,PRKG1,PREX2,TRPM3,CTNND2,ZNRF3,PARD3,ERBB4,PTPRZ1,TNIK,RYR3,LRIG1,PITPNC1,CLU |
5.783e-05 | -9.76 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 13 | 16828 | 49 |
ATP13A4,CDH20,MACF1,CTNND2,PREX2,SPARCL1,ATP1A2,GLIS3,NPAS3,ERBB4,HIF3A,ABLIM1,PTPRZ1 |
6.432e-05 | -9.65 | central nervous system development | biological process | GO:0007417 | 995 | 11 | 18204 | 50 |
RFX4,CLU,SLC1A2,ATP1A2,PTPRZ1,RORA,PRKG1,CTNNA2,MSI2,BMPR1B,ERBB4 |
6.856e-05 | -9.59 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.856e-05 | -9.59 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
7.355e-05 | -9.52 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
7.355e-05 | -9.52 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
7.513e-05 | -9.50 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 50 |
SLC1A3,ATP1A2,SLC1A2 |
7.798e-05 | -9.46 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 30 | 16828 | 49 |
MAML2,LSAMP,RYR3,DTNA,NTM,PARD3,NPAS3,MACF1,CDH20,ATP1A2,GPM6A,PARD3B,TRPS1,GPC5,CLU,LRIG1,SORBS1,PTPRZ1,CST3,ZNRF3,ERBB4,PRKG1,CTNND2,TRPM3,SOX5,NKAIN3,SLC4A4,ATP13A4,FBXL7,SLC1A3 |
7.798e-05 | -9.46 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 30 | 16828 | 49 |
NPAS3,PARD3,DTNA,NTM,LSAMP,RYR3,MAML2,PARD3B,TRPS1,ATP1A2,GPM6A,MACF1,CDH20,ZNRF3,ERBB4,SORBS1,PTPRZ1,CST3,LRIG1,GPC5,CLU,SLC1A3,FBXL7,NKAIN3,SLC4A4,ATP13A4,PRKG1,TRPM3,CTNND2,SOX5 |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
NTM,GPM6A,LSAMP |
8.772e-05 | -9.34 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 17 | 16828 | 49 |
FBXL7,GPM6A,SLC1A3,CTNND2,SOX5,PRKG1,PREX2,CDH20,NKAIN3,PTPRZ1,ERBB4,PARD3,MAML2,GPC5,LSAMP,RYR3,SLC1A2 |
8.772e-05 | -9.34 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 17 | 16828 | 49 |
CDH20,NKAIN3,SOX5,CTNND2,PREX2,PRKG1,SLC1A3,GPM6A,FBXL7,SLC1A2,LSAMP,RYR3,MAML2,GPC5,PARD3,ERBB4,PTPRZ1 |
9.059e-05 | -9.31 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 50 |
SLC1A2,SLC4A4,ATP1A2,SLC1A3 |
9.059e-05 | -9.31 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 50 |
SLC1A2,ATP1A2,SLC1A3,SLC4A4 |
9.079e-05 | -9.31 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 48 | 16828 | 49 |
RYR3,MSI2,PARD3B,GPM6A,ATP1A2,ACSS1,CDH20,MACF1,NFIA,BMPR1B,ZNRF3,SORBS1,SLC1A2,CLU,FBXL7,SLC4A4,TRPM3,ZBTB20,NPAS3,PARD3,ABLIM1,NTM,HIF3A,DTNA,LSAMP,SFXN5,MAML2,PITPNC1,PTGDS,TRPS1,PREX2,ERBB4,CST3,PTPRZ1,RORA,LRIG1,TNIK,GLIS3,GPC5,SLC1A3,NHSL1,ATP13A4,NKAIN3,FGFR3,SOX5,CTNND2,RFX4,PRKG1 |
9.194e-05 | -9.29 | cell junction organization | biological process | GO:0034330 | 532 | 8 | 18204 | 50 |
SORBS1,CTNND2,CDH20,GPM6A,NFIA,ERBB4,PARD3,SPARCL1 |
9.850e-05 | -9.23 | neuron projection development | biological process | GO:0031175 | 693 | 9 | 18204 | 50 |
BMPR1B,PARD3,TNIK,CTNNA2,PRKG1,PTPRZ1,GPM6A,PREX2,CTNND2 |
1.023e-04 | -9.19 | bone | COSMIC cancer mutations | bone | 8157 | 37 | 16828 | 49 |
MACF1,PREX2,PARD3B,SPARCL1,TRPS1,ACSS1,GPM6A,ATP1A2,LSAMP,RYR3,PTGDS,MAML2,SFXN5,PARD3,NPAS3,ZBTB20,DTNA,ABLIM1,HIF3A,NKAIN3,FGFR3,ATP13A4,SLC4A4,PRKG1,SOX5,CTNND2,TRPM3,SLC1A3,TNIK,GLIS3,LRIG1,RORA,GPC5,ERBB4,PTPRZ1,SORBS1,CST3 |
1.101e-04 | -9.11 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.101e-04 | -9.11 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.186e-04 | -9.04 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 4 | 7161 | 21 |
PRKG1,ATP1A2,RYR3,CST3 |
1.186e-04 | -9.04 | Salivary secretion | KEGG pathways | ko04970 | 90 | 4 | 7161 | 21 |
ATP1A2,PRKG1,RYR3,CST3 |
1.378e-04 | -8.89 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 9 | 18094 | 48 |
GPM6A,ATP1A2,ATP13A4,TRPM3,SLC4A4,SLC1A3,SFXN5,RYR3,SLC1A2 |
1.427e-04 | -8.85 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 5 | 18204 | 50 |
SLC4A4,RORA,PRKG1,SORBS1,ZBTB20 |
1.469e-04 | -8.83 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 4 | 19454 | 50 |
CLU,SORBS1,ABLIM1,SPARCL1 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.534e-04 | -8.78 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 7 | 18094 | 48 |
GPM6A,ATP1A2,TRPM3,SLC4A4,SLC1A3,SLC1A2,RYR3 |
1.583e-04 | -8.75 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 13 | 16828 | 49 |
ATP1A2,NHSL1,CTNND2,PREX2,NFIA,RFX4,ATP13A4,SLC4A4,FGFR3,SFXN5,PITPNC1,CLU,SLC1A2 |
1.583e-04 | -8.75 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 13 | 16828 | 49 |
PITPNC1,CLU,SFXN5,SLC1A2,NFIA,PREX2,RFX4,CTNND2,FGFR3,SLC4A4,ATP13A4,ATP1A2,NHSL1 |
1.610e-04 | -8.73 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 50 |
SLC1A3,SLC1A2 |
1.628e-04 | -8.72 | humerus | COSMIC cancer mutations | humerus | 546 | 8 | 16828 | 49 |
NKAIN3,SOX5,SFXN5,PRKG1,GPC5,PARD3B,GPM6A,HIF3A |
1.662e-04 | -8.70 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 50 |
SLC1A3,RYR3,SLC1A2 |
1.773e-04 | -8.64 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 24 | 16828 | 49 |
ATP13A4,FGFR3,SOX5,TRPM3,CTNND2,PRKG1,ERBB4,ZNRF3,PTPRZ1,LRIG1,TNIK,GLIS3,GPC5,TRPS1,SPARCL1,ATP1A2,ACSS1,MACF1,NFIA,PARD3,HIF3A,DTNA,LSAMP,RYR3 |
1.794e-04 | -8.63 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 43 |
SLC1A2,SLC1A3 |
1.841e-04 | -8.60 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 48 |
CTNNA2,CDH20,RORA,CTNND2 |
1.874e-04 | -8.58 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 49 |
NKAIN3,LSAMP,CTNND2,GPM6A |
2.276e-04 | -8.39 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 8 | 18094 | 48 |
GPM6A,ATP1A2,ATP13A4,TRPM3,SLC4A4,SLC1A3,RYR3,SLC1A2 |
2.282e-04 | -8.39 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 6 | 16828 | 49 |
SFXN5,SOX5,GPC5,PRKG1,NKAIN3,GPM6A |
2.300e-04 | -8.38 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 45 | 16828 | 49 |
ZNRF3,BMPR1B,ERBB4,CST3,SORBS1,PTPRZ1,SLC1A2,RORA,LRIG1,GLIS3,TNIK,GPC5,SLC1A3,FBXL7,NHSL1,SLC4A4,ATP13A4,FGFR3,CTNND2,TRPM3,SOX5,PRKG1,RFX4,ZBTB20,PARD3,NPAS3,HIF3A,NTM,ABLIM1,DTNA,RYR3,LSAMP,MAML2,SFXN5,PITPNC1,TRPS1,SPARCL1,PARD3B,ATP1A2,GPM6A,ACSS1,CDH20,MACF1,NFIA,PREX2 |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
NTM,LSAMP |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
NTM,LSAMP |
2.328e-04 | -8.37 | cervix | COSMIC cancer mutations | cervix | 11793 | 45 | 16828 | 49 |
PTPRZ1,CST3,ERBB4,GPC5,GLIS3,TNIK,RORA,LRIG1,NHSL1,SLC1A3,RFX4,PRKG1,SOX5,CTNND2,FGFR3,ATP13A4,DTNA,ABLIM1,NTM,HIF3A,NPAS3,PARD3,ZBTB20,PITPNC1,MAML2,SFXN5,LSAMP,TRPS1,PREX2,SORBS1,BMPR1B,ZNRF3,SLC1A2,FBXL7,TRPM3,SLC4A4,RYR3,ACSS1,GPM6A,ATP1A2,PARD3B,SPARCL1,NFIA,MACF1,CDH20 |
2.357e-04 | -8.35 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 11 | 18204 | 50 |
RFX4,ABLIM1,CTNND2,GPM6A,CTNNA2,PREX2,PTPRZ1,PRKG1,TNIK,BMPR1B,PARD3 |
2.526e-04 | -8.28 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 43 |
SLC1A3,SLC1A2 |
2.526e-04 | -8.28 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 43 |
SLC1A3,SLC1A2 |
2.601e-04 | -8.25 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 19 |
SLC1A3,SLC1A2 |
2.601e-04 | -8.25 | dendrite development | biological process | GO:0016358 | 113 | 4 | 18204 | 50 |
PREX2,CTNNA2,PRKG1,CTNND2 |
2.644e-04 | -8.24 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 30 | 16828 | 49 |
CLU,GPC5,LRIG1,GLIS3,PTPRZ1,SORBS1,ERBB4,TRPM3,RFX4,PRKG1,ATP13A4,SLC4A4,FGFR3,SLC1A3,SFXN5,ABLIM1,HIF3A,DTNA,ZBTB20,PARD3,NFIA,PREX2,CDH20,MACF1,GPM6A,ATP1A2,ACSS1,TRPS1,PARD3B,SPARCL1 |
2.662e-04 | -8.23 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 30 | 16828 | 49 |
SFXN5,ABLIM1,HIF3A,DTNA,ZBTB20,PARD3,NFIA,PREX2,CDH20,MACF1,GPM6A,ATP1A2,ACSS1,TRPS1,PARD3B,SPARCL1,CLU,GPC5,LRIG1,GLIS3,PTPRZ1,SORBS1,ERBB4,TRPM3,RFX4,PRKG1,SLC4A4,ATP13A4,FGFR3,SLC1A3 |
2.833e-04 | -8.17 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 35 | 16828 | 49 |
MAML2,SFXN5,RYR3,LSAMP,ABLIM1,PARD3,PREX2,CDH20,MACF1,ATP1A2,GPM6A,ACSS1,TRPS1,GPC5,CLU,RORA,SLC1A2,LRIG1,TNIK,GLIS3,PTPRZ1,BMPR1B,ERBB4,CTNND2,TRPM3,SOX5,PRKG1,RFX4,ATP13A4,SLC4A4,FGFR3,NKAIN3,FBXL7,NHSL1,SLC1A3 |
2.855e-04 | -8.16 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 15 | 16828 | 49 |
ZBTB20,NPAS3,ERBB4,BMPR1B,ZNRF3,RORA,RYR3,TNIK,MAML2,PARD3B,GPM6A,SLC4A4,MACF1,FGFR3,SOX5 |
2.887e-04 | -8.15 | larynx | COSMIC cancer mutations | larynx | 1948 | 15 | 16828 | 49 |
MAML2,TNIK,RYR3,RORA,ZNRF3,ERBB4,NPAS3,BMPR1B,ZBTB20,SOX5,FGFR3,MACF1,SLC4A4,GPM6A,PARD3B |
2.903e-04 | -8.14 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 17 | 16828 | 49 |
NHSL1,SLC1A3,TRPS1,SPARCL1,PARD3B,TRPM3,NFIA,PREX2,CDH20,MACF1,FGFR3,SORBS1,ZNRF3,NPAS3,PARD3,CLU,RYR3 |
2.903e-04 | -8.14 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 17 | 16828 | 49 |
SORBS1,ZNRF3,NPAS3,PARD3,CLU,RYR3,NHSL1,SLC1A3,TRPS1,SPARCL1,PARD3B,TRPM3,NFIA,PREX2,CDH20,FGFR3,MACF1 |
3.003e-04 | -8.11 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 9 | 18204 | 50 |
TRPM3,SFXN5,SLC4A4,RYR3,SLC1A3,GPM6A,ATP1A2,ATP13A4,SLC1A2 |
3.121e-04 | -8.07 | cell-cell junction | cellular component | GO:0005911 | 513 | 7 | 19108 | 49 |
CTNNA2,CTNND2,PARD3B,SORBS1,ATP1A2,CDH20,PARD3 |
3.155e-04 | -8.06 | plasma membrane region | cellular component | GO:0098590 | 1278 | 11 | 19108 | 49 |
SLC1A3,PARD3B,MACF1,SORBS1,ERBB4,ATP1A2,PARD3,TNIK,GPM6A,SLC4A4,SLC1A2 |
3.162e-04 | -8.06 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 4 | 19454 | 50 |
DTNA,MACF1,PARD3,ABLIM1 |
3.281e-04 | -8.02 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 2 | 18204 | 50 |
PARD3,PARD3B |
3.281e-04 | -8.02 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
3.346e-04 | -8.00 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 4 | 16828 | 49 |
RYR3,SLC1A2,SOX5,PREX2 |
3.355e-04 | -8.00 | cell projection organization | biological process | GO:0030030 | 1200 | 11 | 18204 | 50 |
CTNNA2,GPM6A,RFX4,ABLIM1,CTNND2,TNIK,BMPR1B,PARD3,PRKG1,PREX2,PTPRZ1 |
3.355e-04 | -8.00 | arm | COSMIC cancer mutations | arm | 1331 | 12 | 16828 | 49 |
ZBTB20,ERBB4,NPAS3,NTM,SORBS1,SLC4A4,MACF1,FGFR3,TRPM3,TRPS1,PARD3B,ATP1A2 |
3.918e-04 | -7.84 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 31 | 16828 | 49 |
FBXL7,PRKG1,SOX5,CTNND2,TRPM3,FGFR3,ATP13A4,SLC4A4,PTPRZ1,SORBS1,ERBB4,BMPR1B,GPC5,TNIK,GLIS3,GPM6A,ATP1A2,PARD3B,SPARCL1,TRPS1,PREX2,MACF1,ABLIM1,HIF3A,PARD3,NPAS3,ZBTB20,PITPNC1,MAML2,SFXN5,RYR3 |
3.988e-04 | -7.83 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 4 | 19454 | 50 |
DTNA,ABLIM1,ERBB4,PARD3 |
4.003e-04 | -7.82 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
4.003e-04 | -7.82 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
4.146e-04 | -7.79 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 3 | 18204 | 50 |
BMPR1B,SOX5,TRPS1 |
4.301e-04 | -7.75 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 8 | 19454 | 50 |
TNIK,SLC1A3,PARD3,MACF1,MSI2,DTNA,ERBB4,ABLIM1 |
4.404e-04 | -7.73 | Ig_I-set | interpro domains | IPR013098 | 132 | 4 | 18521 | 50 |
NTM,LRIG1,LSAMP,FGFR3 |
4.439e-04 | -7.72 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 19 |
ATP13A4,ATP1A2 |
4.673e-04 | -7.67 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 15 | 16828 | 49 |
PTPRZ1,ABLIM1,PARD3,ERBB4,ZNRF3,GPC5,RORA,LSAMP,MSI2,GPM6A,TRPS1,PREX2,TRPM3,MACF1,FGFR3 |
4.724e-04 | -7.66 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 24 | 16828 | 49 |
RYR3,ABLIM1,HIF3A,DTNA,PARD3,PREX2,MACF1,GPM6A,ATP1A2,ACSS1,TRPS1,CLU,GLIS3,PTPRZ1,ERBB4,ZNRF3,SOX5,TRPM3,CTNND2,RFX4,PRKG1,FGFR3,NHSL1,SLC1A3 |
4.724e-04 | -7.66 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 24 | 16828 | 49 |
PARD3,DTNA,ABLIM1,HIF3A,RYR3,TRPS1,ACSS1,GPM6A,ATP1A2,MACF1,PREX2,ERBB4,ZNRF3,PTPRZ1,GLIS3,CLU,SLC1A3,NHSL1,FGFR3,RFX4,PRKG1,SOX5,CTNND2,TRPM3 |
4.778e-04 | -7.65 | sarcolemma | cellular component | GO:0042383 | 142 | 4 | 19108 | 49 |
PRKG1,ATP1A2,DTNA,RYR3 |
4.895e-04 | -7.62 | trunk | COSMIC cancer mutations | trunk | 3554 | 21 | 16828 | 49 |
SLC1A3,TRPS1,SPARCL1,ATP1A2,ATP13A4,CDH20,MACF1,FGFR3,SOX5,CTNND2,PREX2,ERBB4,NPAS3,PARD3,ABLIM1,HIF3A,PTPRZ1,LSAMP,RYR3,GLIS3,MAML2 |
5.115e-04 | -7.58 | I-set | pfam domains | PF07679 | 132 | 4 | 17795 | 50 |
LRIG1,FGFR3,NTM,LSAMP |
5.217e-04 | -7.56 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 8 | 16828 | 49 |
ACSS1,ABLIM1,TNIK,FGFR3,MACF1,PRKG1,PREX2,TRPM3 |
5.776e-04 | -7.46 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 2 | 19454 | 50 |
GPM6A,CLU |
6.086e-04 | -7.40 | TNIK (TRAF2 and NCK interacting kinase) | protein interactions | 23043 | 151 | 4 | 19454 | 50 |
MACF1,TNIK,PRKG1,CLU |
6.089e-04 | -7.40 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 40 | 16828 | 49 |
GPM6A,ATP1A2,TRPS1,PARD3B,SPARCL1,PREX2,NFIA,CDH20,MACF1,NTM,ABLIM1,HIF3A,DTNA,NPAS3,PARD3,MAML2,PITPNC1,RYR3,MSI2,FBXL7,SOX5,TRPM3,CTNND2,RFX4,PRKG1,SLC4A4,ATP13A4,NKAIN3,FGFR3,CST3,PTPRZ1,SORBS1,BMPR1B,ERBB4,ZNRF3,CLU,GPC5,LRIG1,RORA,TNIK |
6.145e-04 | -7.39 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.176e-04 | -7.39 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 40 | 16828 | 49 |
MAML2,PITPNC1,MSI2,RYR3,HIF3A,NTM,ABLIM1,DTNA,NPAS3,PARD3,PREX2,NFIA,CDH20,MACF1,ATP1A2,GPM6A,TRPS1,SPARCL1,PARD3B,GPC5,CLU,RORA,LRIG1,TNIK,CST3,SORBS1,PTPRZ1,ZNRF3,BMPR1B,ERBB4,CTNND2,TRPM3,SOX5,PRKG1,RFX4,ATP13A4,SLC4A4,FGFR3,NKAIN3,FBXL7 |
6.556e-04 | -7.33 | Ig_3 | pfam domains | PF13927 | 141 | 4 | 17795 | 50 |
LSAMP,LRIG1,FGFR3,NTM |
6.588e-04 | -7.33 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 50 |
ATP1A2,SLC4A4 |
6.654e-04 | -7.32 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 2 | 19454 | 50 |
PARD3,TNIK |
6.985e-04 | -7.27 | cell development | biological process | GO:0048468 | 2236 | 15 | 18204 | 50 |
CLU,PTPRZ1,SLC1A3,PREX2,NTM,PRKG1,TNIK,ERBB4,PARD3,BMPR1B,CTNND2,GPM6A,RORA,CTNNA2,MSI2 |
7.080e-04 | -7.25 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 4 | 16828 | 49 |
FGFR3,PARD3,GPC5,PRKG1 |
7.170e-04 | -7.24 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 41 | 16828 | 49 |
PITPNC1,SFXN5,RYR3,LSAMP,DTNA,NTM,ABLIM1,HIF3A,PARD3,NPAS3,ZBTB20,PREX2,NFIA,MACF1,CDH20,GPM6A,ATP1A2,PARD3B,TRPS1,GPC5,GLIS3,TNIK,LRIG1,SLC1A2,RORA,PTPRZ1,SORBS1,BMPR1B,ERBB4,ZNRF3,RFX4,PRKG1,SOX5,CTNND2,TRPM3,NKAIN3,FGFR3,ATP13A4,SLC4A4,FBXL7,SLC1A3 |
7.170e-04 | -7.24 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 41 | 16828 | 49 |
PARD3B,TRPS1,GPM6A,ATP1A2,MACF1,CDH20,PREX2,NFIA,NPAS3,PARD3,ZBTB20,DTNA,NTM,ABLIM1,HIF3A,RYR3,LSAMP,PITPNC1,SFXN5,SLC1A3,FBXL7,NKAIN3,FGFR3,SLC4A4,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,TRPM3,BMPR1B,ERBB4,ZNRF3,PTPRZ1,SORBS1,GLIS3,TNIK,LRIG1,RORA,SLC1A2,GPC5 |
7.220e-04 | -7.23 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 3 | 18204 | 50 |
CTNNA2,PREX2,CTNND2 |
7.686e-04 | -7.17 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 18 | 16828 | 49 |
RYR3,GPC5,ZBTB20,PARD3,ERBB4,NPAS3,BMPR1B,HIF3A,PTPRZ1,CDH20,FGFR3,MACF1,SOX5,CTNND2,TRPM3,PRKG1,GPM6A,ACSS1 |
7.721e-04 | -7.17 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 5 | 18094 | 48 |
SLC1A3,SLC1A2,ATP1A2,SLC4A4,ATP13A4 |
7.916e-04 | -7.14 | face | COSMIC cancer mutations | face | 2139 | 15 | 16828 | 49 |
FGFR3,MACF1,PREX2,TRPM3,TRPS1,GPM6A,RORA,LSAMP,MSI2,GPC5,ERBB4,PARD3,ZNRF3,PTPRZ1,ABLIM1 |
8.077e-04 | -7.12 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 48 |
ATP1A2,SLC4A4,SLC1A3,SLC1A2 |
8.086e-04 | -7.12 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 50 |
ZBTB20,LSAMP |
8.632e-04 | -7.05 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 7 | 18094 | 48 |
SLC4A4,TRPM3,SLC1A2,RYR3,SLC1A3,ATP1A2,GPM6A |
8.657e-04 | -7.05 | asymmetric cell division | biological process | GO:0008356 | 16 | 2 | 18204 | 50 |
SOX5,PARD3 |
8.890e-04 | -7.03 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 10 | 18204 | 50 |
SLC1A2,SORBS1,ATP1A2,SLC1A3,NFIA,RYR3,SOX5,FGFR3,ERBB4,BMPR1B |
8.898e-04 | -7.02 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 33 | 16828 | 49 |
TRPM3,CTNND2,SOX5,PRKG1,ATP13A4,SLC4A4,FGFR3,NKAIN3,SLC1A3,RORA,LRIG1,TNIK,GLIS3,CST3,SORBS1,PTPRZ1,ERBB4,PREX2,MACF1,ATP1A2,ACSS1,TRPS1,SPARCL1,PARD3B,MAML2,PTGDS,RYR3,HIF3A,ABLIM1,DTNA,ZBTB20,NPAS3,PARD3 |
8.927e-04 | -7.02 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 5 | 18204 | 50 |
SLC4A4,SLC1A3,ATP1A2,PRKG1,SLC1A2 |
9.003e-04 | -7.01 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 7 | 19454 | 50 |
PARD3,TNIK,ABLIM1,FGFR3,DTNA,NHSL1,CLU |
9.444e-04 | -6.96 | cell adhesion | biological process | GO:0007155 | 942 | 9 | 18204 | 50 |
PARD3,SPARCL1,CTNNA2,SORBS1,CTNND2,NTM,CDH20,LSAMP,PARD3B |
9.648e-04 | -6.94 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 2 | 19454 | 50 |
PARD3,FGFR3 |
9.763e-04 | -6.93 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 5 | 16828 | 49 |
PREX2,SOX5,FGFR3,RYR3,SLC1A2 |
1.022e-03 | -6.89 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 50 |
GPM6A,NTM,LSAMP |
1.026e-03 | -6.88 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.030e-03 | -6.88 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 6 | 19454 | 50 |
PARD3,MACF1,ABLIM1,SORBS1,DTNA,SOX5 |
1.043e-03 | -6.87 | synapse | cellular component | GO:0045202 | 1473 | 11 | 19108 | 49 |
SLC1A2,GPM6A,DTNA,TNIK,SPARCL1,ATP1A2,ERBB4,CLU,PTPRZ1,SLC1A3,CTNND2 |
1.059e-03 | -6.85 | regulation of cartilage development | biological process | GO:0061035 | 73 | 3 | 18204 | 50 |
TRPS1,BMPR1B,SOX5 |
1.063e-03 | -6.85 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.066e-03 | -6.84 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 7 | 16828 | 49 |
RYR3,SLC4A4,TRPS1,ERBB4,FBXL7,CTNND2,PRKG1 |
1.082e-03 | -6.83 | cell junction assembly | biological process | GO:0034329 | 285 | 5 | 18204 | 50 |
SORBS1,PARD3,ERBB4,CDH20,GPM6A |
1.089e-03 | -6.82 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 7 | 16828 | 49 |
RYR3,SLC4A4,CTNND2,PRKG1,TRPS1,ERBB4,FBXL7 |
1.096e-03 | -6.82 | transporter activity | molecular function | GO:0005215 | 1211 | 10 | 18094 | 48 |
SLC4A4,PITPNC1,TRPM3,RYR3,SLC1A2,SLC1A3,SFXN5,ATP13A4,ATP1A2,GPM6A |
1.100e-03 | -6.81 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 2 | 18204 | 50 |
RORA,PRKG1 |
1.112e-03 | -6.80 | monoatomic ion transport | biological process | GO:0006811 | 964 | 9 | 18204 | 50 |
ATP1A2,GPM6A,SLC1A3,ATP13A4,SLC1A2,TRPM3,SLC4A4,SFXN5,RYR3 |
1.113e-03 | -6.80 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 11 | 16828 | 49 |
ZBTB20,TRPS1,PARD3B,ERBB4,NPAS3,NTM,ATP1A2,SORBS1,SLC4A4,MACF1,TRPM3 |
1.138e-03 | -6.78 | Adherens junction | KEGG pathways | ko04520 | 72 | 3 | 7161 | 21 |
SORBS1,CTNNA2,PARD3 |
1.138e-03 | -6.78 | Adherens junction | KEGG pathways | hsa04520 | 72 | 3 | 7161 | 21 |
CTNNA2,SORBS1,PARD3 |
1.150e-03 | -6.77 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 50 |
ATP1A2,ATP13A4 |
1.154e-03 | -6.76 | testis | COSMIC cancer mutations | testis | 733 | 8 | 16828 | 49 |
MACF1,FGFR3,TNIK,PRKG1,PREX2,TRPS1,BMPR1B,ERBB4 |
1.158e-03 | -6.76 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 10 | 16828 | 49 |
FGFR3,MACF1,ATP13A4,SLC4A4,PREX2,PRKG1,CTNND2,ERBB4,SORBS1,NTM |
1.172e-03 | -6.75 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 5 | 19454 | 50 |
TNIK,ABLIM1,PARD3,MACF1,DTNA |
1.186e-03 | -6.74 | PAS_fold | interpro domains | IPR013767 | 19 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
1.194e-03 | -6.73 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 2 | 19454 | 50 |
CST3,CTNND2 |
1.194e-03 | -6.73 | PON1 (paraoxonase 1) | protein interactions | 5444 | 20 | 2 | 19454 | 50 |
SFXN5,CLU |
1.226e-03 | -6.70 | GSC (goosecoid homeobox) | protein interactions | 145258 | 82 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
1.227e-03 | -6.70 | cartilage condensation | biological process | GO:0001502 | 19 | 2 | 18204 | 50 |
SOX5,BMPR1B |
1.235e-03 | -6.70 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 11 | 18204 | 50 |
NFIA,RYR3,PTGDS,FGFR3,SLC1A2,SORBS1,ATP1A2,ERBB4,SOX5,BMPR1B,SLC1A3 |
1.247e-03 | -6.69 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 48 |
SLC4A4,SLC1A2,SLC1A3 |
1.283e-03 | -6.66 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 3 | 18204 | 50 |
SORBS1,ZBTB20,SLC4A4 |
1.283e-03 | -6.66 | PAS | pfam domains | PF00989 | 19 | 2 | 17795 | 50 |
NPAS3,HIF3A |
1.290e-03 | -6.65 | cartilage development | biological process | GO:0051216 | 173 | 4 | 18204 | 50 |
NFIA,SOX5,BMPR1B,FGFR3 |
1.293e-03 | -6.65 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 3 | 18094 | 48 |
FGFR3,BMPR1B,ERBB4 |
1.314e-03 | -6.63 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 8 | 16828 | 49 |
TRPS1,SLC1A3,PARD3,DTNA,ACSS1,CTNND2,SOX5,PRKG1 |
1.318e-03 | -6.63 | TENM1 (teneurin transmembrane protein 1) | protein interactions | 10178 | 21 | 2 | 19454 | 50 |
SORBS1,MACF1 |
1.361e-03 | -6.60 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.361e-03 | -6.60 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 2 | 18204 | 50 |
BMPR1B,SOX5 |
1.502e-03 | -6.50 | positive regulation of purine nucleotide catabolic process | biological process | GO:0033123 | 21 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.502e-03 | -6.50 | positive regulation of nucleotide catabolic process | biological process | GO:0030813 | 21 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.502e-03 | -6.50 | positive regulation of glycolytic process | biological process | GO:0045821 | 21 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.502e-03 | -6.50 | cell aggregation | biological process | GO:0098743 | 21 | 2 | 18204 | 50 |
SOX5,BMPR1B |
1.548e-03 | -6.47 | SFN (stratifin) | protein interactions | 2810 | 671 | 7 | 19454 | 50 |
MACF1,PARD3,NFIA,TNIK,SORBS1,ABLIM1,PARD3B |
1.560e-03 | -6.46 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 22 | 16828 | 49 |
PARD3B,SPARCL1,TRPS1,SLC1A3,NHSL1,MACF1,FGFR3,CDH20,NFIA,PREX2,TRPM3,CTNND2,NPAS3,PARD3,ZNRF3,PTPRZ1,SORBS1,GLIS3,RORA,RYR3,CLU,MAML2 |
1.636e-03 | -6.42 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 32 | 16828 | 49 |
GPM6A,ACSS1,PARD3B,SPARCL1,PREX2,CDH20,MACF1,ABLIM1,PARD3,SFXN5,MAML2,RYR3,LSAMP,NHSL1,FBXL7,SLC1A3,SOX5,CTNND2,RFX4,PRKG1,ATP13A4,NKAIN3,PTPRZ1,BMPR1B,ERBB4,CLU,GPC5,LRIG1,SLC1A2,RORA,GLIS3,TNIK |
1.637e-03 | -6.41 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 37 |
ATP1A2,ATP13A4 |
1.644e-03 | -6.41 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 3 | 18204 | 50 |
SOX5,BMPR1B,FGFR3 |
1.649e-03 | -6.41 | negative regulation of muscle contraction | biological process | GO:0045932 | 22 | 2 | 18204 | 50 |
PRKG1,ATP1A2 |
1.649e-03 | -6.41 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 50 |
SLC1A3,ATP1A2 |
1.664e-03 | -6.40 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 7 | 18204 | 50 |
ATP13A4,GPM6A,ATP1A2,SLC1A3,RYR3,SLC4A4,TRPM3 |
1.683e-03 | -6.39 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.688e-03 | -6.38 | forearm | COSMIC cancer mutations | forearm | 81 | 3 | 16828 | 49 |
FGFR3,ERBB4,PREX2 |
1.689e-03 | -6.38 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 12 | 16828 | 49 |
TRPS1,ATP1A2,MACF1,FGFR3,SLC4A4,ATP13A4,PRKG1,SOX5,PTPRZ1,RORA,LSAMP,GPC5 |
1.748e-03 | -6.35 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 5 | 16828 | 49 |
GPC5,PRKG1,RYR3,TRPS1,MACF1 |
1.751e-03 | -6.35 | neuron projection | cellular component | GO:0043005 | 1331 | 10 | 19108 | 49 |
ATP1A2,SLC1A2,PARD3,DTNA,SLC1A3,CTNND2,BMPR1B,CTNNA2,CLU,GPM6A |
1.757e-03 | -6.34 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 4 | 19454 | 50 |
RYR3,ATP1A2,PARD3,DTNA |
1.781e-03 | -6.33 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 41 | 16828 | 49 |
ACSS1,ATP1A2,PARD3B,TRPS1,PREX2,MACF1,CDH20,DTNA,NTM,PARD3,NPAS3,ZBTB20,PTGDS,MAML2,SFXN5,RYR3,LSAMP,MSI2,FBXL7,NHSL1,SLC1A3,PRKG1,CTNND2,TRPM3,SOX5,FGFR3,SLC4A4,ATP13A4,SORBS1,PTPRZ1,CST3,ZNRF3,ERBB4,BMPR1B,GPC5,CLU,GLIS3,TNIK,SLC1A2,RORA,LRIG1 |
1.803e-03 | -6.32 | relaxation of muscle | biological process | GO:0090075 | 23 | 2 | 18204 | 50 |
ATP1A2,PRKG1 |
1.832e-03 | -6.30 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
1.832e-03 | -6.30 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
1.913e-03 | -6.26 | human chr10p11.22-p11.21 | chromosome location | human chr10p11.22-p11.21 | 1 | 1 | 26134 | 50 |
PARD3 |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.913e-03 | -6.26 | human chr10q11.23-q21.1 | chromosome location | human chr10q11.23-q21.1 | 1 | 1 | 26134 | 50 |
PRKG1 |
1.913e-03 | -6.26 | human chr9q21.12-q21.13 | chromosome location | human chr9q21.12-q21.13 | 1 | 1 | 26134 | 50 |
TRPM3 |
1.928e-03 | -6.25 | anchoring junction | cellular component | GO:0070161 | 902 | 8 | 19108 | 49 |
FGFR3,PARD3,SORBS1,PARD3B,ATP1A2,CDH20,CTNNA2,CTNND2 |
1.997e-03 | -6.22 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 2 | 7161 | 21 |
ATP1A2,SLC4A4 |
1.997e-03 | -6.22 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 2 | 7161 | 21 |
SLC4A4,ATP1A2 |
2.018e-03 | -6.21 | back | COSMIC cancer mutations | back | 310 | 5 | 16828 | 49 |
PREX2,ATP1A2,ERBB4,TNIK,FGFR3 |
2.019e-03 | -6.21 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 22 | 16828 | 49 |
CLU,RORA,GLIS3,SORBS1,PTPRZ1,ZNRF3,CTNND2,TRPM3,FGFR3,NHSL1,SLC1A3,MAML2,RYR3,NPAS3,PARD3,NFIA,PREX2,CDH20,MACF1,TRPS1,SPARCL1,PARD3B |
2.021e-03 | -6.20 | skin-face-malignant_melanoma-lentigo_maligna | COSMIC cancer mutations | skin-face-malignant_melanoma-lentigo_maligna | 23 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.047e-03 | -6.19 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 3 | 19454 | 50 |
SORBS1,PARD3,FGFR3 |
2.090e-03 | -6.17 | regulation of small molecule metabolic process | biological process | GO:0062012 | 331 | 5 | 18204 | 50 |
PRKG1,ZBTB20,SORBS1,SLC4A4,RORA |
2.130e-03 | -6.15 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
2.146e-03 | -6.14 | synapse organization | biological process | GO:0050808 | 333 | 5 | 18204 | 50 |
NFIA,CTNND2,ERBB4,GPM6A,SPARCL1 |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
DTNA,CDH20,CTNNA2 |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
DTNA,ABLIM1 |
2.226e-03 | -6.11 | membrane | cellular component | GO:0016020 | 9220 | 34 | 19108 | 49 |
SLC1A2,LSAMP,NKAIN3,CTNNA2,DTNA,HIF3A,ATP13A4,PREX2,NTM,CST3,MACF1,SFXN5,PARD3B,PTPRZ1,CTNND2,RYR3,GPC5,PTGDS,TRPM3,GPM6A,SLC4A4,FGFR3,BMPR1B,ZNRF3,TNIK,PARD3,LRIG1,PRKG1,CDH20,ERBB4,ATP1A2,CLU,SORBS1,SLC1A3 |
2.282e-03 | -6.08 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 9 | 18094 | 48 |
SFXN5,SLC1A3,RYR3,SLC1A2,TRPM3,SLC4A4,GPM6A,ATP1A2,ATP13A4 |
2.304e-03 | -6.07 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
2.319e-03 | -6.07 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 8 | 19454 | 50 |
SORBS1,PARD3,CTNND2,PARD3B,PTPRZ1,NHSL1,CTNNA2,DTNA |
2.328e-03 | -6.06 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 31 |
SLC1A2,SLC1A3 |
2.345e-03 | -6.06 | LRRC7 (leucine rich repeat containing 7) | protein interactions | 57554 | 28 | 2 | 19454 | 50 |
CTNND2,ERBB4 |
2.476e-03 | -6.00 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 6 | 16828 | 49 |
TRPS1,GPM6A,RYR3,MACF1,PRKG1,GPC5 |
2.478e-03 | -6.00 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 43 |
ATP1A2,ATP13A4 |
2.512e-03 | -5.99 | cell differentiation | biological process | GO:0030154 | 3645 | 19 | 18204 | 50 |
SLC1A3,PTPRZ1,PREX2,NTM,CLU,TNIK,PARD3,ERBB4,BMPR1B,SOX5,PRKG1,GPM6A,RORA,NHSL1,CTNND2,CTNNA2,FGFR3,MSI2,NFIA |
2.514e-03 | -5.99 | INSC (INSC spindle orientation adaptor protein) | protein interactions | 387755 | 29 | 2 | 19454 | 50 |
PARD3B,PARD3 |
2.537e-03 | -5.98 | cellular developmental process | biological process | GO:0048869 | 3648 | 19 | 18204 | 50 |
PRKG1,PARD3,BMPR1B,ERBB4,SOX5,TNIK,CLU,NTM,SLC1A3,PTPRZ1,PREX2,NFIA,FGFR3,MSI2,CTNNA2,CTNND2,NHSL1,RORA,GPM6A |
2.550e-03 | -5.97 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 25 | 16828 | 49 |
FBXL7,TRPS1,SLC1A3,SPARCL1,CTNND2,SOX5,PREX2,PRKG1,ATP13A4,FGFR3,HIF3A,ABLIM1,PTPRZ1,PARD3,NPAS3,BMPR1B,ERBB4,MAML2,CLU,PITPNC1,MSI2,LSAMP,RORA,LRIG1,TNIK |
2.550e-03 | -5.97 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 25 | 16828 | 49 |
PRKG1,SOX5,CTNND2,FGFR3,ATP13A4,FBXL7,SLC1A3,CLU,TNIK,RORA,LRIG1,PTPRZ1,BMPR1B,ERBB4,PREX2,SPARCL1,TRPS1,PITPNC1,MAML2,MSI2,LSAMP,ABLIM1,HIF3A,NPAS3,PARD3 |
2.556e-03 | -5.97 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 7 | 16828 | 49 |
FGFR3,TNIK,PREX2,PRKG1,BMPR1B,ERBB4,TRPS1 |
2.564e-03 | -5.97 | perinuclear endoplasmic reticulum lumen | cellular component | GO:0099020 | 1 | 1 | 19108 | 49 |
CLU |
2.570e-03 | -5.96 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.570e-03 | -5.96 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.577e-03 | -5.96 | upper_back | COSMIC cancer mutations | upper_back | 328 | 5 | 16828 | 49 |
ERBB4,PARD3B,FGFR3,MACF1,GPC5 |
2.602e-03 | -5.95 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 7 | 18094 | 48 |
ATP1A2,GPM6A,SLC4A4,TRPM3,SLC1A2,RYR3,SLC1A3 |
2.614e-03 | -5.95 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 50 |
SLC1A3,RYR3,SLC1A2 |
2.626e-03 | -5.94 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 16 | 16828 | 49 |
MAML2,RYR3,RORA,GLIS3,SORBS1,PTPRZ1,ZNRF3,NPAS3,CTNND2,TRPM3,NFIA,PREX2,FGFR3,MACF1,SPARCL1,PARD3B |
2.626e-03 | -5.94 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 16 | 16828 | 49 |
FGFR3,MACF1,PREX2,NFIA,CTNND2,TRPM3,SPARCL1,PARD3B,GLIS3,RYR3,RORA,MAML2,ZNRF3,NPAS3,SORBS1,PTPRZ1 |
2.670e-03 | -5.93 | glial cell proliferation | biological process | GO:0014009 | 28 | 2 | 18204 | 50 |
NFIA,CLU |
2.671e-03 | -5.93 | human chr20p11.21 | chromosome location | human chr20p11.21 | 40 | 2 | 26134 | 50 |
CST3,ACSS1 |
2.673e-03 | -5.92 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
2.698e-03 | -5.92 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 3 | 19454 | 50 |
MSI2,RYR3,ERBB4 |
2.700e-03 | -5.91 | SORBS1_SH3 | interpro domains | IPR035606 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | Clusterin_CS | interpro domains | IPR033986 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | Clusterin | interpro domains | IPR016016 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | PKcGMP_CC | interpro domains | IPR031831 | 1 | 1 | 18521 | 50 |
PRKG1 |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.700e-03 | -5.91 | MAML2_TAD | interpro domains | IPR048452 | 1 | 1 | 18521 | 50 |
MAML2 |
2.700e-03 | -5.91 | ZNRF3_Znf_RING | interpro domains | IPR045903 | 1 | 1 | 18521 | 50 |
ZNRF3 |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.700e-03 | -5.91 | SORBS1_SH3_1 | interpro domains | IPR035610 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | SORBS1_SH3_2 | interpro domains | IPR035611 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | TRPS1 | interpro domains | IPR028440 | 1 | 1 | 18521 | 50 |
TRPS1 |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
ERBB4,PTPRZ1,CST3,GLIS3,TNIK,LRIG1,RORA,GPC5,SLC1A3,NHSL1,NKAIN3,FGFR3,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,NPAS3,PARD3,ZBTB20,DTNA,ABLIM1,NTM,HIF3A,LSAMP,PTGDS,PITPNC1,SFXN5,MAML2,TRPS1,PREX2,BMPR1B,ZNRF3,SORBS1,SLC1A2,CLU,FBXL7,SLC4A4,TRPM3,RYR3,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,MACF1,CDH20,NFIA |
2.747e-03 | -5.90 | regulation of neuronal signal transduction | biological process | GO:1902847 | 1 | 1 | 18204 | 50 |
CLU |
2.747e-03 | -5.90 | positive regulation of neurofibrillary tangle assembly | biological process | GO:1902998 | 1 | 1 | 18204 | 50 |
CLU |
2.747e-03 | -5.90 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 50 |
CST3 |
2.747e-03 | -5.90 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 50 |
CST3 |
2.774e-03 | -5.89 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 6 | 16828 | 49 |
FGFR3,MACF1,BMPR1B,ERBB4,TNIK,PRKG1 |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
PTPRZ1,CST3,ERBB4,GPC5,TNIK,GLIS3,RORA,LRIG1,NHSL1,SLC1A3,PRKG1,RFX4,CTNND2,SOX5,FGFR3,NKAIN3,ATP13A4,DTNA,HIF3A,ABLIM1,NTM,PARD3,NPAS3,ZBTB20,PTGDS,PITPNC1,SFXN5,MAML2,LSAMP,TRPS1,PREX2,SORBS1,ZNRF3,BMPR1B,CLU,SLC1A2,FBXL7,TRPM3,SLC4A4,RYR3,ACSS1,ATP1A2,GPM6A,SPARCL1,PARD3B,NFIA,MACF1,CDH20 |
2.810e-03 | -5.87 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 50 |
FGFR3 |
2.810e-03 | -5.87 | PKcGMP_CC | pfam domains | PF16808 | 1 | 1 | 17795 | 50 |
PRKG1 |
2.810e-03 | -5.87 | MAML2_TAD | pfam domains | PF20804 | 1 | 1 | 17795 | 50 |
MAML2 |
2.853e-03 | -5.86 | MKRN2 (makorin ring finger protein 2) | protein interactions | 23609 | 380 | 5 | 19454 | 50 |
FGFR3,PARD3,MACF1,BMPR1B,PRKG1 |
2.857e-03 | -5.86 | cell body | cellular component | GO:0044297 | 556 | 6 | 19108 | 49 |
BMPR1B,CTNND2,SLC1A3,ATP1A2,GPM6A,SLC1A2 |
2.857e-03 | -5.86 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 49 |
CDH20,CTNNA2 |
2.870e-03 | -5.85 | SH2B1 (SH2B adaptor protein 1) | protein interactions | 25970 | 31 | 2 | 19454 | 50 |
FGFR3,ERBB4 |
2.870e-03 | -5.85 | SH2D1B (SH2 domain containing 1B) | protein interactions | 117157 | 31 | 2 | 19454 | 50 |
ERBB4,ABLIM1 |
2.919e-03 | -5.84 | non_seminoma | COSMIC cancer mutations | non_seminoma | 492 | 6 | 16828 | 49 |
PRKG1,FGFR3,MACF1,TNIK,ERBB4,BMPR1B |
2.972e-03 | -5.82 | - | gene3d domains | 6.10.250.880 | 1 | 1 | 14470 | 43 |
ERBB4 |
2.972e-03 | -5.82 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 43 |
FGFR3 |
2.991e-03 | -5.81 | TBR1 (T-box brain transcription factor 1) | protein interactions | 10716 | 112 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
2.993e-03 | -5.81 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 8 | 19454 | 50 |
SORBS1,PARD3,MACF1,NHSL1,PARD3B,PITPNC1,ABLIM1,FGFR3 |
3.002e-03 | -5.81 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 3 | 18204 | 50 |
NFIA,SOX5,RORA |
3.014e-03 | -5.80 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 31 |
FGFR3 |
3.028e-03 | -5.80 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 10 | 16828 | 49 |
CTNND2,ATP13A4,RYR3,TNIK,FGFR3,MACF1,ABLIM1,NTM,GPM6A,TRPS1 |
3.028e-03 | -5.80 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 10 | 16828 | 49 |
ABLIM1,NTM,GPM6A,TRPS1,CTNND2,ATP13A4,RYR3,FGFR3,MACF1,TNIK |
3.044e-03 | -5.79 | glial cell differentiation | biological process | GO:0010001 | 219 | 4 | 18204 | 50 |
CLU,NFIA,PTPRZ1,PARD3 |
3.055e-03 | -5.79 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 7 | 19454 | 50 |
SORBS1,MACF1,PARD3,CTNND2,NHSL1,CTNNA2,ABLIM1 |
3.062e-03 | -5.79 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
3.132e-03 | -5.77 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 14 | 16828 | 49 |
SLC4A4,FGFR3,SOX5,PREX2,PRKG1,NFIA,TRPS1,PARD3B,ATP1A2,TNIK,BMPR1B,ERBB4,PTPRZ1,DTNA |
3.219e-03 | -5.74 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 4 | 16828 | 49 |
PRKG1,NTM,ATP13A4,SLC4A4 |
3.222e-03 | -5.74 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 3 | 19454 | 50 |
PARD3,BMPR1B,SOX5 |
3.225e-03 | -5.74 | axonogenesis | biological process | GO:0007409 | 366 | 5 | 18204 | 50 |
PARD3,BMPR1B,CTNNA2,PTPRZ1,PRKG1 |
3.309e-03 | -5.71 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 8 | 16828 | 49 |
PREX2,PRKG1,MACF1,FGFR3,TNIK,TRPS1,ERBB4,BMPR1B |
3.349e-03 | -5.70 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 19 | 16828 | 49 |
GPC5,MAML2,TNIK,LRIG1,RYR3,PTPRZ1,ABLIM1,PARD3,ZBTB20,PREX2,SOX5,TRPM3,CTNND2,MACF1,SLC4A4,GPM6A,NHSL1,ATP1A2,SPARCL1 |
3.371e-03 | -5.69 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 19 | 16828 | 49 |
CTNND2,TRPM3,SOX5,PREX2,SLC4A4,MACF1,ATP1A2,GPM6A,NHSL1,SPARCL1,MAML2,GPC5,RYR3,LRIG1,TNIK,ABLIM1,PTPRZ1,ZBTB20,PARD3 |
3.391e-03 | -5.69 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 4 | 10285 | 31 |
TRPM3,ATP13A4,ATP1A2,RYR3 |
3.394e-03 | -5.69 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 7 | 10285 | 31 |
ATP13A4,ATP1A2,SLC4A4,SLC1A3,TRPM3,RYR3,SLC1A2 |
3.401e-03 | -5.68 | Protein_kinase_ATP_BS | interpro domains | IPR017441 | 377 | 5 | 18521 | 50 |
TNIK,FGFR3,PRKG1,ERBB4,BMPR1B |
3.415e-03 | -5.68 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
3.430e-03 | -5.68 | skin-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-malignant_melanoma-acral_lentiginous | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.430e-03 | -5.68 | lentigo_maligna | COSMIC cancer mutations | lentigo_maligna | 30 | 2 | 16828 | 49 |
FGFR3,PREX2 |
3.445e-03 | -5.67 | brain development | biological process | GO:0007420 | 724 | 7 | 18204 | 50 |
SLC1A2,RFX4,RORA,ATP1A2,PRKG1,ERBB4,CTNNA2 |
3.468e-03 | -5.66 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 31 | 16828 | 49 |
NHSL1,FBXL7,SLC1A3,RFX4,PRKG1,SOX5,CTNND2,NKAIN3,FGFR3,ATP13A4,SLC4A4,ERBB4,BMPR1B,CLU,GPC5,GLIS3,LRIG1,SLC1A2,RORA,ACSS1,GPM6A,ATP1A2,PREX2,MACF1,CDH20,ABLIM1,PARD3,MAML2,SFXN5,LSAMP,RYR3 |
3.479e-03 | -5.66 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 2 | 18204 | 50 |
SOX5,BMPR1B |
3.479e-03 | -5.66 | centrosome localization | biological process | GO:0051642 | 32 | 2 | 18204 | 50 |
PARD3,PARD3B |
3.479e-03 | -5.66 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
3.479e-03 | -5.66 | positive regulation of ATP metabolic process | biological process | GO:1903580 | 32 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
3.479e-03 | -5.66 | microtubule organizing center localization | biological process | GO:0061842 | 32 | 2 | 18204 | 50 |
PARD3,PARD3B |
3.529e-03 | -5.65 | CLUSTERIN_2 | prosite domains | PS00493 | 1 | 1 | 12186 | 43 |
CLU |
3.529e-03 | -5.65 | CLUSTERIN_1 | prosite domains | PS00492 | 1 | 1 | 12186 | 43 |
CLU |
3.531e-03 | -5.65 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 3 | 16828 | 49 |
PARD3,GPC5,PRKG1 |
3.621e-03 | -5.62 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 41 | 16828 | 49 |
MACF1,CDH20,PREX2,PARD3B,TRPS1,ACSS1,ATP1A2,LSAMP,RYR3,MSI2,PTGDS,MAML2,SFXN5,PARD3,NPAS3,ZBTB20,DTNA,NTM,FGFR3,ATP13A4,SLC4A4,PRKG1,SOX5,CTNND2,TRPM3,SLC1A3,NHSL1,FBXL7,GLIS3,TNIK,SLC1A2,RORA,LRIG1,CLU,GPC5,BMPR1B,ERBB4,ZNRF3,PTPRZ1,SORBS1,CST3 |
3.624e-03 | -5.62 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 8 | 16828 | 49 |
ERBB4,ACSS1,HIF3A,FGFR3,GLIS3,LRIG1,PREX2,NFIA |
3.637e-03 | -5.62 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
3.688e-03 | -5.60 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 3 | 18094 | 48 |
SLC4A4,SLC1A3,SLC1A2 |
3.688e-03 | -5.60 | calcium channel activity | molecular function | GO:0005262 | 117 | 3 | 18094 | 48 |
TRPM3,GPM6A,RYR3 |
3.697e-03 | -5.60 | response to auditory stimulus | biological process | GO:0010996 | 33 | 2 | 18204 | 50 |
SLC1A3,ATP1A2 |
3.741e-03 | -5.59 | connective tissue development | biological process | GO:0061448 | 232 | 4 | 18204 | 50 |
NFIA,SOX5,BMPR1B,FGFR3 |
3.785e-03 | -5.58 | regulation of circadian rhythm | biological process | GO:0042752 | 114 | 3 | 18204 | 50 |
RORA,PTGDS,PRKG1 |
3.792e-03 | -5.57 | PAS | interpro domains | IPR000014 | 34 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.792e-03 | -5.57 | PAS-like_dom_sf | interpro domains | IPR035965 | 34 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.808e-03 | -5.57 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 37 |
MACF1 |
3.878e-03 | -5.55 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
3.908e-03 | -5.54 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 8 | 16828 | 49 |
PTPRZ1,ABLIM1,ATP1A2,NPAS3,SPARCL1,PTGDS,FGFR3,LRIG1 |
3.912e-03 | -5.54 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 50 |
NTM,LSAMP,LRIG1,FGFR3 |
3.923e-03 | -5.54 | seminoma | COSMIC cancer mutations | seminoma | 700 | 7 | 16828 | 49 |
TRPS1,ERBB4,BMPR1B,TNIK,FGFR3,PREX2,PRKG1 |
3.969e-03 | -5.53 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 4 | 19454 | 50 |
ERBB4,TNIK,NHSL1,SORBS1 |
3.979e-03 | -5.53 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 5 | 19108 | 49 |
ERBB4,SLC1A2,TNIK,GPM6A,SPARCL1 |
3.982e-03 | -5.53 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 3 | 10285 | 31 |
SLC4A4,SLC1A3,SLC1A2 |
4.005e-03 | -5.52 | PAS | smart domains | SM00091 | 25 | 2 | 9717 | 37 |
NPAS3,HIF3A |
4.071e-03 | -5.50 | HPCA (hippocalcin) | protein interactions | 3208 | 37 | 2 | 19454 | 50 |
CST3,GPM6A |
4.071e-03 | -5.50 | MAGI2 (membrane associated guanylate kinase, WW and PDZ domain containing 2) | protein interactions | 9863 | 37 | 2 | 19454 | 50 |
ERBB4,CTNND2 |
4.238e-03 | -5.46 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 8 | 16828 | 49 |
SPARCL1,NPAS3,PTPRZ1,ATP1A2,ABLIM1,FGFR3,LRIG1,PTGDS |
4.244e-03 | -5.46 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.370e-03 | -5.43 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 50 |
ATP1A2,DTNA,RYR3 |
4.470e-03 | -5.41 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 9 | 16828 | 49 |
GPC5,PRKG1,SOX5,ATP13A4,RYR3,CDH20,SLC1A2,ERBB4,PARD3 |
4.478e-03 | -5.41 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.616e-03 | -5.38 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 28 | 16828 | 49 |
PREX2,NFIA,MACF1,ATP1A2,MAML2,PITPNC1,RYR3,ABLIM1,NTM,ZBTB20,PARD3,SOX5,TRPM3,CTNND2,RFX4,PRKG1,ATP13A4,SLC4A4,FGFR3,CLU,GPC5,LRIG1,RORA,TNIK,PTPRZ1,ERBB4,BMPR1B,ZNRF3 |
4.616e-03 | -5.38 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 28 | 16828 | 49 |
ATP13A4,SLC4A4,FGFR3,CTNND2,TRPM3,SOX5,PRKG1,RFX4,ZNRF3,ERBB4,BMPR1B,PTPRZ1,LRIG1,RORA,TNIK,GPC5,CLU,ATP1A2,MACF1,PREX2,NFIA,ZBTB20,PARD3,ABLIM1,NTM,RYR3,MAML2,PITPNC1 |
4.631e-03 | -5.38 | positive regulation of glucose import | biological process | GO:0046326 | 37 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
4.631e-03 | -5.38 | positive regulation of purine nucleotide metabolic process | biological process | GO:1900544 | 37 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
4.631e-03 | -5.38 | positive regulation of nucleotide metabolic process | biological process | GO:0045981 | 37 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
4.691e-03 | -5.36 | monoatomic cation transport | biological process | GO:0006812 | 766 | 7 | 18204 | 50 |
RYR3,TRPM3,SLC4A4,GPM6A,ATP1A2,SLC1A3,ATP13A4 |
4.873e-03 | -5.32 | PDZ | pfam domains | PF00595 | 122 | 3 | 17795 | 50 |
PARD3B,PREX2,PARD3 |
4.880e-03 | -5.32 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
4.915e-03 | -5.32 | transcription cis-regulatory region binding | molecular function | GO:0000976 | 1485 | 10 | 18094 | 48 |
SOX5,NPAS3,GLIS3,RFX4,HIF3A,ZBTB20,ERBB4,NFIA,RORA,TRPS1 |
4.962e-03 | -5.31 | transcription regulatory region nucleic acid binding | molecular function | GO:0001067 | 1487 | 10 | 18094 | 48 |
RFX4,HIF3A,ZBTB20,NPAS3,SOX5,GLIS3,NFIA,RORA,TRPS1,ERBB4 |
4.963e-03 | -5.31 | head development | biological process | GO:0060322 | 774 | 7 | 18204 | 50 |
SLC1A2,RFX4,RORA,ATP1A2,PRKG1,ERBB4,CTNNA2 |
4.969e-03 | -5.30 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 6 | 18204 | 50 |
ZBTB20,SLC1A3,ATP1A2,ATP13A4,RYR3,SLC4A4 |
4.969e-03 | -5.30 | PAS | prosite domains | PS50112 | 30 | 2 | 12186 | 43 |
HIF3A,NPAS3 |
4.980e-03 | -5.30 | RASSF7 (Ras association domain family member 7) | protein interactions | 8045 | 41 | 2 | 19454 | 50 |
CLU,PARD3 |
5.097e-03 | -5.28 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 43 |
ATP13A4,ATP1A2 |
5.097e-03 | -5.28 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 43 |
ATP13A4,ATP1A2 |
5.109e-03 | -5.28 | forebrain development | biological process | GO:0030900 | 408 | 5 | 18204 | 50 |
SLC1A2,PRKG1,RFX4,ERBB4,ATP1A2 |
5.127e-03 | -5.27 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 4 | 18521 | 50 |
RYR3,MACF1,SPARCL1,DTNA |
5.127e-03 | -5.27 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 7 | 19454 | 50 |
PARD3,MACF1,TNIK,SLC1A3,ABLIM1,DTNA,PARD3B |
5.134e-03 | -5.27 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | cdh11.S (cadherin 11 S homeolog) | protein interactions | 100337621 | 2 | 1 | 19454 | 50 |
ERBB4 |
5.134e-03 | -5.27 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | TRIM39-RPP21 (TRIM39-RPP21 readthrough) | protein interactions | 202658 | 2 | 1 | 19454 | 50 |
PRKG1 |
5.134e-03 | -5.27 | olfactory lobe development | biological process | GO:0021988 | 39 | 2 | 18204 | 50 |
ATP1A2,ERBB4 |
5.134e-03 | -5.27 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 50 |
ATP1A2,SLC1A3 |
5.135e-03 | -5.27 | prostate | COSMIC cancer mutations | prostate | 13883 | 47 | 16828 | 49 |
RYR3,MSI2,NFIA,CDH20,MACF1,ATP1A2,GPM6A,ACSS1,SPARCL1,PARD3B,CLU,SLC1A2,SORBS1,ZNRF3,BMPR1B,TRPM3,SLC4A4,FBXL7,SFXN5,MAML2,PITPNC1,LSAMP,HIF3A,NTM,ABLIM1,DTNA,ZBTB20,PARD3,NPAS3,PREX2,TRPS1,GPC5,RORA,LRIG1,TNIK,GLIS3,PTPRZ1,ERBB4,CTNND2,SOX5,PRKG1,RFX4,ATP13A4,FGFR3,NKAIN3,NHSL1,SLC1A3 |
5.154e-03 | -5.27 | spindle | COSMIC cancer mutations | spindle | 386 | 5 | 16828 | 49 |
TRPM3,CTNND2,PREX2,FGFR3,MACF1 |
5.157e-03 | -5.27 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 8 | 16828 | 49 |
PRKG1,PREX2,TNIK,FGFR3,MACF1,ATP1A2,BMPR1B,ERBB4 |
5.251e-03 | -5.25 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 49 |
DTNA,FGFR3,CDH20 |
5.299e-03 | -5.24 | cGMP-dependent protein kinase activity | molecular function | GO:0004692 | 2 | 1 | 18094 | 48 |
PRKG1 |
5.366e-03 | -5.23 | NFIB (nuclear factor I B) | protein interactions | 4781 | 138 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
5.373e-03 | -5.23 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 11 | 18204 | 50 |
ATP1A2,RORA,ZBTB20,MACF1,SFXN5,PTPRZ1,CLU,PARD3,SOX5,BMPR1B,ERBB4 |
5.392e-03 | -5.22 | STKc_cGK | interpro domains | IPR035014 | 2 | 1 | 18521 | 50 |
PRKG1 |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | Ac_CoA_lig | interpro domains | IPR011904 | 2 | 1 | 18521 | 50 |
ACSS1 |
5.392e-03 | -5.22 | ZNRF-3_ecto | interpro domains | IPR040700 | 2 | 1 | 18521 | 50 |
ZNRF3 |
5.392e-03 | -5.22 | cGMP_dep_kinase | interpro domains | IPR002374 | 2 | 1 | 18521 | 50 |
PRKG1 |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | Clusterin_C | interpro domains | IPR016015 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | Clusterin_N | interpro domains | IPR016014 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Clusterin-like | interpro domains | IPR000753 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.422e-03 | -5.22 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 13 | 16828 | 49 |
TNIK,DTNA,PTPRZ1,ERBB4,BMPR1B,NFIA,PRKG1,PREX2,SOX5,FGFR3,SLC4A4,ATP1A2,TRPS1 |
5.486e-03 | -5.21 | acetyl-CoA biosynthetic process from acetate | biological process | GO:0019427 | 2 | 1 | 18204 | 50 |
ACSS1 |
5.486e-03 | -5.21 | Wnt receptor catabolic process | biological process | GO:0038018 | 2 | 1 | 18204 | 50 |
ZNRF3 |
5.486e-03 | -5.21 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 50 |
CST3 |
5.486e-03 | -5.21 | regulation of neurofibrillary tangle assembly | biological process | GO:1902996 | 2 | 1 | 18204 | 50 |
CLU |
5.486e-03 | -5.21 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 50 |
FGFR3 |
5.486e-03 | -5.21 | negative regulation of inositol phosphate biosynthetic process | biological process | GO:0010920 | 2 | 1 | 18204 | 50 |
PRKG1 |
5.486e-03 | -5.21 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 50 |
CST3 |
5.486e-03 | -5.21 | propionate biosynthetic process | biological process | GO:0019542 | 2 | 1 | 18204 | 50 |
ACSS1 |
5.486e-03 | -5.21 | acetate biosynthetic process | biological process | GO:0019413 | 2 | 1 | 18204 | 50 |
ACSS1 |
5.486e-03 | -5.21 | establishment of planar polarity involved in nephron morphogenesis | biological process | GO:0072046 | 2 | 1 | 18204 | 50 |
ERBB4 |
5.492e-03 | -5.20 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 4 | 18094 | 48 |
SLC4A4,SLC1A2,SFXN5,SLC1A3 |
5.505e-03 | -5.20 | acral_lentiginous | COSMIC cancer mutations | acral_lentiginous | 745 | 7 | 16828 | 49 |
PARD3,ERBB4,PREX2,CDH20,ATP13A4,FGFR3,MACF1 |
5.545e-03 | -5.19 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
5.547e-03 | -5.19 | Ser-Thr/Tyr_kinase_cat_dom | interpro domains | IPR001245 | 133 | 3 | 18521 | 50 |
ERBB4,BMPR1B,FGFR3 |
5.612e-03 | -5.18 | Clusterin | pfam domains | PF01093 | 2 | 1 | 17795 | 50 |
CLU |
5.612e-03 | -5.18 | ZNRF_3_ecto | pfam domains | PF18212 | 2 | 1 | 17795 | 50 |
ZNRF3 |
5.612e-03 | -5.18 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 3 | 18094 | 48 |
RYR3,GPM6A,TRPM3 |
5.696e-03 | -5.17 | SNTB2 (syntrophin beta 2) | protein interactions | 6645 | 141 | 3 | 19454 | 50 |
FGFR3,ERBB4,DTNA |
5.697e-03 | -5.17 | amino acid transport | biological process | GO:0006865 | 132 | 3 | 18204 | 50 |
SLC1A2,SLC1A3,SFXN5 |
5.766e-03 | -5.16 | axon development | biological process | GO:0061564 | 420 | 5 | 18204 | 50 |
PRKG1,PTPRZ1,CTNNA2,BMPR1B,PARD3 |
5.802e-03 | -5.15 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 4 | 16828 | 49 |
NPAS3,ERBB4,GPC5,NFIA |
5.802e-03 | -5.15 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 4 | 16828 | 49 |
GPC5,NFIA,NPAS3,ERBB4 |
5.813e-03 | -5.15 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 3 | 17795 | 50 |
ERBB4,BMPR1B,FGFR3 |
5.885e-03 | -5.14 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 4 | 16828 | 49 |
FGFR3,MACF1,GLIS3,PTPRZ1 |
5.935e-03 | -5.13 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 43 |
CTNNA2 |
5.935e-03 | -5.13 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 43 |
RYR3 |
5.935e-03 | -5.13 | regulation of amino acid transport | biological process | GO:0051955 | 42 | 2 | 18204 | 50 |
PRKG1,ATP1A2 |
5.944e-03 | -5.13 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 11 | 16828 | 49 |
PARD3B,ABLIM1,DTNA,SORBS1,PTPRZ1,CDH20,RORA,MACF1,FGFR3,CTNND2,PREX2 |
5.944e-03 | -5.13 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 11 | 16828 | 49 |
RORA,ABLIM1,PTPRZ1,DTNA,SORBS1,CDH20,FGFR3,MACF1,CTNND2,PREX2,PARD3B |
5.968e-03 | -5.12 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 4 | 16828 | 49 |
MACF1,ZNRF3,FGFR3,TNIK |
5.998e-03 | -5.12 | growth | biological process | GO:0040007 | 424 | 5 | 18204 | 50 |
PRKG1,SLC1A2,BMPR1B,ERBB4,FGFR3 |
5.998e-03 | -5.12 | developmental growth | biological process | GO:0048589 | 424 | 5 | 18204 | 50 |
PRKG1,SLC1A2,ERBB4,FGFR3,BMPR1B |
6.037e-03 | -5.11 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 3 | 19454 | 50 |
ABLIM1,ZBTB20,MACF1 |
6.108e-03 | -5.10 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 5 | 19454 | 50 |
CTNND2,DTNA,ERBB4,MACF1,PARD3 |
6.237e-03 | -5.08 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 5 | 18204 | 50 |
RYR3,ATP13A4,SLC4A4,ATP1A2,SLC1A3 |
6.257e-03 | -5.07 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 5 | 18094 | 48 |
SLC1A3,SLC1A2,ATP1A2,SLC4A4,ATP13A4 |
6.263e-03 | -5.07 | PAS domain | gene3d domains | 3.30.450.20 | 40 | 2 | 14470 | 43 |
HIF3A,NPAS3 |
6.272e-03 | -5.07 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 4 | 19454 | 50 |
SORBS1,DTNA,PARD3B,PARD3 |
6.272e-03 | -5.07 | DSCR9 (Down syndrome critical region 9) | protein interactions | 257203 | 146 | 3 | 19454 | 50 |
SPARCL1,MACF1,CLU |
6.348e-03 | -5.06 | VASP (vasodilator stimulated phosphoprotein) | protein interactions | 7408 | 288 | 4 | 19454 | 50 |
PARD3,NHSL1,SORBS1,PRKG1 |
6.368e-03 | -5.06 | prostate-adenoma | COSMIC cancer mutations | prostate-adenoma | 1634 | 11 | 16828 | 49 |
MACF1,SOX5,TRPM3,PRKG1,GPC5,ZBTB20,ERBB4,PARD3,NPAS3,HIF3A,PTPRZ1 |
6.441e-03 | -5.04 | regulation of generation of precursor metabolites and energy | biological process | GO:0043467 | 138 | 3 | 18204 | 50 |
SLC4A4,SORBS1,ZBTB20 |
6.454e-03 | -5.04 | leg | COSMIC cancer mutations | leg | 969 | 8 | 16828 | 49 |
ATP13A4,SLC4A4,FGFR3,PRKG1,ZBTB20,NTM,HIF3A,PTPRZ1 |
6.493e-03 | -5.04 | spleen | COSMIC cancer mutations | spleen | 408 | 5 | 16828 | 49 |
SORBS1,PTPRZ1,NTM,PARD3B,TNIK |
6.498e-03 | -5.04 | positive regulation of glucose transmembrane transport | biological process | GO:0010828 | 44 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
6.500e-03 | -5.04 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 50 |
PTPRZ1,GPM6A |
6.500e-03 | -5.04 | LRIG3 (leucine rich repeats and immunoglobulin like domains 3) | protein interactions | 121227 | 47 | 2 | 19454 | 50 |
LRIG1,ERBB4 |
6.545e-03 | -5.03 | sequence-specific double-stranded DNA binding | molecular function | GO:1990837 | 1547 | 10 | 18094 | 48 |
ZBTB20,HIF3A,RFX4,GLIS3,NPAS3,SOX5,RORA,TRPS1,NFIA,ERBB4 |
6.634e-03 | -5.02 | GSE1 (Gse1 coiled-coil protein) | protein interactions | 23199 | 149 | 3 | 19454 | 50 |
NFIA,TNIK,SOX5 |
6.676e-03 | -5.01 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 6 | 18204 | 50 |
SLC1A3,ATP1A2,GPM6A,TRPM3,SLC4A4,RYR3 |
6.702e-03 | -5.01 | neurotransmitter transport | biological process | GO:0006836 | 140 | 3 | 18204 | 50 |
SLC1A3,ATP1A2,SLC1A2 |
6.709e-03 | -5.00 | apical junction complex | cellular component | GO:0043296 | 150 | 3 | 19108 | 49 |
PARD3,SORBS1,PARD3B |
6.788e-03 | -4.99 | acidic amino acid transport | biological process | GO:0015800 | 45 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
6.798e-03 | -4.99 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 5 | 18204 | 50 |
RYR3,ATP1A2,SLC1A3,SLC4A4,ATP13A4 |
6.804e-03 | -4.99 | gliogenesis | biological process | GO:0042063 | 275 | 4 | 18204 | 50 |
PTPRZ1,PARD3,NFIA,CLU |
6.875e-03 | -4.98 | transmembrane transport | biological process | GO:0055085 | 1264 | 9 | 18204 | 50 |
ATP13A4,ATP1A2,GPM6A,SLC1A3,SLC1A2,SLC4A4,SFXN5,TRPM3,RYR3 |
6.890e-03 | -4.98 | telencephalon development | biological process | GO:0021537 | 276 | 4 | 18204 | 50 |
RFX4,SLC1A2,ATP1A2,ERBB4 |
6.935e-03 | -4.97 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 19 |
ATP13A4,ATP1A2 |
6.939e-03 | -4.97 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 8 | 16828 | 49 |
GPC5,PRKG1,SOX5,CTNND2,NKAIN3,PARD3,RORA,LSAMP |
6.941e-03 | -4.97 | lung-carcinoma-bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-bronchioloalveolar_adenocarcinoma | 778 | 7 | 16828 | 49 |
PRKG1,CTNND2,SOX5,FGFR3,ERBB4,TNIK,BMPR1B |
6.941e-03 | -4.97 | bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | bronchioloalveolar_adenocarcinoma | 778 | 7 | 16828 | 49 |
ERBB4,BMPR1B,FGFR3,TNIK,PRKG1,CTNND2,SOX5 |
6.969e-03 | -4.97 | positive regulation of small molecule metabolic process | biological process | GO:0062013 | 142 | 3 | 18204 | 50 |
SLC4A4,ZBTB20,SORBS1 |
6.969e-03 | -4.97 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 50 |
SLC1A3,SLC4A4,SLC1A2 |
7.045e-03 | -4.96 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 43 |
SPARCL1 |
7.045e-03 | -4.96 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 43 |
SPARCL1 |
7.084e-03 | -4.95 | regulation of myelination | biological process | GO:0031641 | 46 | 2 | 18204 | 50 |
PARD3,PTPRZ1 |
7.087e-03 | -4.95 | symporter activity | molecular function | GO:0015293 | 148 | 3 | 18094 | 48 |
SLC4A4,SLC1A2,SLC1A3 |
7.101e-03 | -4.95 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 43 |
ATP13A4,ATP1A2 |
7.135e-03 | -4.94 | SOX6 (SRY-box transcription factor 6) | protein interactions | 55553 | 153 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
7.175e-03 | -4.94 | PDZ | interpro domains | IPR001478 | 146 | 3 | 18521 | 50 |
PARD3B,PARD3,PREX2 |
7.257e-03 | -4.93 | CGMPKINASE | prints domains | PR00104 | 2 | 1 | 5227 | 19 |
PRKG1 |
7.312e-03 | -4.92 | metal ion transport | biological process | GO:0030001 | 630 | 6 | 18204 | 50 |
TRPM3,SLC4A4,RYR3,SLC1A3,ATP1A2,GPM6A |
7.456e-03 | -4.90 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 9 | 16828 | 49 |
LSAMP,RORA,NKAIN3,TNIK,CTNND2,SOX5,GPC5,PRKG1,PARD3 |
7.493e-03 | -4.89 | cell surface | cellular component | GO:0009986 | 896 | 7 | 19108 | 49 |
SLC1A3,SLC4A4,FGFR3,CLU,ATP1A2,SLC1A2,GPC5 |
7.515e-03 | -4.89 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 4 | 18204 | 50 |
MACF1,TNIK,CTNND2,ZNRF3 |
7.521e-03 | -4.89 | adult behavior | biological process | GO:0030534 | 146 | 3 | 18204 | 50 |
PREX2,ATP1A2,SLC1A2 |
7.587e-03 | -4.88 | PDZ_sf | interpro domains | IPR036034 | 149 | 3 | 18521 | 50 |
PARD3B,PARD3,PREX2 |
7.592e-03 | -4.88 | enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 49 |
MACF1,ZNRF3 |
7.592e-03 | -4.88 | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 49 |
ZNRF3,MACF1 |
7.601e-03 | -4.88 | CLa | smart domains | SM00035 | 2 | 1 | 9717 | 37 |
CLU |
7.601e-03 | -4.88 | CLb | smart domains | SM00030 | 2 | 1 | 9717 | 37 |
CLU |
7.617e-03 | -4.88 | Ndc80 (NDC80 kinetochore complex component) | protein interactions | 67052 | 51 | 2 | 19454 | 50 |
NHSL1,MACF1 |
7.631e-03 | -4.88 | human chr8q23.3 | chromosome location | human chr8q23.3 | 4 | 1 | 26134 | 50 |
TRPS1 |
7.691e-03 | -4.87 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 50 |
ABLIM1 |
7.691e-03 | -4.87 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Hk2 (hexokinase 2) | protein interactions | 25059 | 3 | 1 | 19454 | 50 |
PTGDS |
7.691e-03 | -4.87 | NRG3 (neuregulin 3) | protein interactions | 10718 | 3 | 1 | 19454 | 50 |
ERBB4 |
7.691e-03 | -4.87 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Lep (leptin) | protein interactions | 16846 | 3 | 1 | 19454 | 50 |
CLU |
7.691e-03 | -4.87 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 50 |
PTPRZ1 |
7.691e-03 | -4.87 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 50 |
GLIS3 |
7.691e-03 | -4.87 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.720e-03 | -4.86 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 10 | 16828 | 49 |
SORBS1,PARD3,TRPS1,GPC5,CTNND2,TRPM3,TNIK,RYR3,SLC4A4,LSAMP |
7.761e-03 | -4.86 | C20 prostanoid biosynthesis | BIOCYC pathways | META_PWY66-374 | 7 | 1 | 902 | 1 |
PTGDS |
7.761e-03 | -4.86 | C20 prostanoid biosynthesis | BIOCYC pathways | HUMAN_PWY66-374 | 7 | 1 | 902 | 1 |
PTGDS |
7.909e-03 | -4.84 | SH2B2 (SH2B adaptor protein 2) | protein interactions | 10603 | 52 | 2 | 19454 | 50 |
ERBB4,SORBS1 |
7.909e-03 | -4.84 | SNAP91 (synaptosome associated protein 91) | protein interactions | 9892 | 52 | 2 | 19454 | 50 |
ERBB4,GPM6A |
7.938e-03 | -4.84 | epidermal growth factor receptor activity | molecular function | GO:0005006 | 3 | 1 | 18094 | 48 |
ERBB4 |
7.938e-03 | -4.84 | prostaglandin-D synthase activity | molecular function | GO:0004667 | 3 | 1 | 18094 | 48 |
PTGDS |
7.938e-03 | -4.84 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 48 |
SLC1A2 |
7.938e-03 | -4.84 | neuregulin receptor activity | molecular function | GO:0038131 | 3 | 1 | 18094 | 48 |
ERBB4 |
8.061e-03 | -4.82 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 5 | 16828 | 49 |
PRKG1,FGFR3,BMPR1B,ERBB4,TNIK |
8.061e-03 | -4.82 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 5 | 16828 | 49 |
PRKG1,BMPR1B,ERBB4,TNIK,FGFR3 |
8.065e-03 | -4.82 | SOX5 (SRY-box transcription factor 5) | protein interactions | 6660 | 160 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
8.078e-03 | -4.82 | MAML_N_sf | interpro domains | IPR046370 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | MAML1-3 | interpro domains | IPR046369 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SoHo_dom | interpro domains | IPR003127 | 3 | 1 | 18521 | 50 |
SORBS1 |
8.078e-03 | -4.82 | HIF_alpha-like | interpro domains | IPR021537 | 3 | 1 | 18521 | 50 |
HIF3A |
8.078e-03 | -4.82 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | TM_ErbB1 | interpro domains | IPR049328 | 3 | 1 | 18521 | 50 |
ERBB4 |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Mastermind-like_N | interpro domains | IPR019082 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.085e-03 | -4.82 | signaling | biological process | GO:0023052 | 4968 | 22 | 18204 | 50 |
PREX2,SLC1A3,CLU,MAML2,PARD3,ERBB4,BMPR1B,TNIK,PRKG1,RORA,ATP1A2,SLC1A2,ZNRF3,PITPNC1,SORBS1,DTNA,CTNND2,FGFR3,SPARCL1,MACF1,NFIA,RYR3 |
8.100e-03 | -4.82 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 4 | 19454 | 50 |
PARD3,MACF1,DTNA,SORBS1 |
8.124e-03 | -4.81 | neuronal cell body | cellular component | GO:0043025 | 489 | 5 | 19108 | 49 |
GPM6A,ATP1A2,CTNND2,SLC1A3,BMPR1B |
8.218e-03 | -4.80 | acetate metabolic process | biological process | GO:0006083 | 3 | 1 | 18204 | 50 |
ACSS1 |
8.218e-03 | -4.80 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 50 |
CTNNA2 |
8.218e-03 | -4.80 | protein targeting to lysosome involved in chaperone-mediated autophagy | biological process | GO:0061740 | 3 | 1 | 18204 | 50 |
CLU |
8.218e-03 | -4.80 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | immune complex clearance | biological process | GO:0002434 | 3 | 1 | 18204 | 50 |
CLU |
8.218e-03 | -4.80 | central nervous system morphogenesis | biological process | GO:0021551 | 3 | 1 | 18204 | 50 |
ERBB4 |
8.218e-03 | -4.80 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 50 |
ATP1A2 |
8.327e-03 | -4.79 | cell surface receptor signaling pathway via JAK-STAT | biological process | GO:0007259 | 50 | 2 | 18204 | 50 |
FGFR3,ERBB4 |
8.406e-03 | -4.78 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 50 |
MACF1 |
8.406e-03 | -4.78 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 50 |
GPM6A |
8.406e-03 | -4.78 | Sorb | pfam domains | PF02208 | 3 | 1 | 17795 | 50 |
SORBS1 |
8.406e-03 | -4.78 | HIF-1 | pfam domains | PF11413 | 3 | 1 | 17795 | 50 |
HIF3A |
8.406e-03 | -4.78 | MamL-1 | pfam domains | PF09596 | 3 | 1 | 17795 | 50 |
MAML2 |
8.406e-03 | -4.78 | TM_ErbB1 | pfam domains | PF21314 | 3 | 1 | 17795 | 50 |
ERBB4 |
8.436e-03 | -4.78 | protein binding | molecular function | GO:0005515 | 13983 | 44 | 18094 | 48 |
CLU,FBXL7,CST3,SLC1A3,LSAMP,CTNNA2,CDH20,PARD3,ZNRF3,PTGDS,SORBS1,SPARCL1,MAML2,LRIG1,NPAS3,ATP1A2,GPC5,NFIA,MSI2,SOX5,NTM,ABLIM1,SFXN5,PRKG1,RORA,ACSS1,PTPRZ1,ERBB4,BMPR1B,RYR3,TNIK,HIF3A,TRPS1,CTNND2,FGFR3,RFX4,DTNA,SLC1A2,MACF1,SLC4A4,PITPNC1,GLIS3,PARD3B,GPM6A |
8.458e-03 | -4.77 | DNA-binding transcription factor activity, RNA polymerase II-specific | molecular function | GO:0000981 | 1355 | 9 | 18094 | 48 |
HIF3A,RFX4,ZBTB20,GLIS3,SOX5,NPAS3,RORA,TRPS1,NFIA |
8.478e-03 | -4.77 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 4 | 14470 | 43 |
SPARCL1,RYR3,MACF1,DTNA |
8.507e-03 | -4.77 | SYNM (synemin) | protein interactions | 23336 | 54 | 2 | 19454 | 50 |
ERBB4,DTNA |
8.508e-03 | -4.77 | cellular component organization | biological process | GO:0016043 | 5636 | 24 | 18204 | 50 |
NFIA,SPARCL1,RFX4,ABLIM1,CTNND2,CST3,PRKG1,ERBB4,PARD3,PREX2,PARD3B,CDH20,RYR3,CTNNA2,MACF1,SLC1A2,PITPNC1,SORBS1,GPM6A,TNIK,TRPM3,BMPR1B,CLU,PTPRZ1 |
8.567e-03 | -4.76 | NEDD4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 4734 | 494 | 5 | 19454 | 50 |
FGFR3,ERBB4,TNIK,MAML2,GLIS3 |
8.603e-03 | -4.76 | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | 48 | 2 | 16828 | 49 |
RYR3,PARD3 |
8.638e-03 | -4.75 | OCLN (occludin) | protein interactions | 100506658 | 495 | 5 | 19454 | 50 |
TNIK,ABLIM1,MACF1,PARD3,DTNA |
8.693e-03 | -4.75 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 5 | 18204 | 50 |
SLC1A2,RYR3,RORA,SLC1A3,ATP1A2 |
8.702e-03 | -4.74 | hindbrain development | biological process | GO:0030902 | 154 | 3 | 18204 | 50 |
PRKG1,CTNNA2,RORA |
8.711e-03 | -4.74 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.712e-03 | -4.74 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
8.736e-03 | -4.74 | Amyotrophic lateral sclerosis (ALS) | WikiPathways | WP2447 | 38 | 2 | 5310 | 20 |
SLC1A2,CST3 |
8.771e-03 | -4.74 | EGR2 (early growth response 2) | protein interactions | 1959 | 165 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
8.772e-03 | -4.74 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 5 | 16828 | 49 |
PRKG1,FGFR3,BMPR1B,ERBB4,TNIK |
8.836e-03 | -4.73 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 4 | 16828 | 49 |
ERBB4,TNIK,ATP1A2,PREX2 |
8.873e-03 | -4.72 | muscle system process | biological process | GO:0003012 | 297 | 4 | 18204 | 50 |
ATP1A2,PRKG1,RYR3,DTNA |
8.889e-03 | -4.72 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 43 |
RYR3 |
8.889e-03 | -4.72 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 43 |
CTNNA2 |
8.889e-03 | -4.72 | - | gene3d domains | 6.10.250.970 | 3 | 1 | 14470 | 43 |
MAML2 |
8.972e-03 | -4.71 | chest | COSMIC cancer mutations | chest | 147 | 3 | 16828 | 49 |
ERBB4,FGFR3,PREX2 |
8.978e-03 | -4.71 | cell communication | biological process | GO:0007154 | 5010 | 22 | 18204 | 50 |
SLC1A3,PREX2,MAML2,CLU,TNIK,BMPR1B,ERBB4,PARD3,PRKG1,ATP1A2,RORA,CTNND2,DTNA,PITPNC1,SORBS1,SLC1A2,ZNRF3,MACF1,SPARCL1,FGFR3,RYR3,NFIA |
8.982e-03 | -4.71 | regulation of nucleotide catabolic process | biological process | GO:0030811 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
8.982e-03 | -4.71 | regulation of purine nucleotide catabolic process | biological process | GO:0033121 | 52 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
8.982e-03 | -4.71 | regulation of glycolytic process | biological process | GO:0006110 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
9.013e-03 | -4.71 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 3 | 18204 | 50 |
NFIA,GPM6A,BMPR1B |
9.125e-03 | -4.70 | SEPTIN3 (septin 3) | protein interactions | 55964 | 56 | 2 | 19454 | 50 |
GPM6A,PRKG1 |
9.147e-03 | -4.69 | presynaptic membrane | cellular component | GO:0042734 | 168 | 3 | 19108 | 49 |
ERBB4,GPM6A,SLC1A2 |
9.303e-03 | -4.68 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 5 | 18521 | 50 |
ERBB4,BMPR1B,TNIK,FGFR3,PRKG1 |
9.318e-03 | -4.68 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
9.428e-03 | -4.66 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 10 | 16828 | 49 |
PTPRZ1,SORBS1,DTNA,PARD3B,NPAS3,PREX2,GPC5,MACF1,FGFR3,RYR3 |
9.492e-03 | -4.66 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 50 |
SLC4A4,SLC1A3,SLC1A2 |
9.616e-03 | -4.64 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 48 | 16828 | 49 |
NFIA,MACF1,CDH20,ACSS1,GPM6A,ATP1A2,PARD3B,SPARCL1,RYR3,MSI2,TRPM3,SLC4A4,FBXL7,CLU,SLC1A2,SORBS1,BMPR1B,ZNRF3,PREX2,TRPS1,PTGDS,PITPNC1,SFXN5,MAML2,LSAMP,DTNA,ABLIM1,NTM,HIF3A,NPAS3,PARD3,ZBTB20,RFX4,PRKG1,SOX5,CTNND2,NKAIN3,FGFR3,ATP13A4,NHSL1,SLC1A3,GPC5,GLIS3,TNIK,RORA,LRIG1,PTPRZ1,ERBB4 |
9.634e-03 | -4.64 | biliary_tract | COSMIC cancer mutations | biliary_tract | 15309 | 49 | 16828 | 49 |
FBXL7,SLC4A4,TRPM3,BMPR1B,ZNRF3,SORBS1,SLC1A2,CLU,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,MACF1,CDH20,NFIA,RYR3,MSI2,SLC1A3,NHSL1,NKAIN3,FGFR3,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,ERBB4,PTPRZ1,CST3,TNIK,GLIS3,LRIG1,RORA,GPC5,TRPS1,PREX2,PARD3,NPAS3,ZBTB20,DTNA,NTM,ABLIM1,HIF3A,LSAMP,PITPNC1,PTGDS,SFXN5,MAML2 |
9.659e-03 | -4.64 | cell surface receptor signaling pathway via STAT | biological process | GO:0097696 | 54 | 2 | 18204 | 50 |
ERBB4,FGFR3 |
9.704e-03 | -4.64 | RNA polymerase II transcription regulatory region sequence-specific DNA binding | molecular function | GO:0000977 | 1385 | 9 | 18094 | 48 |
NFIA,RORA,TRPS1,NPAS3,SOX5,GLIS3,ZBTB20,RFX4,HIF3A |
9.709e-03 | -4.63 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 11 | 19454 | 50 |
PARD3B,BMPR1B,DTNA,TRPS1,ABLIM1,FGFR3,MSI2,NFIA,ZBTB20,MACF1,PARD3 |
9.762e-03 | -4.63 | Hippo signaling pathway | KEGG pathways | hsa04390 | 154 | 3 | 7161 | 21 |
PARD3,CTNNA2,BMPR1B |
9.762e-03 | -4.63 | Hippo signaling pathway | KEGG pathways | ko04390 | 154 | 3 | 7161 | 21 |
PARD3,CTNNA2,BMPR1B |
9.773e-03 | -4.63 | - | gene3d domains | 2.30.42.10 | 149 | 3 | 14470 | 43 |
PARD3,PREX2,PARD3B |
9.833e-03 | -4.62 | ROR2 (receptor tyrosine kinase like orphan receptor 2) | protein interactions | 4920 | 327 | 4 | 19454 | 50 |
PARD3,TNIK,DTNA,SORBS1 |
9.858e-03 | -4.62 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 6 | 16828 | 49 |
ERBB4,SORBS1,PTPRZ1,NTM,PREX2,NFIA |
9.877e-03 | -4.62 | double-stranded DNA binding | molecular function | GO:0003690 | 1643 | 10 | 18094 | 48 |
NFIA,RORA,TRPS1,ERBB4,ZBTB20,RFX4,HIF3A,SOX5,NPAS3,GLIS3 |
9.962e-03 | -4.61 | medullary_carcinoma | COSMIC cancer mutations | medullary_carcinoma | 290 | 4 | 16828 | 49 |
PRKG1,PARD3B,FGFR3,SLC1A2 |
9.962e-03 | -4.61 | thyroid-carcinoma-medullary_carcinoma | COSMIC cancer mutations | thyroid-carcinoma-medullary_carcinoma | 290 | 4 | 16828 | 49 |
SLC1A2,PARD3B,FGFR3,PRKG1 |
1.001e-02 | -4.60 | establishment or maintenance of epithelial cell apical/basal polarity | biological process | GO:0045197 | 55 | 2 | 18204 | 50 |
PARD3,PARD3B |
1.001e-02 | -4.60 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.002e-02 | -4.60 | Znf_NHR/GATA | interpro domains | IPR013088 | 56 | 2 | 18521 | 50 |
RORA,TRPS1 |
1.009e-02 | -4.60 | VEGFA (vascular endothelial growth factor A) | protein interactions | 7422 | 59 | 2 | 19454 | 50 |
CLU,PTPRZ1 |
1.012e-02 | -4.59 | PROTEIN_KINASE_ATP | prosite domains | PS00107 | 377 | 5 | 12186 | 43 |
PRKG1,BMPR1B,TNIK,FGFR3,ERBB4 |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
CTNNA2,DTNA,CDH20 |
1.022e-02 | -4.58 | internode region of axon | cellular component | GO:0033269 | 4 | 1 | 19108 | 49 |
PARD3 |
1.023e-02 | -4.58 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 31 |
SLC1A3,SLC1A2 |
1.023e-02 | -4.58 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 5 | 16828 | 49 |
PRKG1,BMPR1B,ERBB4,TNIK,FGFR3 |
1.024e-02 | -4.58 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 50 |
RORA |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Ctbp2 (C-terminal binding protein 2) | protein interactions | 13017 | 4 | 1 | 19454 | 50 |
TRPS1 |
1.024e-02 | -4.58 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 50 |
GLIS3 |
1.024e-02 | -4.58 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.025e-02 | -4.58 | sequence-specific DNA binding | molecular function | GO:0043565 | 1652 | 10 | 18094 | 48 |
ERBB4,NFIA,RORA,TRPS1,SOX5,NPAS3,GLIS3,ZBTB20,RFX4,HIF3A |
1.029e-02 | -4.58 | LHX3 (LIM homeobox 3) | protein interactions | 8022 | 175 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
1.042e-02 | -4.56 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 5 | 16828 | 49 |
FGFR3,ERBB4,TNIK,BMPR1B,PRKG1 |
1.042e-02 | -4.56 | ITGA8 (integrin subunit alpha 8) | protein interactions | 8516 | 60 | 2 | 19454 | 50 |
CLU,ZNRF3 |
1.042e-02 | -4.56 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 50 |
DTNA,FGFR3 |
1.049e-02 | -4.56 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 50 |
ATP1A2,SLC1A3,SLC1A2 |
1.055e-02 | -4.55 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 43 |
CTNNA2 |
1.055e-02 | -4.55 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 43 |
GPM6A |
1.055e-02 | -4.55 | SOHO | prosite domains | PS50831 | 3 | 1 | 12186 | 43 |
SORBS1 |
1.055e-02 | -4.55 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 43 |
GPM6A |
1.057e-02 | -4.55 | acetate-CoA ligase activity | molecular function | GO:0003987 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.057e-02 | -4.55 | propionate-CoA ligase activity | molecular function | GO:0050218 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.057e-02 | -4.55 | tricarboxylic acid transmembrane transporter activity | molecular function | GO:0015142 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | short-chain fatty acid-CoA ligase activity | molecular function | GO:0031955 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.057e-02 | -4.55 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 48 |
RYR3 |
1.057e-02 | -4.55 | citrate transmembrane transporter activity | molecular function | GO:0015137 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.072e-02 | -4.54 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 50 |
ATP1A2,SLC1A2 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | Tyr_kinase_EGF/ERB/XmrK_rcpt | interpro domains | IPR016245 | 4 | 1 | 18521 | 50 |
ERBB4 |
1.076e-02 | -4.53 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | TRPM_tetra_sf | interpro domains | IPR037162 | 4 | 1 | 18521 | 50 |
TRPM3 |
1.076e-02 | -4.53 | TRPM_tetra | interpro domains | IPR032415 | 4 | 1 | 18521 | 50 |
TRPM3 |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 50 |
FGFR3 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | ACAS_N | interpro domains | IPR032387 | 4 | 1 | 18521 | 50 |
ACSS1 |
1.076e-02 | -4.53 | PRKG1 (protein kinase cGMP-dependent 1) | protein interactions | 5592 | 61 | 2 | 19454 | 50 |
TNIK,PRKG1 |
1.087e-02 | -4.52 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 19 |
RORA |
1.087e-02 | -4.52 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 19 |
GPM6A |
1.087e-02 | -4.52 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 19 |
RYR3 |
1.087e-02 | -4.52 | PGNDSYNTHASE | prints domains | PR01254 | 3 | 1 | 5227 | 19 |
PTGDS |
1.094e-02 | -4.52 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 50 |
CST3 |
1.094e-02 | -4.52 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 50 |
SOX5 |
1.094e-02 | -4.52 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 50 |
BMPR1B |
1.094e-02 | -4.52 | negative regulation of germ cell proliferation | biological process | GO:1905937 | 4 | 1 | 18204 | 50 |
PTGDS |
1.094e-02 | -4.52 | positive regulation of inclusion body assembly | biological process | GO:0090261 | 4 | 1 | 18204 | 50 |
CLU |
1.094e-02 | -4.52 | negative regulation of male germ cell proliferation | biological process | GO:2000255 | 4 | 1 | 18204 | 50 |
PTGDS |
1.094e-02 | -4.52 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | short-chain fatty acid biosynthetic process | biological process | GO:0051790 | 4 | 1 | 18204 | 50 |
ACSS1 |
1.094e-02 | -4.52 | cardiac muscle tissue regeneration | biological process | GO:0061026 | 4 | 1 | 18204 | 50 |
ERBB4 |
1.094e-02 | -4.52 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.096e-02 | -4.51 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 12 | 16828 | 49 |
ATP13A4,FGFR3,CTNND2,PREX2,SPARCL1,ATP1A2,RORA,PARD3,BMPR1B,ERBB4,ABLIM1,SORBS1 |
1.096e-02 | -4.51 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 12 | 16828 | 49 |
SPARCL1,ERBB4,BMPR1B,PARD3,SORBS1,ATP1A2,ABLIM1,FGFR3,ATP13A4,RORA,PREX2,CTNND2 |
1.096e-02 | -4.51 | large_cell_carcinoma | COSMIC cancer mutations | large_cell_carcinoma | 849 | 7 | 16828 | 49 |
FGFR3,BMPR1B,ERBB4,TNIK,LRIG1,PRKG1,PTPRZ1 |
1.096e-02 | -4.51 | lung-carcinoma-large_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-large_cell_carcinoma | 849 | 7 | 16828 | 49 |
ERBB4,BMPR1B,PTPRZ1,LRIG1,TNIK,FGFR3,PRKG1 |
1.098e-02 | -4.51 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 5 | 16828 | 49 |
FGFR3,ERBB4,TNIK,BMPR1B,PRKG1 |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
DTNA,HIF3A,NTM,ABLIM1,PARD3,NPAS3,ZBTB20,PITPNC1,PTGDS,MAML2,SFXN5,LSAMP,TRPS1,PREX2,PTPRZ1,CST3,ERBB4,GPC5,GLIS3,TNIK,RORA,LRIG1,NHSL1,SLC1A3,PRKG1,RFX4,CTNND2,SOX5,FGFR3,NKAIN3,ATP13A4,RYR3,MSI2,ACSS1,ATP1A2,GPM6A,SPARCL1,PARD3B,NFIA,MACF1,CDH20,SORBS1,ZNRF3,BMPR1B,CLU,SLC1A2,FBXL7,TRPM3,SLC4A4 |
1.103e-02 | -4.51 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 7 | 16828 | 49 |
HIF3A,ACSS1,ERBB4,PREX2,NFIA,LRIG1,GLIS3 |
1.104e-02 | -4.51 | EZR (ezrin) | protein interactions | 7430 | 526 | 5 | 19454 | 50 |
MACF1,TNIK,ABLIM1,SORBS1,DTNA |
1.110e-02 | -4.50 | cellular homeostasis | biological process | GO:0019725 | 689 | 6 | 18204 | 50 |
ZBTB20,ATP13A4,ATP1A2,SLC1A3,RYR3,SLC4A4 |
1.110e-02 | -4.50 | MYOD1 (myogenic differentiation 1) | protein interactions | 4654 | 180 | 3 | 19454 | 50 |
RORA,NFIA,TRPS1 |
1.110e-02 | -4.50 | EPHA4 (EPH receptor A4) | protein interactions | 2043 | 180 | 3 | 19454 | 50 |
PARD3,FGFR3,CTNNA2 |
1.111e-02 | -4.50 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 12 | 19108 | 49 |
SLC1A2,GPM6A,DTNA,CTNNA2,BMPR1B,PARD3,ABLIM1,ATP1A2,CLU,MACF1,CTNND2,SLC1A3 |
1.119e-02 | -4.49 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 50 |
ATP13A4 |
1.119e-02 | -4.49 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 50 |
NKAIN3 |
1.119e-02 | -4.49 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 50 |
ABLIM1 |
1.119e-02 | -4.49 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | TRPM_tetra | pfam domains | PF16519 | 4 | 1 | 17795 | 50 |
TRPM3 |
1.119e-02 | -4.49 | ACAS_N | pfam domains | PF16177 | 4 | 1 | 17795 | 50 |
ACSS1 |
1.119e-02 | -4.49 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 50 |
NHSL1 |
1.120e-02 | -4.49 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 5 | 18204 | 50 |
NFIA,FGFR3,BMPR1B,ERBB4,SOX5 |
1.138e-02 | -4.48 | Sorb | smart domains | SM00459 | 3 | 1 | 9717 | 37 |
SORBS1 |
1.138e-02 | -4.48 | MamL-1 | smart domains | SM01275 | 3 | 1 | 9717 | 37 |
MAML2 |
1.138e-02 | -4.48 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 37 |
GPM6A |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.145e-02 | -4.47 | establishment or maintenance of bipolar cell polarity | biological process | GO:0061245 | 59 | 2 | 18204 | 50 |
PARD3,PARD3B |
1.145e-02 | -4.47 | establishment or maintenance of apical/basal cell polarity | biological process | GO:0035088 | 59 | 2 | 18204 | 50 |
PARD3B,PARD3 |
1.145e-02 | -4.47 | endochondral bone morphogenesis | biological process | GO:0060350 | 59 | 2 | 18204 | 50 |
BMPR1B,FGFR3 |
1.156e-02 | -4.46 | oligodendroglioma_Grade_III | COSMIC cancer mutations | oligodendroglioma_Grade_III | 303 | 4 | 16828 | 49 |
PTPRZ1,GLIS3,FGFR3,MACF1 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.171e-02 | -4.45 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 40 | 16828 | 49 |
GPC5,LRIG1,SLC1A2,RORA,GLIS3,TNIK,PTPRZ1,ERBB4,BMPR1B,SOX5,CTNND2,TRPM3,RFX4,PRKG1,SLC4A4,ATP13A4,NKAIN3,FGFR3,NHSL1,FBXL7,SLC1A3,MAML2,SFXN5,LSAMP,MSI2,RYR3,NTM,ABLIM1,HIF3A,DTNA,PARD3,NPAS3,PREX2,NFIA,CDH20,MACF1,ATP1A2,ACSS1,PARD3B,SPARCL1 |
1.175e-02 | -4.44 | skeletal system development | biological process | GO:0001501 | 500 | 5 | 18204 | 50 |
TRPS1,FGFR3,SOX5,BMPR1B,NFIA |
1.178e-02 | -4.44 | transmembrane receptor protein tyrosine kinase activity | molecular function | GO:0004714 | 62 | 2 | 18094 | 48 |
FGFR3,ERBB4 |
1.179e-02 | -4.44 | VSX1 (visual system homeobox 1) | protein interactions | 30813 | 64 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.179e-02 | -4.44 | SYNC (syncoilin, intermediate filament protein) | protein interactions | 81493 | 64 | 2 | 19454 | 50 |
MAML2,DTNA |
1.182e-02 | -4.44 | regulation of glucose import | biological process | GO:0046324 | 60 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
1.182e-02 | -4.44 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 50 |
SLC4A4,ATP1A2 |
1.182e-02 | -4.44 | regulation of smooth muscle contraction | biological process | GO:0006940 | 60 | 2 | 18204 | 50 |
ATP1A2,PRKG1 |
1.184e-02 | -4.44 | TRPM, tetramerisation domain | gene3d domains | 1.20.5.1010 | 4 | 1 | 14470 | 43 |
TRPM3 |
1.184e-02 | -4.44 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 43 |
MACF1 |
1.184e-02 | -4.44 | cadherin binding | molecular function | GO:0045296 | 335 | 4 | 18094 | 48 |
CTNNA2,CDH20,MACF1,CTNND2 |
1.192e-02 | -4.43 | chemical homeostasis | biological process | GO:0048878 | 914 | 7 | 18204 | 50 |
RYR3,ZBTB20,SLC1A3,ATP1A2,RORA,ATP13A4,SLC4A4 |
1.200e-02 | -4.42 | Erythroid Transcription Factor GATA-1, subunit A | gene3d domains | 3.30.50.10 | 56 | 2 | 14470 | 43 |
TRPS1,RORA |
1.223e-02 | -4.40 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 5 | 18204 | 50 |
SLC4A4,ATP13A4,SLC1A3,ATP1A2,RYR3 |
1.224e-02 | -4.40 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 2 | 10285 | 31 |
ATP1A2,RYR3 |
1.228e-02 | -4.40 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 6 | 16828 | 49 |
SPARCL1,ERBB4,BMPR1B,PRKG1,FGFR3,TNIK |
1.230e-02 | -4.40 | KLF5 (KLF transcription factor 5) | protein interactions | 688 | 187 | 3 | 19454 | 50 |
CLU,TRPS1,NFIA |
1.230e-02 | -4.40 | regulation of lipid metabolic process | biological process | GO:0019216 | 327 | 4 | 18204 | 50 |
SORBS1,ZBTB20,PRKG1,RORA |
1.240e-02 | -4.39 | DNA-binding transcription factor activity | molecular function | GO:0003700 | 1441 | 9 | 18094 | 48 |
NFIA,RORA,TRPS1,NPAS3,SOX5,GLIS3,RFX4,HIF3A,ZBTB20 |
1.247e-02 | -4.38 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 37 |
LSAMP,FGFR3,NTM,LRIG1 |
1.248e-02 | -4.38 | HNF1B (HNF1 homeobox B) | protein interactions | 6928 | 188 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
1.250e-02 | -4.38 | MAML1 (mastermind like transcriptional coactivator 1) | protein interactions | 9794 | 66 | 2 | 19454 | 50 |
NFIA,MAML2 |
1.250e-02 | -4.38 | MICB (MHC class I polypeptide-related sequence B) | protein interactions | 4277 | 66 | 2 | 19454 | 50 |
SFXN5,CLU |
1.250e-02 | -4.38 | ORM1 (orosomucoid 1) | protein interactions | 5004 | 66 | 2 | 19454 | 50 |
CLU,PTGDS |
1.252e-02 | -4.38 | circulatory system process | biological process | GO:0003013 | 508 | 5 | 18204 | 50 |
SLC4A4,SLC1A3,ATP1A2,PRKG1,SLC1A2 |
1.259e-02 | -4.38 | regulation of carbohydrate catabolic process | biological process | GO:0043470 | 62 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.262e-02 | -4.37 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 6 | 16828 | 49 |
ERBB4,BMPR1B,SPARCL1,PRKG1,TNIK,FGFR3 |
1.276e-02 | -4.36 | neurofibrillary tangle | cellular component | GO:0097418 | 5 | 1 | 19108 | 49 |
CLU |
1.279e-02 | -4.36 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | TRPM6 (transient receptor potential cation channel subfamily M member 6) | protein interactions | 140803 | 5 | 1 | 19454 | 50 |
TRPM3 |
1.279e-02 | -4.36 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | PPP1R17 (protein phosphatase 1 regulatory subunit 17) | protein interactions | 10842 | 5 | 1 | 19454 | 50 |
PRKG1 |
1.279e-02 | -4.36 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 50 |
GLIS3 |
1.279e-02 | -4.36 | NRG2 (neuregulin 2) | protein interactions | 9542 | 5 | 1 | 19454 | 50 |
ERBB4 |
1.279e-02 | -4.36 | RFX4 (regulatory factor X4) | protein interactions | 5992 | 5 | 1 | 19454 | 50 |
RFX4 |
1.279e-02 | -4.36 | SLC10A3 (solute carrier family 10 member 3) | protein interactions | 8273 | 5 | 1 | 19454 | 50 |
SORBS1 |
1.279e-02 | -4.36 | EPPIN (epididymal peptidase inhibitor) | protein interactions | 57119 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | ADCYAP1R1 (ADCYAP receptor type I) | protein interactions | 117 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | PTGER2 (prostaglandin E receptor 2) | protein interactions | 5732 | 5 | 1 | 19454 | 50 |
PTGDS |
1.279e-02 | -4.36 | Hk3 (hexokinase 3) | protein interactions | 25060 | 5 | 1 | 19454 | 50 |
PTGDS |
1.302e-02 | -4.34 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 48 | 16828 | 49 |
SFXN5,MAML2,PITPNC1,PTGDS,LSAMP,HIF3A,ABLIM1,NTM,ZBTB20,NPAS3,PARD3,PREX2,TRPS1,GPC5,LRIG1,RORA,TNIK,GLIS3,CST3,PTPRZ1,ERBB4,CTNND2,SOX5,PRKG1,RFX4,ATP13A4,FGFR3,NKAIN3,NHSL1,SLC1A3,RYR3,MSI2,NFIA,CDH20,MACF1,ATP1A2,GPM6A,ACSS1,SPARCL1,PARD3B,CLU,SLC1A2,SORBS1,ZNRF3,BMPR1B,TRPM3,SLC4A4,FBXL7 |
1.309e-02 | -4.34 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 2 | 10285 | 31 |
ATP1A2,ATP13A4 |
1.313e-02 | -4.33 | Kinase-like_dom_sf | interpro domains | IPR011009 | 523 | 5 | 18521 | 50 |
BMPR1B,ERBB4,PRKG1,TNIK,FGFR3 |
1.314e-02 | -4.33 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 6 | 18204 | 50 |
GPM6A,ATP1A2,SLC1A3,RYR3,TRPM3,SLC4A4 |
1.317e-02 | -4.33 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SFXN5 |
1.318e-02 | -4.33 | main axon | cellular component | GO:0044304 | 68 | 2 | 19108 | 49 |
SLC1A2,PARD3 |
1.320e-02 | -4.33 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 48 |
BMPR1B |
1.320e-02 | -4.33 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 48 |
FGFR3 |
1.322e-02 | -4.33 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 5 | 18204 | 50 |
SLC1A3,ATP1A2,ATP13A4,SLC4A4,RYR3 |
1.323e-02 | -4.33 | CXADR (CXADR Ig-like cell adhesion molecule) | protein interactions | 1525 | 357 | 4 | 19454 | 50 |
SORBS1,PARD3,MACF1,TNIK |
1.327e-02 | -4.32 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.336e-02 | -4.32 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 3 | 18094 | 48 |
SLC1A3,SFXN5,SLC1A2 |
1.339e-02 | -4.31 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 43 | 16828 | 49 |
TRPS1,PREX2,NPAS3,PARD3,ZBTB20,NTM,ABLIM1,HIF3A,LSAMP,PITPNC1,SFXN5,MAML2,SLC1A3,NHSL1,NKAIN3,FGFR3,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,ERBB4,PTPRZ1,GLIS3,TNIK,RORA,LRIG1,GPC5,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,MACF1,CDH20,NFIA,RYR3,FBXL7,TRPM3,BMPR1B,SORBS1,SLC1A2,CLU |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.343e-02 | -4.31 | Mtc | interpro domains | IPR004686 | 5 | 1 | 18521 | 50 |
SFXN5 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.359e-02 | -4.30 | Axon guidance | KEGG pathways | ko04360 | 174 | 3 | 7161 | 21 |
PARD3,BMPR1B,ABLIM1 |
1.359e-02 | -4.30 | Axon guidance | KEGG pathways | hsa04360 | 174 | 3 | 7161 | 21 |
ABLIM1,BMPR1B,PARD3 |
1.363e-02 | -4.30 | temporoparietal | COSMIC cancer mutations | temporoparietal | 61 | 2 | 16828 | 49 |
RYR3,PARD3 |
1.366e-02 | -4.29 | stem cell differentiation | biological process | GO:0048863 | 182 | 3 | 18204 | 50 |
MSI2,ERBB4,GPM6A |
1.366e-02 | -4.29 | otolith morphogenesis | biological process | GO:0032474 | 5 | 1 | 18204 | 50 |
LRIG1 |
1.366e-02 | -4.29 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 50 |
ATP1A2 |
1.366e-02 | -4.29 | tricarboxylic acid transport | biological process | GO:0006842 | 5 | 1 | 18204 | 50 |
SFXN5 |
1.366e-02 | -4.29 | propionate metabolic process | biological process | GO:0019541 | 5 | 1 | 18204 | 50 |
ACSS1 |
1.366e-02 | -4.29 | ERBB2-ERBB4 signaling pathway | biological process | GO:0038135 | 5 | 1 | 18204 | 50 |
ERBB4 |
1.366e-02 | -4.29 | positive regulation of amyloid fibril formation | biological process | GO:1905908 | 5 | 1 | 18204 | 50 |
CLU |
1.366e-02 | -4.29 | negative regulation of glutamate secretion | biological process | GO:0014050 | 5 | 1 | 18204 | 50 |
PRKG1 |
1.366e-02 | -4.29 | citrate transport | biological process | GO:0015746 | 5 | 1 | 18204 | 50 |
SFXN5 |
1.366e-02 | -4.29 | central nervous system myelin maintenance | biological process | GO:0032286 | 5 | 1 | 18204 | 50 |
CLU |
1.366e-02 | -4.29 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 50 |
BMPR1B |
1.367e-02 | -4.29 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 49 |
CST3,PTPRZ1,ERBB4,GPC5,LRIG1,RORA,GLIS3,TNIK,NHSL1,SLC1A3,CTNND2,SOX5,PRKG1,RFX4,ATP13A4,FGFR3,NKAIN3,HIF3A,ABLIM1,NTM,DTNA,ZBTB20,NPAS3,PARD3,SFXN5,MAML2,PTGDS,LSAMP,TRPS1,PREX2,SORBS1,ZNRF3,BMPR1B,CLU,SLC1A2,FBXL7,TRPM3,SLC4A4,RYR3,MSI2,ATP1A2,GPM6A,ACSS1,SPARCL1,PARD3B,NFIA,CDH20,MACF1 |
1.375e-02 | -4.29 | skin-upper_back-malignant_melanoma | COSMIC cancer mutations | skin-upper_back-malignant_melanoma | 319 | 4 | 16828 | 49 |
GPC5,PARD3B,ERBB4,MACF1 |
1.377e-02 | -4.29 | apoptotic mitochondrial changes | biological process | GO:0008637 | 65 | 2 | 18204 | 50 |
CLU,ERBB4 |
1.386e-02 | -4.28 | PDZ | prosite domains | PS50106 | 143 | 3 | 12186 | 43 |
PARD3,PARD3B,PREX2 |
1.389e-02 | -4.28 | regulation of Wnt signaling pathway | biological process | GO:0030111 | 339 | 4 | 18204 | 50 |
CTNND2,ZNRF3,MACF1,GPC5 |
1.390e-02 | -4.28 | cellular component organization or biogenesis | biological process | GO:0071840 | 5850 | 24 | 18204 | 50 |
BMPR1B,TRPM3,TNIK,PTPRZ1,CLU,MACF1,CTNNA2,RYR3,GPM6A,SORBS1,PITPNC1,SLC1A2,ERBB4,PARD3,CST3,PRKG1,CDH20,PARD3B,PREX2,SPARCL1,NFIA,CTNND2,ABLIM1,RFX4 |
1.392e-02 | -4.27 | extracellular matrix | cellular component | GO:0031012 | 559 | 5 | 19108 | 49 |
LRIG1,PTPRZ1,CLU,GPC5,SPARCL1 |
1.397e-02 | -4.27 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 50 |
SPARCL1 |
1.397e-02 | -4.27 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 50 |
PITPNC1 |
1.397e-02 | -4.27 | SFXNs | pfam domains | PF03820 | 5 | 1 | 17795 | 50 |
SFXN5 |
1.397e-02 | -4.27 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 50 |
CTNNA2 |
1.397e-02 | -4.27 | VHL (von Hippel-Lindau tumor suppressor) | protein interactions | 7428 | 558 | 5 | 19454 | 50 |
PRKG1,HIF3A,CLU,PARD3,FGFR3 |
1.399e-02 | -4.27 | MTMR9 (myotubularin related protein 9) | protein interactions | 66036 | 70 | 2 | 19454 | 50 |
CLU,ERBB4 |
1.402e-02 | -4.27 | external encapsulating structure | cellular component | GO:0030312 | 560 | 5 | 19108 | 49 |
SPARCL1,GPC5,CLU,PTPRZ1,LRIG1 |
1.404e-02 | -4.27 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 43 |
NFIA |
1.404e-02 | -4.27 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 43 |
NFIA |
1.408e-02 | -4.26 | cell population proliferation | biological process | GO:0008283 | 726 | 6 | 18204 | 50 |
NFIA,FGFR3,SOX5,CLU,ZNRF3,RORA |
1.412e-02 | -4.26 | membrane protein complex | cellular component | GO:0098796 | 1261 | 8 | 19108 | 49 |
RYR3,BMPR1B,CTNNA2,SLC1A3,SORBS1,ATP1A2,CDH20,SLC1A2 |
1.413e-02 | -4.26 | lower_leg | COSMIC cancer mutations | lower_leg | 174 | 3 | 16828 | 49 |
PREX2,ERBB4,FGFR3 |
1.418e-02 | -4.26 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
RFX4,PRKG1,SOX5,CTNND2,NKAIN3,FGFR3,ATP13A4,NHSL1,SLC1A3,GPC5,TNIK,GLIS3,LRIG1,RORA,PTPRZ1,CST3,ERBB4,PREX2,TRPS1,PTGDS,PITPNC1,MAML2,SFXN5,LSAMP,DTNA,ABLIM1,NTM,HIF3A,PARD3,NPAS3,ZBTB20,TRPM3,SLC4A4,FBXL7,CLU,SLC1A2,SORBS1,BMPR1B,ZNRF3,NFIA,MACF1,CDH20,ACSS1,GPM6A,ATP1A2,PARD3B,SPARCL1,RYR3 |
1.418e-02 | -4.26 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
SLC1A3,NHSL1,NKAIN3,FGFR3,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,ERBB4,PTPRZ1,CST3,TNIK,GLIS3,RORA,LRIG1,GPC5,TRPS1,PREX2,NPAS3,PARD3,ZBTB20,DTNA,NTM,ABLIM1,HIF3A,LSAMP,PTGDS,PITPNC1,SFXN5,MAML2,FBXL7,SLC4A4,TRPM3,BMPR1B,ZNRF3,SORBS1,SLC1A2,CLU,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,MACF1,CDH20,NFIA,RYR3 |
1.418e-02 | -4.26 | positive regulation of tyrosine phosphorylation of STAT protein | biological process | GO:0042531 | 66 | 2 | 18204 | 50 |
ERBB4,FGFR3 |
1.418e-02 | -4.26 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.425e-02 | -4.25 | DNAJC5 (DnaJ heat shock protein family (Hsp40) member C5) | protein interactions | 80331 | 365 | 4 | 19454 | 50 |
CLU,DTNA,PARD3,MACF1 |
1.427e-02 | -4.25 | response to growth factor | biological process | GO:0070848 | 525 | 5 | 18204 | 50 |
BMPR1B,FGFR3,SOX5,ERBB4,NFIA |
1.433e-02 | -4.25 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 4 | 16828 | 49 |
PARD3B,PTPRZ1,SORBS1,NTM |
1.433e-02 | -4.25 | NFIX (nuclear factor I X) | protein interactions | 4784 | 198 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.437e-02 | -4.24 | AKR7L (aldo-keto reductase family 7 like (gene/pseudogene)) | protein interactions | 246181 | 71 | 2 | 19454 | 50 |
MACF1,PARD3 |
1.446e-02 | -4.24 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 19 |
CTNNA2 |
1.448e-02 | -4.24 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.448e-02 | -4.24 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.451e-02 | -4.23 | NTRK3 (neurotrophic receptor tyrosine kinase 3) | protein interactions | 4916 | 367 | 4 | 19454 | 50 |
CLU,ABLIM1,TNIK,PARD3 |
1.456e-02 | -4.23 | Transferase(Phosphotransferase) domain 1 | gene3d domains | 1.10.510.10 | 490 | 5 | 14470 | 43 |
BMPR1B,ERBB4,FGFR3,TNIK,PRKG1 |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
GPM6A,TNIK |
1.476e-02 | -4.22 | PPP3CC (protein phosphatase 3 catalytic subunit gamma) | protein interactions | 5533 | 72 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
1.476e-02 | -4.22 | Ppp1cb (protein phosphatase 1 catalytic subunit beta) | protein interactions | 19046 | 72 | 2 | 19454 | 50 |
ABLIM1,PARD3 |
1.500e-02 | -4.20 | adenoid_cystic_carcinoma | COSMIC cancer mutations | adenoid_cystic_carcinoma | 1123 | 8 | 16828 | 49 |
ERBB4,RYR3,RORA,FGFR3,TNIK,MAML2,CTNND2,PRKG1 |
1.501e-02 | -4.20 | lung-carcinoid-endocrine_tumour | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour | 502 | 5 | 16828 | 49 |
PRKG1,FGFR3,TNIK,BMPR1B,ERBB4 |
1.510e-02 | -4.19 | regulation of lipid biosynthetic process | biological process | GO:0046890 | 189 | 3 | 18204 | 50 |
PRKG1,SORBS1,ZBTB20 |
1.512e-02 | -4.19 | FEV (FEV transcription factor, ETS family member) | protein interactions | 54738 | 202 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
1.520e-02 | -4.19 | ORF3a (ORF3a protein) | protein interactions | 43740569 | 789 | 6 | 19454 | 50 |
CLU,PARD3B,BMPR1B,ZNRF3,SLC4A4,PARD3 |
1.529e-02 | -4.18 | PAR polarity complex | cellular component | GO:0120157 | 6 | 1 | 19108 | 49 |
PARD3 |
1.532e-02 | -4.18 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | Taok2 (TAO kinase 2) | protein interactions | 381921 | 6 | 1 | 19454 | 50 |
CLU |
1.532e-02 | -4.18 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 50 |
GLIS3 |
1.532e-02 | -4.18 | RSPO3 (R-spondin 3) | protein interactions | 84870 | 6 | 1 | 19454 | 50 |
ZNRF3 |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | Zbtb2 (zinc finger and BTB domain containing 2) | protein interactions | 381990 | 6 | 1 | 19454 | 50 |
SORBS1 |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | NRG4 (neuregulin 4) | protein interactions | 145957 | 6 | 1 | 19454 | 50 |
ERBB4 |
1.539e-02 | -4.17 | skin-ankle-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-ankle-malignant_melanoma-acral_lentiginous | 330 | 4 | 16828 | 49 |
PREX2,ATP13A4,PARD3,ERBB4 |
1.541e-02 | -4.17 | GJA1 (gap junction protein alpha 1) | protein interactions | 2697 | 572 | 5 | 19454 | 50 |
DTNA,TNIK,ERBB4,MACF1,PARD3 |
1.549e-02 | -4.17 | skin-ear-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-ear-carcinoma-squamous_cell_carcinoma | 506 | 5 | 16828 | 49 |
PRKG1,ZBTB20,NPAS3,SPARCL1,FGFR3 |
1.552e-02 | -4.17 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 3 | 19454 | 50 |
ABLIM1,DTNA,PARD3B |
1.552e-02 | -4.17 | NFIC (nuclear factor I C) | protein interactions | 4782 | 204 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
1.554e-02 | -4.16 | TEC (tec protein tyrosine kinase) | protein interactions | 7006 | 74 | 2 | 19454 | 50 |
MSI2,ERBB4 |
1.555e-02 | -4.16 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 4 | 16828 | 49 |
PTPRZ1,SORBS1,NTM,PARD3B |
1.572e-02 | -4.15 | UTRN (utrophin) | protein interactions | 7402 | 205 | 3 | 19454 | 50 |
PARD3,FGFR3,DTNA |
1.573e-02 | -4.15 | lung-carcinoid-endocrine_tumour-atypical | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour-atypical | 508 | 5 | 16828 | 49 |
FGFR3,BMPR1B,TNIK,ERBB4,PRKG1 |
1.581e-02 | -4.15 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 48 |
ATP1A2 |
1.581e-02 | -4.15 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 48 |
SLC4A4 |
1.581e-02 | -4.15 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 48 |
RYR3 |
1.595e-02 | -4.14 | cell projection | cellular component | GO:0042995 | 2398 | 12 | 19108 | 49 |
CTNND2,SLC1A3,MACF1,CLU,ATP1A2,ABLIM1,PARD3,BMPR1B,CTNNA2,DTNA,GPM6A,SLC1A2 |
1.597e-02 | -4.14 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 20 |
ATP1A2,SLC1A3 |
1.598e-02 | -4.14 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 5 | 18094 | 48 |
PTPRZ1,CTNNA2,CDH20,CTNND2,MACF1 |
1.600e-02 | -4.13 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 49 |
TRPS1,PREX2,ZBTB20,PARD3,NPAS3,HIF3A,NTM,ABLIM1,DTNA,LSAMP,SFXN5,MAML2,PTGDS,SLC1A3,NHSL1,ATP13A4,FGFR3,NKAIN3,CTNND2,SOX5,PRKG1,RFX4,ERBB4,CST3,PTPRZ1,LRIG1,RORA,GLIS3,TNIK,GPC5,SPARCL1,PARD3B,ATP1A2,GPM6A,ACSS1,CDH20,MACF1,NFIA,RYR3,MSI2,FBXL7,SLC4A4,TRPM3,ZNRF3,BMPR1B,SORBS1,SLC1A2,CLU |
1.600e-02 | -4.13 | PDGFRA (platelet derived growth factor receptor alpha) | protein interactions | 5156 | 378 | 4 | 19454 | 50 |
LRIG1,FGFR3,CLU,DTNA |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.609e-02 | -4.13 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | RIH_dom | interpro domains | IPR000699 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | GF_recep_IV | interpro domains | IPR032778 | 6 | 1 | 18521 | 50 |
ERBB4 |
1.609e-02 | -4.13 | GLI-like | interpro domains | IPR043359 | 6 | 1 | 18521 | 50 |
GLIS3 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.618e-02 | -4.12 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 14 | 16828 | 49 |
SOX5,CTNND2,PREX2,ATP13A4,CDH20,ATP1A2,SLC1A3,TRPS1,MAML2,LSAMP,RYR3,PTPRZ1,ERBB4,PARD3 |
1.622e-02 | -4.12 | salivary_gland | COSMIC cancer mutations | salivary_gland | 1139 | 8 | 16828 | 49 |
ERBB4,TNIK,FGFR3,RORA,RYR3,PRKG1,CTNND2,MAML2 |
1.625e-02 | -4.12 | Constitutive Signaling by Aberrant PI3K in Cancer | REACTOME pathways | R-HSA-2219530 | 65 | 2 | 10285 | 31 |
ERBB4,FGFR3 |
1.633e-02 | -4.11 | BCL2L1 (BCL2 like 1) | protein interactions | 598 | 208 | 3 | 19454 | 50 |
RYR3,ABLIM1,CLU |
1.637e-02 | -4.11 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 50 |
CST3 |
1.637e-02 | -4.11 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 50 |
SLC1A3 |
1.637e-02 | -4.11 | protein targeting to vacuole involved in autophagy | biological process | GO:0071211 | 6 | 1 | 18204 | 50 |
CLU |
1.637e-02 | -4.11 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 50 |
BMPR1B |
1.637e-02 | -4.11 | ERBB4-ERBB4 signaling pathway | biological process | GO:0038138 | 6 | 1 | 18204 | 50 |
ERBB4 |
1.637e-02 | -4.11 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 50 |
SOX5 |
1.637e-02 | -4.11 | relaxation of vascular associated smooth muscle | biological process | GO:0060087 | 6 | 1 | 18204 | 50 |
PRKG1 |
1.660e-02 | -4.10 | atypical | COSMIC cancer mutations | atypical | 515 | 5 | 16828 | 49 |
FGFR3,ERBB4,BMPR1B,TNIK,PRKG1 |
1.672e-02 | -4.09 | regulation of ATP metabolic process | biological process | GO:1903578 | 72 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.674e-02 | -4.09 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | GF_recep_IV | pfam domains | PF14843 | 6 | 1 | 17795 | 50 |
ERBB4 |
1.674e-02 | -4.09 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 1 | 17795 | 50 |
RYR3 |
1.674e-02 | -4.09 | RYDR_ITPR | pfam domains | PF01365 | 6 | 1 | 17795 | 50 |
RYR3 |
1.674e-02 | -4.09 | RIH_assoc | pfam domains | PF08454 | 6 | 1 | 17795 | 50 |
RYR3 |
1.674e-02 | -4.09 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 50 |
GPC5 |
1.674e-02 | -4.09 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 50 |
DTNA |
1.675e-02 | -4.09 | ABI1 (abl interactor 1) | protein interactions | 10006 | 210 | 3 | 19454 | 50 |
SORBS1,NHSL1,SLC1A3 |
1.683e-02 | -4.08 | PDZ | smart domains | SM00228 | 143 | 3 | 9717 | 37 |
PREX2,PARD3B,PARD3 |
1.694e-02 | -4.08 | signal transduction | biological process | GO:0007165 | 4637 | 20 | 18204 | 50 |
ZNRF3,SORBS1,PITPNC1,DTNA,CTNND2,RORA,ATP1A2,NFIA,RYR3,FGFR3,SPARCL1,MACF1,CLU,MAML2,PREX2,PRKG1,BMPR1B,ERBB4,PARD3,TNIK |
1.696e-02 | -4.08 | CDK6 (cyclin dependent kinase 6) | protein interactions | 1021 | 211 | 3 | 19454 | 50 |
FGFR3,SORBS1,SOX5 |
1.701e-02 | -4.07 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 9 | 16828 | 49 |
ATP1A2,PARD3B,ERBB4,CTNND2,TRPM3,MACF1,FGFR3,RYR3,ATP13A4 |
1.705e-02 | -4.07 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.709e-02 | -4.07 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 50 |
BMPR1B |
1.715e-02 | -4.07 | extremity | COSMIC cancer mutations | extremity | 1876 | 11 | 16828 | 49 |
PREX2,ATP13A4,CDH20,FGFR3,FBXL7,ACSS1,PITPNC1,RYR3,PTPRZ1,ERBB4,PARD3 |
1.717e-02 | -4.06 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 2 | 19454 | 50 |
SOX5,MSI2 |
1.717e-02 | -4.06 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 15 | 18204 | 50 |
MACF1,SFXN5,PTGDS,TRPS1,ATP1A2,RORA,ZBTB20,BMPR1B,SOX5,ERBB4,PARD3,PRKG1,CST3,PTPRZ1,CLU |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.759e-02 | -4.04 | PRDM1 (PR/SET domain 1) | protein interactions | 639 | 79 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.761e-02 | -4.04 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 3 | 19454 | 50 |
NHSL1,TNIK,ERBB4 |
1.765e-02 | -4.04 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 7 | 18204 | 50 |
ERBB4,SOX5,BMPR1B,FGFR3,CTNNA2,LRIG1,ABLIM1 |
1.766e-02 | -4.04 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 19 | 16828 | 49 |
ACSS1,ATP1A2,PARD3B,TRPS1,PREX2,RFX4,CTNND2,MACF1,FGFR3,ATP13A4,SLC4A4,CDH20,ABLIM1,PARD3,ERBB4,GPC5,LRIG1,RORA,SLC1A2 |
1.770e-02 | -4.03 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 43 |
MACF1 |
1.770e-02 | -4.03 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 43 |
MACF1 |
1.770e-02 | -4.03 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 1 | 14470 | 43 |
RYR3 |
1.770e-02 | -4.03 | Single helix bin | gene3d domains | 1.20.5.490 | 6 | 1 | 14470 | 43 |
PRKG1 |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | C7 (complement C7) | protein interactions | 730 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | CYP4F8 (cytochrome P450 family 4 subfamily F member 8) | protein interactions | 11283 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | SOAT2 (sterol O-acyltransferase 2) | protein interactions | 8435 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | C8B (complement C8 beta chain) | protein interactions | 732 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 50 |
GLIS3 |
1.786e-02 | -4.03 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 50 |
ZBTB20 |
1.786e-02 | -4.03 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 50 |
PTPRZ1 |
1.786e-02 | -4.03 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 50 |
FGFR3 |
1.786e-02 | -4.03 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.795e-02 | -4.02 | protein kinase activity | molecular function | GO:0004672 | 577 | 5 | 18094 | 48 |
PRKG1,FGFR3,TNIK,ERBB4,BMPR1B |
1.802e-02 | -4.02 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 21 |
SLC4A4,ATP1A2 |
1.802e-02 | -4.02 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 21 |
SLC4A4,ATP1A2 |
1.805e-02 | -4.01 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 19 |
SLC4A4 |
1.805e-02 | -4.01 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 19 |
PITPNC1 |
1.826e-02 | -4.00 | GFAP (glial fibrillary acidic protein) | protein interactions | 2670 | 217 | 3 | 19454 | 50 |
NKAIN3,ABLIM1,RORA |
1.836e-02 | -4.00 | plasma membrane protein complex | cellular component | GO:0098797 | 600 | 5 | 19108 | 49 |
CDH20,ATP1A2,BMPR1B,CTNNA2,SORBS1 |
1.838e-02 | -4.00 | animal organ development | biological process | GO:0048513 | 2846 | 14 | 18204 | 50 |
BMPR1B,ERBB4,SOX5,PRKG1,RORA,GPM6A,ATP1A2,SLC1A2,ABLIM1,RFX4,FGFR3,LRIG1,CTNNA2,NFIA |
1.840e-02 | -4.00 | actin filament binding | molecular function | GO:0051015 | 211 | 3 | 18094 | 48 |
CTNNA2,ABLIM1,MACF1 |
1.843e-02 | -3.99 | mitogen-activated protein kinase p38 binding | molecular function | GO:0048273 | 7 | 1 | 18094 | 48 |
PRKG1 |
1.843e-02 | -3.99 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 48 |
PITPNC1 |
1.843e-02 | -3.99 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | SOX17 (SRY-box transcription factor 17) | protein interactions | 64321 | 81 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.852e-02 | -3.99 | regulation of tyrosine phosphorylation of STAT protein | biological process | GO:0042509 | 76 | 2 | 18204 | 50 |
ERBB4,FGFR3 |
1.871e-02 | -3.98 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 25 | 18204 | 50 |
SLC1A3,SLC4A4,ERBB4,PARD3,SOX5,NPAS3,PRKG1,GLIS3,ATP1A2,GPC5,RORA,RFX4,FGFR3,NFIA,PTPRZ1,MAML2,CLU,TNIK,BMPR1B,GPM6A,SLC1A2,ZBTB20,SORBS1,MACF1,SFXN5 |
1.872e-02 | -3.98 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 3 | 18204 | 50 |
RYR3,GPM6A,TRPM3 |
1.875e-02 | -3.98 | Rcpt_L-dom | interpro domains | IPR000494 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPARCL1 |
1.875e-02 | -3.98 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 50 |
BMPR1B |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.875e-02 | -3.98 | Furin-like_Cys-rich_dom | interpro domains | IPR006211 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Rcpt_L-dom_sf | interpro domains | IPR036941 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.882e-02 | -3.97 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.886e-02 | -3.97 | TNNT1 (troponin T1, slow skeletal type) | protein interactions | 7138 | 82 | 2 | 19454 | 50 |
BMPR1B,PRKG1 |
1.889e-02 | -3.97 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 47 | 16828 | 49 |
FBXL7,TRPM3,SLC4A4,SORBS1,BMPR1B,ZNRF3,CLU,SLC1A2,ACSS1,GPM6A,ATP1A2,PARD3B,SPARCL1,NFIA,MACF1,CDH20,RYR3,MSI2,NHSL1,SLC1A3,RFX4,PRKG1,SOX5,CTNND2,NKAIN3,FGFR3,ATP13A4,PTPRZ1,ERBB4,GPC5,GLIS3,TNIK,RORA,LRIG1,TRPS1,PREX2,DTNA,ABLIM1,NTM,HIF3A,NPAS3,PARD3,ZBTB20,PITPNC1,MAML2,SFXN5,LSAMP |
1.891e-02 | -3.97 | system process | biological process | GO:0003008 | 2015 | 11 | 18204 | 50 |
DTNA,ABLIM1,SLC1A2,ATP1A2,RYR3,CTNNA2,LRIG1,PTPRZ1,SLC1A3,PRKG1,SLC4A4 |
1.897e-02 | -3.96 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 50 |
GLIS3 |
1.898e-02 | -3.96 | regulation of organic acid transport | biological process | GO:0032890 | 77 | 2 | 18204 | 50 |
PRKG1,ATP1A2 |
1.898e-02 | -3.96 | BMP signaling pathway | biological process | GO:0030509 | 77 | 2 | 18204 | 50 |
NFIA,BMPR1B |
1.907e-02 | -3.96 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 50 |
PTPRZ1 |
1.907e-02 | -3.96 | chaperone-mediated autophagy | biological process | GO:0061684 | 7 | 1 | 18204 | 50 |
CLU |
1.907e-02 | -3.96 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 50 |
NFIA |
1.907e-02 | -3.96 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 50 |
CTNNA2 |
1.907e-02 | -3.96 | relaxation of smooth muscle | biological process | GO:0044557 | 7 | 1 | 18204 | 50 |
PRKG1 |
1.907e-02 | -3.96 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 50 |
RYR3 |
1.907e-02 | -3.96 | regulation of testosterone biosynthetic process | biological process | GO:2000224 | 7 | 1 | 18204 | 50 |
PRKG1 |
1.907e-02 | -3.96 | regulation of male germ cell proliferation | biological process | GO:2000254 | 7 | 1 | 18204 | 50 |
PTGDS |
1.907e-02 | -3.96 | positive regulation of transcription of Notch receptor target | biological process | GO:0007221 | 7 | 1 | 18204 | 50 |
MAML2 |
1.907e-02 | -3.96 | negative regulation of non-canonical Wnt signaling pathway | biological process | GO:2000051 | 7 | 1 | 18204 | 50 |
ZNRF3 |
1.914e-02 | -3.96 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | 73 | 2 | 16828 | 49 |
MACF1,FGFR3 |
1.921e-02 | -3.95 | caveola | cellular component | GO:0005901 | 83 | 2 | 19108 | 49 |
ATP1A2,SORBS1 |
1.929e-02 | -3.95 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 15 | 16828 | 49 |
NPAS3,PARD3,BMPR1B,ERBB4,HIF3A,NTM,MSI2,MAML2,SPARCL1,ATP1A2,SLC4A4,MACF1,FGFR3,TRPM3,PRKG1 |
1.929e-02 | -3.95 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 15 | 16828 | 49 |
MSI2,MAML2,NPAS3,PARD3,BMPR1B,ERBB4,HIF3A,NTM,SLC4A4,FGFR3,MACF1,TRPM3,PRKG1,SPARCL1,ATP1A2 |
1.930e-02 | -3.95 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 50 |
GPM6A,FGFR3 |
1.930e-02 | -3.95 | PAX2 (paired box 2) | protein interactions | 5076 | 83 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.943e-02 | -3.94 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
MACF1,PARD3,ATP13A4,SLC1A2,PREX2,GPC5,TRPM3 |
1.943e-02 | -3.94 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
PREX2,GPC5,TRPM3,PARD3,MACF1,SLC1A2,ATP13A4 |
1.944e-02 | -3.94 | regulation of glucose transmembrane transport | biological process | GO:0010827 | 78 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
1.944e-02 | -3.94 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.951e-02 | -3.94 | Recep_L_domain | pfam domains | PF01030 | 7 | 1 | 17795 | 50 |
ERBB4 |
1.951e-02 | -3.94 | Furin-like | pfam domains | PF00757 | 7 | 1 | 17795 | 50 |
ERBB4 |
1.951e-02 | -3.94 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 50 |
SPARCL1 |
1.951e-02 | -3.94 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 50 |
BMPR1B |
1.964e-02 | -3.93 | oligodendroglioma_Grade_II | COSMIC cancer mutations | oligodendroglioma_Grade_II | 74 | 2 | 16828 | 49 |
MACF1,FGFR3 |
1.974e-02 | -3.93 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 50 |
ERBB4,FGFR3 |
1.978e-02 | -3.92 | cytoskeleton organization | biological process | GO:0007010 | 1251 | 8 | 18204 | 50 |
MACF1,CTNNA2,TNIK,PARD3,PRKG1,PARD3B,ABLIM1,SORBS1 |
1.985e-02 | -3.92 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 3 | 19454 | 50 |
ABLIM1,MACF1,GPM6A |
2.002e-02 | -3.91 | YWHAH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta) | protein interactions | 7533 | 1083 | 7 | 19454 | 50 |
PARD3B,NHSL1,ABLIM1,PITPNC1,SORBS1,MACF1,PARD3 |
2.004e-02 | -3.91 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 6 | 19108 | 49 |
ATP1A2,BMPR1B,CTNND2,SLC1A3,CLU,GPM6A |
2.008e-02 | -3.91 | KLF3 (KLF transcription factor 3) | protein interactions | 51274 | 225 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
2.020e-02 | -3.90 | SOX2 (SRY-box transcription factor 2) | protein interactions | 6657 | 1342 | 8 | 19454 | 50 |
CLU,TRPS1,LSAMP,MSI2,MACF1,NFIA,SOX5,GLIS3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.034e-02 | -3.90 | zonula adherens | cellular component | GO:0005915 | 8 | 1 | 19108 | 49 |
SORBS1 |
2.034e-02 | -3.90 | spherical high-density lipoprotein particle | cellular component | GO:0034366 | 8 | 1 | 19108 | 49 |
CLU |
2.034e-02 | -3.90 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 49 |
BMPR1B |
2.035e-02 | -3.89 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 43 |
ATP1A2,ATP13A4 |
2.038e-02 | -3.89 | Chmp2a (charged multivesicular body protein 2A) | protein interactions | 68953 | 8 | 1 | 19454 | 50 |
CLU |
2.038e-02 | -3.89 | INSM1 (INSM transcriptional repressor 1) | protein interactions | 3642 | 8 | 1 | 19454 | 50 |
SORBS1 |
2.038e-02 | -3.89 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | PTGER1 (prostaglandin E receptor 1) | protein interactions | 5731 | 8 | 1 | 19454 | 50 |
PTGDS |
2.038e-02 | -3.89 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 50 |
NTM |
2.038e-02 | -3.89 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.044e-02 | -3.89 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 25 | 16828 | 49 |
ERBB4,PTPRZ1,CST3,GLIS3,LRIG1,RORA,SLC1A3,NKAIN3,FGFR3,ATP13A4,SLC4A4,SOX5,TRPM3,CTNND2,NPAS3,PARD3,ZBTB20,DTNA,ABLIM1,RYR3,MAML2,SPARCL1,ATP1A2,MACF1,PREX2 |
2.053e-02 | -3.89 | stress fiber | cellular component | GO:0001725 | 86 | 2 | 19108 | 49 |
SORBS1,ABLIM1 |
2.053e-02 | -3.89 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 2 | 19108 | 49 |
ABLIM1,SORBS1 |
2.062e-02 | -3.88 | Receptor L-domain | gene3d domains | 3.80.20.20 | 7 | 1 | 14470 | 43 |
ERBB4 |
2.063e-02 | -3.88 | EGLN1 (egl-9 family hypoxia inducible factor 1) | protein interactions | 54583 | 86 | 2 | 19454 | 50 |
FGFR3,HIF3A |
2.063e-02 | -3.88 | SYNJ1 (synaptojanin 1) | protein interactions | 8867 | 86 | 2 | 19454 | 50 |
GPM6A,SORBS1 |
2.067e-02 | -3.88 | kidney-Wilms_tumour | COSMIC cancer mutations | kidney-Wilms_tumour | 545 | 5 | 16828 | 49 |
BMPR1B,ERBB4,TNIK,FGFR3,PRKG1 |
2.082e-02 | -3.87 | Wilms_tumour | COSMIC cancer mutations | Wilms_tumour | 546 | 5 | 16828 | 49 |
PRKG1,FGFR3,TNIK,ERBB4,BMPR1B |
2.084e-02 | -3.87 | dendrite | cellular component | GO:0030425 | 620 | 5 | 19108 | 49 |
ATP1A2,BMPR1B,CTNND2,CLU,GPM6A |
2.087e-02 | -3.87 | adult locomotory behavior | biological process | GO:0008344 | 81 | 2 | 18204 | 50 |
ATP1A2,PREX2 |
2.091e-02 | -3.87 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 31 |
FGFR3 |
2.099e-02 | -3.86 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 43 |
MACF1 |
2.099e-02 | -3.86 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 43 |
GPC5 |
2.101e-02 | -3.86 | EF_hand_dom | interpro domains | IPR002048 | 218 | 3 | 18521 | 50 |
MACF1,SPARCL1,RYR3 |
2.103e-02 | -3.86 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 48 |
BMPR1B |
2.103e-02 | -3.86 | cyclic nucleotide-dependent protein kinase activity | molecular function | GO:0004690 | 8 | 1 | 18094 | 48 |
PRKG1 |
2.103e-02 | -3.86 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 48 |
SLC1A3 |
2.106e-02 | -3.86 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 4 | 16828 | 49 |
MACF1,CTNND2,TRPM3,PREX2 |
2.108e-02 | -3.86 | NHLH1 (nescient helix-loop-helix 1) | protein interactions | 4807 | 87 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.108e-02 | -3.86 | Kctd5 (potassium channel tetramerisation domain containing 5) | protein interactions | 69259 | 87 | 2 | 19454 | 50 |
TRPS1,SLC1A3 |
2.108e-02 | -3.86 | ZNF608 (zinc finger protein 608) | protein interactions | 57507 | 87 | 2 | 19454 | 50 |
SOX5,NFIA |
2.110e-02 | -3.86 | dendritic tree | cellular component | GO:0097447 | 622 | 5 | 19108 | 49 |
CTNND2,BMPR1B,ATP1A2,GPM6A,CLU |
2.111e-02 | -3.86 | anion binding | molecular function | GO:0043168 | 2412 | 12 | 18094 | 48 |
ACSS1,PARD3,ATP13A4,FGFR3,ATP1A2,PTGDS,BMPR1B,ERBB4,SLC1A3,PRKG1,TNIK,PITPNC1 |
2.123e-02 | -3.85 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
MSI2,RYR3,SPARCL1,PARD3B,ACSS1,ATP1A2,GPM6A,MACF1,CDH20,NFIA,ZNRF3,BMPR1B,SORBS1,SLC1A2,CLU,FBXL7,SLC4A4,TRPM3,NPAS3,PARD3,ZBTB20,DTNA,HIF3A,ABLIM1,LSAMP,PTGDS,PITPNC1,MAML2,SFXN5,TRPS1,PREX2,ERBB4,PTPRZ1,TNIK,GLIS3,RORA,LRIG1,GPC5,SLC1A3,NHSL1,FGFR3,NKAIN3,ATP13A4,PRKG1,CTNND2,SOX5 |
2.123e-02 | -3.85 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
SLC4A4,TRPM3,FBXL7,SLC1A2,CLU,BMPR1B,ZNRF3,SORBS1,MACF1,CDH20,NFIA,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,MSI2,RYR3,NKAIN3,FGFR3,ATP13A4,PRKG1,SOX5,CTNND2,SLC1A3,NHSL1,TNIK,GLIS3,RORA,LRIG1,GPC5,ERBB4,PTPRZ1,PREX2,TRPS1,LSAMP,PTGDS,PITPNC1,MAML2,SFXN5,NPAS3,PARD3,ZBTB20,DTNA,ABLIM1,HIF3A |
2.127e-02 | -3.85 | DST (dystonin) | protein interactions | 667 | 230 | 3 | 19454 | 50 |
TNIK,ATP1A2,PARD3 |
2.128e-02 | -3.85 | mesothelioma | COSMIC cancer mutations | mesothelioma | 4477 | 20 | 16828 | 49 |
ZNRF3,ERBB4,BMPR1B,HIF3A,PTPRZ1,MSI2,RORA,LRIG1,TNIK,MAML2,PITPNC1,CLU,TRPS1,FBXL7,ATP13A4,FGFR3,CTNND2,SOX5,PRKG1,PREX2 |
2.140e-02 | -3.84 | TRPM_SLOG | interpro domains | IPR041491 | 8 | 1 | 18521 | 50 |
TRPM3 |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.140e-02 | -3.84 | RFX-like | interpro domains | IPR039779 | 8 | 1 | 18521 | 50 |
RFX4 |
2.153e-02 | -3.84 | RAP2A (RAP2A, member of RAS oncogene family) | protein interactions | 5911 | 88 | 2 | 19454 | 50 |
TNIK,BMPR1B |
2.153e-02 | -3.84 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 50 |
NTM,FGFR3,LSAMP,LRIG1 |
2.162e-02 | -3.83 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 19 |
BMPR1B |
2.174e-02 | -3.83 | EGFR (epidermal growth factor receptor) | protein interactions | 1956 | 3105 | 14 | 19454 | 50 |
PARD3,TNIK,TRPM3,SPARCL1,ERBB4,CTNNA2,CTNND2,CLU,LRIG1,SORBS1,ABLIM1,TRPS1,DTNA,PTGDS |
2.177e-02 | -3.83 | ERBB4 signaling pathway | biological process | GO:0038130 | 8 | 1 | 18204 | 50 |
ERBB4 |
2.177e-02 | -3.83 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 50 |
CTNNA2 |
2.177e-02 | -3.83 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 50 |
ATP1A2 |
2.177e-02 | -3.83 | regulation of germ cell proliferation | biological process | GO:1905936 | 8 | 1 | 18204 | 50 |
PTGDS |
2.177e-02 | -3.83 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | protein import | biological process | GO:0017038 | 8 | 1 | 18204 | 50 |
CLU |
2.177e-02 | -3.83 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 50 |
SLC1A3 |
2.177e-02 | -3.83 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 50 |
RORA |
2.184e-02 | -3.82 | regulation of amine transport | biological process | GO:0051952 | 83 | 2 | 18204 | 50 |
PRKG1,ATP1A2 |
2.199e-02 | -3.82 | SOX10 (SRY-box transcription factor 10) | protein interactions | 6663 | 89 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.224e-02 | -3.81 | HMG20A (high mobility group 20A) | protein interactions | 10363 | 234 | 3 | 19454 | 50 |
SOX5,DTNA,NFIA |
2.226e-02 | -3.80 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 50 |
ABLIM1 |
2.226e-02 | -3.80 | LSDAT_euk | pfam domains | PF18139 | 8 | 1 | 17795 | 50 |
TRPM3 |
2.233e-02 | -3.80 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 50 |
ATP1A2,NKAIN3 |
2.233e-02 | -3.80 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
2.233e-02 | -3.80 | stem cell development | biological process | GO:0048864 | 84 | 2 | 18204 | 50 |
MSI2,ERBB4 |
2.249e-02 | -3.79 | MARK3 (microtubule affinity regulating kinase 3) | protein interactions | 4140 | 235 | 3 | 19454 | 50 |
PARD3,MACF1,DTNA |
2.262e-02 | -3.79 | thyroid | COSMIC cancer mutations | thyroid | 9867 | 36 | 16828 | 49 |
CLU,GPC5,GLIS3,TNIK,RORA,SLC1A2,LRIG1,PTPRZ1,CST3,ERBB4,ZNRF3,PRKG1,SOX5,CTNND2,TRPM3,FGFR3,SLC4A4,ATP13A4,NHSL1,PTGDS,MAML2,RYR3,LSAMP,DTNA,ABLIM1,HIF3A,PARD3,NFIA,PREX2,MACF1,CDH20,ACSS1,ATP1A2,PARD3B,SPARCL1,TRPS1 |
2.264e-02 | -3.79 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 37 |
MACF1 |
2.268e-02 | -3.79 | breast-carcinoma-lobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-lobular_carcinoma | 763 | 6 | 16828 | 49 |
PRKG1,CDH20,FGFR3,ERBB4,BMPR1B,TNIK |
2.268e-02 | -3.79 | lobular_carcinoma | COSMIC cancer mutations | lobular_carcinoma | 763 | 6 | 16828 | 49 |
ERBB4,BMPR1B,TNIK,FGFR3,CDH20,PRKG1 |
2.283e-02 | -3.78 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 2 | 18204 | 50 |
PTPRZ1,CLU |
2.285e-02 | -3.78 | flotillin complex | cellular component | GO:0016600 | 9 | 1 | 19108 | 49 |
SORBS1 |
2.290e-02 | -3.78 | MUC4 (mucin 4, cell surface associated) | protein interactions | 4585 | 9 | 1 | 19454 | 50 |
ERBB4 |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 50 |
BMPR1B |
2.290e-02 | -3.78 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 50 |
MACF1 |
2.290e-02 | -3.78 | KLB (klotho beta) | protein interactions | 152831 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.292e-02 | -3.78 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 2 | 19454 | 50 |
SORBS1,TNIK |
2.292e-02 | -3.78 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 50 |
NTM,GPM6A |
2.292e-02 | -3.78 | FOXI1 (forkhead box I1) | protein interactions | 2299 | 91 | 2 | 19454 | 50 |
NFIA,TRPS1 |
2.298e-02 | -3.77 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 3 | 10285 | 31 |
ATP1A2,RYR3,SORBS1 |
2.306e-02 | -3.77 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.309e-02 | -3.77 | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | 561 | 5 | 16828 | 49 |
MAML2,TNIK,ERBB4,FGFR3,RYR3 |
2.324e-02 | -3.76 | LCOR (ligand dependent nuclear receptor corepressor) | protein interactions | 84458 | 238 | 3 | 19454 | 50 |
CLU,SPARCL1,MACF1 |
2.329e-02 | -3.76 | actomyosin | cellular component | GO:0042641 | 92 | 2 | 19108 | 49 |
SORBS1,ABLIM1 |
2.331e-02 | -3.76 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 2 | 18094 | 48 |
CST3,CLU |
2.339e-02 | -3.76 | FNTA (farnesyltransferase, CAAX box, subunit alpha) | protein interactions | 2339 | 92 | 2 | 19454 | 50 |
FGFR3,TNIK |
2.339e-02 | -3.76 | SOX9 (SRY-box transcription factor 9) | protein interactions | 6662 | 92 | 2 | 19454 | 50 |
NFIA,TRPS1 |
2.339e-02 | -3.76 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 50 |
DTNA,FGFR3 |
2.352e-02 | -3.75 | organic anion transport | biological process | GO:0015711 | 398 | 4 | 18204 | 50 |
SLC1A3,SLC4A4,SFXN5,SLC1A2 |
2.353e-02 | -3.75 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 43 |
ABLIM1 |
2.381e-02 | -3.74 | collagen-containing extracellular matrix | cellular component | GO:0062023 | 428 | 4 | 19108 | 49 |
PTPRZ1,CLU,GPC5,SPARCL1 |
2.384e-02 | -3.74 | DISC1 (DISC1 scaffold protein) | protein interactions | 27185 | 427 | 4 | 19454 | 50 |
CLU,SPARCL1,MACF1,TNIK |
2.387e-02 | -3.74 | Diseases of signal transduction | REACTOME pathways | R-HSA-5663202 | 369 | 4 | 10285 | 31 |
ERBB4,MAML2,FGFR3,MACF1 |
2.387e-02 | -3.74 | Downregulation of ERBB4 signaling | REACTOME pathways | R-HSA-1253288 | 8 | 1 | 10285 | 31 |
ERBB4 |
2.387e-02 | -3.74 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 31 |
GPC5 |
2.387e-02 | -3.74 | MPDZ (multiple PDZ domain crumbs cell polarity complex component) | protein interactions | 8777 | 93 | 2 | 19454 | 50 |
PARD3,FGFR3 |
2.387e-02 | -3.74 | ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 9459 | 93 | 2 | 19454 | 50 |
ABLIM1,BMPR1B |
2.387e-02 | -3.74 | ODR4 (odr-4 GPCR localization factor homolog) | protein interactions | 54953 | 93 | 2 | 19454 | 50 |
LRIG1,GPM6A |
2.388e-02 | -3.73 | hand | COSMIC cancer mutations | hand | 566 | 5 | 16828 | 49 |
FGFR3,ERBB4,SLC4A4,PREX2,HIF3A |
2.404e-02 | -3.73 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 50 |
CST3 |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.404e-02 | -3.73 | DNA-bd_RFX | interpro domains | IPR003150 | 9 | 1 | 18521 | 50 |
RFX4 |
2.404e-02 | -3.73 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 50 |
BMPR1B |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.408e-02 | -3.73 | ion binding | molecular function | GO:0043167 | 6007 | 23 | 18094 | 48 |
DTNA,SLC1A2,MACF1,PITPNC1,GLIS3,TRPS1,ATP1A2,FGFR3,RYR3,ERBB4,BMPR1B,SPARCL1,TNIK,SLC1A3,ABLIM1,RORA,PRKG1,PARD3,ACSS1,PTGDS,ZBTB20,ZNRF3,ATP13A4 |
2.433e-02 | -3.72 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 20 |
SOX5,FGFR3 |
2.435e-02 | -3.72 | QSER1 (glutamine and serine rich 1) | protein interactions | 79832 | 94 | 2 | 19454 | 50 |
SOX5,NFIA |
2.435e-02 | -3.72 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 50 |
TNIK,ABLIM1 |
2.435e-02 | -3.72 | FOXP4 (forkhead box P4) | protein interactions | 116113 | 94 | 2 | 19454 | 50 |
NFIA,SOX5 |
2.435e-02 | -3.72 | TTR (transthyretin) | protein interactions | 7276 | 94 | 2 | 19454 | 50 |
CLU,CTNND2 |
2.437e-02 | -3.71 | renal_cell_carcinoma | COSMIC cancer mutations | renal_cell_carcinoma | 4535 | 20 | 16828 | 49 |
TRPS1,FBXL7,FGFR3,MACF1,PREX2,PRKG1,CTNND2,SOX5,ZNRF3,BMPR1B,ERBB4,PTPRZ1,HIF3A,TNIK,MSI2,RORA,LRIG1,PITPNC1,CLU,MAML2 |
2.437e-02 | -3.71 | kidney-carcinoma-renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma | 4535 | 20 | 16828 | 49 |
FBXL7,TRPS1,CTNND2,SOX5,PREX2,PRKG1,FGFR3,MACF1,HIF3A,PTPRZ1,ZNRF3,BMPR1B,ERBB4,MAML2,PITPNC1,CLU,MSI2,RORA,LRIG1,TNIK |
2.438e-02 | -3.71 | postsynapse | cellular component | GO:0098794 | 646 | 5 | 19108 | 49 |
ATP1A2,ERBB4,CTNND2,TNIK,GPM6A |
2.445e-02 | -3.71 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 43 |
BMPR1B |
2.446e-02 | -3.71 | microglial cell proliferation | biological process | GO:0061518 | 9 | 1 | 18204 | 50 |
CLU |
2.446e-02 | -3.71 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 50 |
RYR3 |
2.446e-02 | -3.71 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 50 |
ATP13A4 |
2.446e-02 | -3.71 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 50 |
ATP1A2 |
2.446e-02 | -3.71 | macrophage proliferation | biological process | GO:0061517 | 9 | 1 | 18204 | 50 |
CLU |
2.446e-02 | -3.71 | cyclooxygenase pathway | biological process | GO:0019371 | 9 | 1 | 18204 | 50 |
PTGDS |
2.446e-02 | -3.71 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.459e-02 | -3.71 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 50 |
FBXL7 |
2.468e-02 | -3.70 | skeletal system morphogenesis | biological process | GO:0048705 | 228 | 3 | 18204 | 50 |
BMPR1B,SOX5,FGFR3 |
2.469e-02 | -3.70 | neck | COSMIC cancer mutations | neck | 1231 | 8 | 16828 | 49 |
GPC5,PREX2,CTNND2,TRPM3,FGFR3,ATP13A4,ATP1A2,ERBB4 |
2.479e-02 | -3.70 | DDX31 (DEAD-box helicase 31) | protein interactions | 64794 | 244 | 3 | 19454 | 50 |
PRKG1,CLU,CST3 |
2.487e-02 | -3.69 | positive regulation of lipid biosynthetic process | biological process | GO:0046889 | 89 | 2 | 18204 | 50 |
SORBS1,ZBTB20 |
2.495e-02 | -3.69 | axon | cellular component | GO:0030424 | 650 | 5 | 19108 | 49 |
GPM6A,SLC1A2,PARD3,CTNNA2,DTNA |
2.501e-02 | -3.69 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 50 |
SLC4A4 |
2.501e-02 | -3.69 | RFX_DNA_binding | pfam domains | PF02257 | 9 | 1 | 17795 | 50 |
RFX4 |
2.501e-02 | -3.69 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 50 |
BMPR1B |
2.504e-02 | -3.69 | upper_aerodigestive_tract-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-carcinoma | 383 | 4 | 16828 | 49 |
FGFR3,TNIK,ERBB4,MAML2 |
2.504e-02 | -3.69 | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
FGFR3,ERBB4,TNIK,MAML2 |
2.504e-02 | -3.69 | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
ERBB4,TNIK,FGFR3,MAML2 |
2.504e-02 | -3.69 | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
MAML2,ERBB4,TNIK,FGFR3 |
2.504e-02 | -3.69 | salivary_gland-carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma | 383 | 4 | 16828 | 49 |
FGFR3,ERBB4,TNIK,MAML2 |
2.521e-02 | -3.68 | actin filament bundle | cellular component | GO:0032432 | 96 | 2 | 19108 | 49 |
ABLIM1,SORBS1 |
2.529e-02 | -3.68 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 19 | 19454 | 50 |
SLC4A4,TNIK,PARD3,MACF1,CTNND2,CLU,CTNNA2,ACSS1,CST3,NTM,SLC1A3,LRIG1,LSAMP,MSI2,GPM6A,PTPRZ1,DTNA,ATP1A2,PITPNC1 |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.539e-02 | -3.67 | regulation of purine nucleotide metabolic process | biological process | GO:1900542 | 90 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
PTPRZ1 |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 50 |
GLIS3 |
2.541e-02 | -3.67 | PTPRT (protein tyrosine phosphatase receptor type T) | protein interactions | 11122 | 10 | 1 | 19454 | 50 |
ERBB4 |
2.541e-02 | -3.67 | EREG (epiregulin) | protein interactions | 2069 | 10 | 1 | 19454 | 50 |
ERBB4 |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.541e-02 | -3.67 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 50 |
ABLIM1 |
2.547e-02 | -3.67 | YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) | protein interactions | 7534 | 1138 | 7 | 19454 | 50 |
SORBS1,MACF1,PARD3,PARD3B,NHSL1,ABLIM1,PITPNC1 |
2.551e-02 | -3.67 | lipid binding | molecular function | GO:0008289 | 861 | 6 | 18094 | 48 |
PARD3,PARD3B,ATP1A2,PITPNC1,RORA,PTGDS |
2.566e-02 | -3.66 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 12 | 16828 | 49 |
NHSL1,ATP1A2,SOX5,CTNND2,TRPM3,RFX4,ZBTB20,ZNRF3,PTPRZ1,SLC1A2,LRIG1,MAML2 |
2.581e-02 | -3.66 | PLCB3 (phospholipase C beta 3) | protein interactions | 5331 | 97 | 2 | 19454 | 50 |
PRKG1,PARD3 |
2.581e-02 | -3.66 | SOCS3 (suppressor of cytokine signaling 3) | protein interactions | 9021 | 97 | 2 | 19454 | 50 |
ERBB4,FGFR3 |
2.581e-02 | -3.66 | BTG3 (BTG anti-proliferation factor 3) | protein interactions | 10950 | 97 | 2 | 19454 | 50 |
SPARCL1,CLU |
2.585e-02 | -3.66 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 50 |
TNIK,NFIA,SOX5 |
2.585e-02 | -3.66 | ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) | protein interactions | 25 | 248 | 3 | 19454 | 50 |
ERBB4,CTNND2,SORBS1 |
2.586e-02 | -3.66 | parotid | COSMIC cancer mutations | parotid | 578 | 5 | 16828 | 49 |
MAML2,FGFR3,ERBB4,TNIK,RYR3 |
2.589e-02 | -3.65 | shoulder | COSMIC cancer mutations | shoulder | 387 | 4 | 16828 | 49 |
ERBB4,MACF1,FGFR3,PREX2 |
2.591e-02 | -3.65 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.592e-02 | -3.65 | cellular response to BMP stimulus | biological process | GO:0071773 | 91 | 2 | 18204 | 50 |
NFIA,BMPR1B |
2.592e-02 | -3.65 | regulation of nucleotide metabolic process | biological process | GO:0006140 | 91 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
2.592e-02 | -3.65 | response to BMP | biological process | GO:0071772 | 91 | 2 | 18204 | 50 |
NFIA,BMPR1B |
2.609e-02 | -3.65 | PROTEIN_KINASE_DOM | prosite domains | PS50011 | 480 | 5 | 12186 | 43 |
TNIK,PRKG1,BMPR1B,ERBB4,FGFR3 |
2.610e-02 | -3.65 | cGMP signaling | KEGG pathways | hsa_M00694 | 9 | 1 | 7161 | 21 |
PRKG1 |
2.610e-02 | -3.65 | cGMP signaling | KEGG pathways | M00694 | 9 | 1 | 7161 | 21 |
PRKG1 |
2.621e-02 | -3.64 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 44 | 16828 | 49 |
NHSL1,FBXL7,SLC1A3,SOX5,TRPM3,CTNND2,RFX4,PRKG1,SLC4A4,ATP13A4,NKAIN3,FGFR3,CST3,PTPRZ1,SORBS1,ERBB4,BMPR1B,ZNRF3,CLU,GPC5,RORA,SLC1A2,LRIG1,GLIS3,TNIK,GPM6A,ATP1A2,ACSS1,TRPS1,PARD3B,SPARCL1,PREX2,CDH20,MACF1,NTM,HIF3A,ZBTB20,PARD3,NPAS3,MAML2,SFXN5,PTGDS,RYR3,LSAMP |
2.622e-02 | -3.64 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 48 |
ATP13A4 |
2.622e-02 | -3.64 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 48 |
PITPNC1 |
2.631e-02 | -3.64 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 50 |
GPM6A,LSAMP |
2.636e-02 | -3.64 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 37 |
MACF1 |
2.636e-02 | -3.64 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 37 |
BMPR1B |
2.637e-02 | -3.64 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 6 | 18204 | 50 |
TNIK,FGFR3,RYR3,PRKG1,PREX2,ATP1A2 |
2.645e-02 | -3.63 | protein tetramerization | biological process | GO:0051262 | 92 | 2 | 18204 | 50 |
TRPM3,RYR3 |
2.646e-02 | -3.63 | human chr2p13.2 | chromosome location | human chr2p13.2 | 14 | 1 | 26134 | 50 |
SFXN5 |
2.654e-02 | -3.63 | upper_arm | COSMIC cancer mutations | upper_arm | 582 | 5 | 16828 | 49 |
PREX2,SLC4A4,FGFR3,PARD3B,ERBB4 |
2.666e-02 | -3.62 | TGFBR1 (transforming growth factor beta receptor 1) | protein interactions | 7046 | 251 | 3 | 19454 | 50 |
CLU,BMPR1B,PREX2 |
2.668e-02 | -3.62 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | MIR_motif | interpro domains | IPR016093 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.680e-02 | -3.62 | ZFHX3 (zinc finger homeobox 3) | protein interactions | 463 | 99 | 2 | 19454 | 50 |
SOX5,TRPS1 |
2.681e-02 | -3.62 | Terminal pathway of complement | REACTOME pathways | R-HSA-166665 | 9 | 1 | 10285 | 31 |
CLU |
2.683e-02 | -3.62 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
2.693e-02 | -3.61 | behavior | biological process | GO:0007610 | 619 | 5 | 18204 | 50 |
SLC1A3,PTPRZ1,PREX2,ATP1A2,SLC1A2 |
2.693e-02 | -3.61 | CRX (cone-rod homeobox) | protein interactions | 1406 | 252 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
2.714e-02 | -3.61 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 50 |
SOX5 |
2.714e-02 | -3.61 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 1 | 18204 | 50 |
ATP1A2 |
2.714e-02 | -3.61 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 50 |
RYR3 |
2.714e-02 | -3.61 | otolith development | biological process | GO:0048840 | 10 | 1 | 18204 | 50 |
LRIG1 |
2.714e-02 | -3.61 | action potential propagation | biological process | GO:0098870 | 10 | 1 | 18204 | 50 |
ATP1A2 |
2.714e-02 | -3.61 | mitochondrial fragmentation involved in apoptotic process | biological process | GO:0043653 | 10 | 1 | 18204 | 50 |
ERBB4 |
2.719e-02 | -3.60 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 50 |
ERBB4,FGFR3 |
2.719e-02 | -3.60 | response to organic cyclic compound | biological process | GO:0014070 | 843 | 6 | 18204 | 50 |
RYR3,PTGDS,SLC1A2,ATP1A2,SLC1A3,RORA |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
ATP1A2,GPM6A |
2.741e-02 | -3.60 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 5 | 16828 | 49 |
CTNND2,TRPM3,PREX2,FGFR3,MACF1 |
2.756e-02 | -3.59 | protein localization to cell periphery | biological process | GO:1990778 | 238 | 3 | 18204 | 50 |
ERBB4,TNIK,MACF1 |
2.756e-02 | -3.59 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 50 |
DTNA,RYR3,ATP1A2 |
2.771e-02 | -3.59 | actin binding | molecular function | GO:0003779 | 434 | 4 | 18094 | 48 |
SORBS1,CTNNA2,MACF1,ABLIM1 |
2.775e-02 | -3.58 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 50 |
SLC4A4 |
2.775e-02 | -3.58 | MIR | pfam domains | PF02815 | 10 | 1 | 17795 | 50 |
RYR3 |
2.775e-02 | -3.58 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 50 |
NPAS3 |
2.776e-02 | -3.58 | DYNLL2 (dynein light chain LC8-type 2) | protein interactions | 140735 | 255 | 3 | 19454 | 50 |
TRPS1,NHSL1,NFIA |
2.781e-02 | -3.58 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 50 |
FGFR3,CTNNA2 |
2.781e-02 | -3.58 | ILKAP (ILK associated serine/threonine phosphatase) | protein interactions | 80895 | 101 | 2 | 19454 | 50 |
FGFR3,ERBB4 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.789e-02 | -3.58 | GATA_ZN_FINGER_1 | prosite domains | PS00344 | 8 | 1 | 12186 | 43 |
TRPS1 |
2.789e-02 | -3.58 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 43 |
ABLIM1 |
2.792e-02 | -3.58 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
NHSL1 |
2.792e-02 | -3.58 | MSRB1 (methionine sulfoxide reductase B1) | protein interactions | 51734 | 11 | 1 | 19454 | 50 |
CLU |
2.792e-02 | -3.58 | IRAG1 (inositol 1,4,5-triphosphate receptor associated 1) | protein interactions | 10335 | 11 | 1 | 19454 | 50 |
PRKG1 |
2.792e-02 | -3.58 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 50 |
ABLIM1 |
2.792e-02 | -3.58 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 50 |
FGFR3 |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | GAL3ST1 (galactose-3-O-sulfotransferase 1) | protein interactions | 9514 | 11 | 1 | 19454 | 50 |
LRIG1 |
2.792e-02 | -3.58 | PTGDR (prostaglandin D2 receptor) | protein interactions | 5729 | 11 | 1 | 19454 | 50 |
PTGDS |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.806e-02 | -3.57 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | REACTOME pathways | R-HSA-6811558 | 87 | 2 | 10285 | 31 |
ERBB4,FGFR3 |
2.809e-02 | -3.57 | enzyme-linked receptor protein signaling pathway | biological process | GO:0007167 | 626 | 5 | 18204 | 50 |
ERBB4,FGFR3,BMPR1B,NFIA,SORBS1 |
2.831e-02 | -3.56 | ankle | COSMIC cancer mutations | ankle | 398 | 4 | 16828 | 49 |
PREX2,PARD3,ERBB4,ATP13A4 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.849e-02 | -3.56 | transcription regulator activity | molecular function | GO:0140110 | 1937 | 10 | 18094 | 48 |
SOX5,NPAS3,GLIS3,ZBTB20,RFX4,HIF3A,MAML2,NFIA,TRPS1,RORA |
2.862e-02 | -3.55 | pleura | COSMIC cancer mutations | pleura | 4914 | 21 | 16828 | 49 |
NTM,HIF3A,PTPRZ1,ERBB4,BMPR1B,ZNRF3,MAML2,CLU,PITPNC1,RORA,LRIG1,MSI2,TNIK,FBXL7,TRPS1,SOX5,CTNND2,PREX2,PRKG1,ATP13A4,FGFR3 |
2.865e-02 | -3.55 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 46 | 16828 | 49 |
CTNND2,SOX5,PRKG1,RFX4,ATP13A4,FGFR3,SLC1A3,GPC5,LRIG1,RORA,TNIK,GLIS3,PTPRZ1,ERBB4,PREX2,TRPS1,SFXN5,MAML2,PTGDS,PITPNC1,LSAMP,HIF3A,NTM,ABLIM1,DTNA,ZBTB20,PARD3,NPAS3,TRPM3,SLC4A4,FBXL7,CLU,SLC1A2,SORBS1,ZNRF3,BMPR1B,NFIA,CDH20,MACF1,ATP1A2,GPM6A,ACSS1,SPARCL1,PARD3B,RYR3,MSI2 |
2.873e-02 | -3.55 | LIPOCALIN | prints domains | PR00179 | 8 | 1 | 5227 | 19 |
PTGDS |
2.873e-02 | -3.55 | GATAZNFINGER | prints domains | PR00619 | 8 | 1 | 5227 | 19 |
TRPS1 |
2.875e-02 | -3.55 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.875e-02 | -3.55 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 49 |
FGFR3 |
2.880e-02 | -3.55 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 48 |
SLC1A2 |
2.884e-02 | -3.55 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 50 |
BMPR1B,GPM6A |
2.889e-02 | -3.54 | MARK2 (microtubule affinity regulating kinase 2) | protein interactions | 2011 | 259 | 3 | 19454 | 50 |
PARD3,PARD3B,DTNA |
2.893e-02 | -3.54 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
NTM,LSAMP,LRIG1,FGFR3 |
2.917e-02 | -3.53 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
2.917e-02 | -3.53 | nerve development | biological process | GO:0021675 | 97 | 2 | 18204 | 50 |
LRIG1,SLC1A3 |
2.933e-02 | -3.53 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 43 |
SLC4A4 |
2.946e-02 | -3.52 | DIRAS3 (DIRAS family GTPase 3) | protein interactions | 9077 | 261 | 3 | 19454 | 50 |
MACF1,PARD3,DTNA |
2.972e-02 | -3.52 | kidney-carcinoma | COSMIC cancer mutations | kidney-carcinoma | 3720 | 17 | 16828 | 49 |
MAML2,PITPNC1,LRIG1,RORA,MSI2,TNIK,HIF3A,PTPRZ1,ERBB4,BMPR1B,SOX5,CTNND2,PREX2,PRKG1,FGFR3,FBXL7,TRPS1 |
2.975e-02 | -3.51 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 31 |
FGFR3 |
2.975e-02 | -3.51 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 1 | 10285 | 31 |
SLC4A4 |
2.975e-02 | -3.51 | PI3K events in ERBB4 signaling | REACTOME pathways | R-HSA-1250342 | 10 | 1 | 10285 | 31 |
ERBB4 |
2.981e-02 | -3.51 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 50 |
ATP13A4 |
2.981e-02 | -3.51 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 50 |
RYR3 |
2.981e-02 | -3.51 | negative regulation of platelet aggregation | biological process | GO:0090331 | 11 | 1 | 18204 | 50 |
PRKG1 |
2.981e-02 | -3.51 | physiological muscle hypertrophy | biological process | GO:0003298 | 11 | 1 | 18204 | 50 |
PRKG1 |
2.981e-02 | -3.51 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 50 |
BMPR1B |
2.981e-02 | -3.51 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | physiological cardiac muscle hypertrophy | biological process | GO:0003301 | 11 | 1 | 18204 | 50 |
PRKG1 |
2.981e-02 | -3.51 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | cell growth involved in cardiac muscle cell development | biological process | GO:0061049 | 11 | 1 | 18204 | 50 |
PRKG1 |
2.988e-02 | -3.51 | PI3K/AKT Signaling in Cancer | REACTOME pathways | R-HSA-2219528 | 90 | 2 | 10285 | 31 |
FGFR3,ERBB4 |
2.988e-02 | -3.51 | IRF2BP2 (interferon regulatory factor 2 binding protein 2) | protein interactions | 359948 | 105 | 2 | 19454 | 50 |
ERBB4,NFIA |
2.988e-02 | -3.51 | BEND3 (BEN domain containing 3) | protein interactions | 57673 | 105 | 2 | 19454 | 50 |
TRPS1,TNIK |
3.007e-02 | -3.50 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 37 |
ABLIM1 |
3.028e-02 | -3.50 | bone morphogenesis | biological process | GO:0060349 | 99 | 2 | 18204 | 50 |
BMPR1B,FGFR3 |
3.030e-02 | -3.50 | abdomen | COSMIC cancer mutations | abdomen | 603 | 5 | 16828 | 49 |
CTNND2,PREX2,LRIG1,ERBB4,FGFR3 |
3.034e-02 | -3.50 | response to wounding | biological process | GO:0009611 | 431 | 4 | 18204 | 50 |
MACF1,SLC1A3,NFIA,SLC1A2 |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.039e-02 | -3.49 | skin-hand-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-hand-carcinoma-squamous_cell_carcinoma | 407 | 4 | 16828 | 49 |
SLC4A4,FGFR3,ERBB4,HIF3A |
3.042e-02 | -3.49 | OAS2 (2'-5'-oligoadenylate synthetase 2) | protein interactions | 4939 | 12 | 1 | 19454 | 50 |
PRKG1 |
3.042e-02 | -3.49 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 50 |
BMPR1B |
3.042e-02 | -3.49 | TREM2 (triggering receptor expressed on myeloid cells 2) | protein interactions | 54209 | 12 | 1 | 19454 | 50 |
CLU |
3.042e-02 | -3.49 | LGR5 (leucine rich repeat containing G protein-coupled receptor 5) | protein interactions | 8549 | 12 | 1 | 19454 | 50 |
ZNRF3 |
3.042e-02 | -3.49 | IL15 (interleukin 15) | protein interactions | 3600 | 12 | 1 | 19454 | 50 |
LRIG1 |
3.042e-02 | -3.49 | PTPN20 (protein tyrosine phosphatase non-receptor type 20) | protein interactions | 26095 | 12 | 1 | 19454 | 50 |
ERBB4 |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.042e-02 | -3.49 | MMP25 (matrix metallopeptidase 25) | protein interactions | 64386 | 12 | 1 | 19454 | 50 |
CLU |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.042e-02 | -3.49 | Pard6b (par-6 family cell polarity regulator beta) | protein interactions | 58220 | 12 | 1 | 19454 | 50 |
PARD3 |
3.042e-02 | -3.49 | SMIM20 (small integral membrane protein 20) | protein interactions | 389203 | 12 | 1 | 19454 | 50 |
ERBB4 |
3.049e-02 | -3.49 | PAS_11 | pfam domains | PF14598 | 11 | 1 | 17795 | 50 |
HIF3A |
3.049e-02 | -3.49 | LRRCT | pfam domains | PF01463 | 11 | 1 | 17795 | 50 |
LRIG1 |
3.079e-02 | -3.48 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 50 |
RYR3,ATP13A4,SLC1A3,ATP1A2 |
3.087e-02 | -3.48 | eye | COSMIC cancer mutations | eye | 606 | 5 | 16828 | 49 |
PREX2,TRPM3,CTNND2,MACF1,FGFR3 |
3.105e-02 | -3.47 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 2 | 7161 | 21 |
SLC4A4,ATP1A2 |
3.105e-02 | -3.47 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 2 | 7161 | 21 |
ATP1A2,SLC4A4 |
3.111e-02 | -3.47 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 31 |
NTM,LSAMP |
3.132e-02 | -3.46 | RFX_DBD | prosite domains | PS51526 | 9 | 1 | 12186 | 43 |
RFX4 |
3.132e-02 | -3.46 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 43 |
CST3 |
3.142e-02 | -3.46 | regulation of glucose metabolic process | biological process | GO:0010906 | 101 | 2 | 18204 | 50 |
SORBS1,RORA |
3.142e-02 | -3.46 | regulation of carbohydrate biosynthetic process | biological process | GO:0043255 | 101 | 2 | 18204 | 50 |
PRKG1,SORBS1 |
3.147e-02 | -3.46 | PAX8 (paired box 8) | protein interactions | 7849 | 108 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.147e-02 | -3.46 | EN1 (engrailed homeobox 1) | protein interactions | 2019 | 108 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.147e-02 | -3.46 | BIN1 (bridging integrator 1) | protein interactions | 274 | 108 | 2 | 19454 | 50 |
GPM6A,CLU |
3.157e-02 | -3.46 | calcium ion transport | biological process | GO:0006816 | 251 | 3 | 18204 | 50 |
RYR3,GPM6A,TRPM3 |
3.158e-02 | -3.46 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 49 |
FGFR3 |
3.166e-02 | -3.45 | Circadian entrainment | KEGG pathways | hsa04713 | 96 | 2 | 7161 | 21 |
PRKG1,RYR3 |
3.166e-02 | -3.45 | Circadian entrainment | KEGG pathways | ko04713 | 96 | 2 | 7161 | 21 |
RYR3,PRKG1 |
3.193e-02 | -3.44 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 50 |
NFIA |
3.193e-02 | -3.44 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 50 |
BMPR1B |
3.193e-02 | -3.44 | Lipocalin | interpro domains | IPR002345 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | Lipocalin_CS | interpro domains | IPR022272 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 37 | 16828 | 49 |
ERBB4,PTPRZ1,GLIS3,TNIK,SLC1A2,LRIG1,RORA,GPC5,SLC1A3,NHSL1,FBXL7,NKAIN3,SLC4A4,ATP13A4,RFX4,PRKG1,SOX5,TRPM3,CTNND2,NPAS3,PARD3,NTM,ABLIM1,HIF3A,MSI2,RYR3,LSAMP,MAML2,SFXN5,PARD3B,SPARCL1,ACSS1,ATP1A2,MACF1,CDH20,PREX2,NFIA |
3.193e-02 | -3.44 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 37 | 16828 | 49 |
NFIA,PREX2,CDH20,MACF1,ATP1A2,ACSS1,SPARCL1,PARD3B,MAML2,SFXN5,RYR3,LSAMP,MSI2,HIF3A,NTM,ABLIM1,PARD3,NPAS3,TRPM3,CTNND2,SOX5,PRKG1,RFX4,ATP13A4,SLC4A4,NKAIN3,FBXL7,NHSL1,SLC1A3,GPC5,RORA,LRIG1,SLC1A2,GLIS3,TNIK,PTPRZ1,ERBB4 |
3.200e-02 | -3.44 | PRR20A (proline rich 20A) | protein interactions | 122183 | 109 | 2 | 19454 | 50 |
SOX5,TRPM3 |
3.207e-02 | -3.44 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 48 | 16828 | 49 |
SLC1A3,NHSL1,FGFR3,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,ERBB4,PTPRZ1,CST3,GLIS3,TNIK,RORA,LRIG1,GPC5,TRPS1,PREX2,PARD3,NPAS3,ZBTB20,DTNA,NTM,ABLIM1,HIF3A,LSAMP,PITPNC1,PTGDS,MAML2,SFXN5,FBXL7,SLC4A4,TRPM3,BMPR1B,ZNRF3,SORBS1,SLC1A2,CLU,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,MACF1,CDH20,NFIA,MSI2,RYR3 |
3.207e-02 | -3.44 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 48 | 16828 | 49 |
RYR3,MSI2,ATP1A2,GPM6A,ACSS1,SPARCL1,PARD3B,NFIA,CDH20,MACF1,SORBS1,ZNRF3,BMPR1B,CLU,SLC1A2,FBXL7,TRPM3,SLC4A4,HIF3A,NTM,ABLIM1,DTNA,ZBTB20,NPAS3,PARD3,MAML2,SFXN5,PITPNC1,PTGDS,LSAMP,TRPS1,PREX2,CST3,PTPRZ1,ERBB4,GPC5,RORA,LRIG1,GLIS3,TNIK,NHSL1,SLC1A3,CTNND2,SOX5,PRKG1,RFX4,ATP13A4,FGFR3 |
3.237e-02 | -3.43 | Negative regulation of the PI3K/AKT network | REACTOME pathways | R-HSA-199418 | 94 | 2 | 10285 | 31 |
FGFR3,ERBB4 |
3.248e-02 | -3.43 | auditory behavior | biological process | GO:0031223 | 12 | 1 | 18204 | 50 |
SLC1A3 |
3.248e-02 | -3.43 | negative regulation of smooth muscle contraction | biological process | GO:0045986 | 12 | 1 | 18204 | 50 |
PRKG1 |
3.248e-02 | -3.43 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 50 |
SLC1A2 |
3.248e-02 | -3.43 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 50 |
BMPR1B |
3.248e-02 | -3.43 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 50 |
BMPR1B |
3.248e-02 | -3.43 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 50 |
CST3 |
3.248e-02 | -3.43 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 50 |
CST3 |
3.250e-02 | -3.43 | DNA-binding transcription repressor activity, RNA polymerase II-specific | molecular function | GO:0001227 | 263 | 3 | 18094 | 48 |
TRPS1,ZBTB20,GLIS3 |
3.254e-02 | -3.43 | LZTR1 (leucine zipper like post translational regulator 1) | protein interactions | 8216 | 110 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
3.255e-02 | -3.43 | cellular component assembly | biological process | GO:0022607 | 2472 | 12 | 18204 | 50 |
CDH20,CLU,ERBB4,PARD3,TNIK,TRPM3,GPM6A,SLC1A2,SORBS1,ABLIM1,RFX4,RYR3 |
3.257e-02 | -3.42 | cerebellum development | biological process | GO:0021549 | 103 | 2 | 18204 | 50 |
PRKG1,RORA |
3.271e-02 | -3.42 | RDX (radixin) | protein interactions | 5962 | 272 | 3 | 19454 | 50 |
MACF1,ABLIM1,FGFR3 |
3.276e-02 | -3.42 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 48 |
RORA,ATP1A2 |
3.291e-02 | -3.41 | JAM2 (junctional adhesion molecule 2) | protein interactions | 58494 | 13 | 1 | 19454 | 50 |
PARD3 |
3.291e-02 | -3.41 | PLPPR4 (phospholipid phosphatase related 4) | protein interactions | 9890 | 13 | 1 | 19454 | 50 |
ZNRF3 |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.291e-02 | -3.41 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 50 |
NFIA |
3.310e-02 | -3.41 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 46 | 16828 | 49 |
SLC1A3,RFX4,PRKG1,SOX5,CTNND2,FGFR3,ATP13A4,PTPRZ1,ERBB4,GPC5,TNIK,GLIS3,RORA,LRIG1,TRPS1,PREX2,DTNA,ABLIM1,NTM,HIF3A,PARD3,NPAS3,ZBTB20,PITPNC1,PTGDS,MAML2,SFXN5,LSAMP,FBXL7,TRPM3,SLC4A4,SORBS1,BMPR1B,ZNRF3,CLU,SLC1A2,ACSS1,GPM6A,ATP1A2,PARD3B,SPARCL1,NFIA,MACF1,CDH20,RYR3,MSI2 |
3.310e-02 | -3.41 | bladder | COSMIC cancer mutations | bladder | 14112 | 46 | 16828 | 49 |
BMPR1B,ZNRF3,SORBS1,SLC1A2,CLU,FBXL7,SLC4A4,TRPM3,MSI2,RYR3,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,MACF1,CDH20,NFIA,ERBB4,PTPRZ1,TNIK,GLIS3,RORA,LRIG1,GPC5,SLC1A3,FGFR3,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,PARD3,NPAS3,ZBTB20,DTNA,NTM,ABLIM1,HIF3A,LSAMP,PTGDS,PITPNC1,MAML2,SFXN5,TRPS1,PREX2 |
3.315e-02 | -3.41 | regulation of steroid metabolic process | biological process | GO:0019218 | 104 | 2 | 18204 | 50 |
PRKG1,RORA |
3.318e-02 | -3.41 | protein complex oligomerization | biological process | GO:0051259 | 256 | 3 | 18204 | 50 |
TRPM3,RYR3,SLC1A2 |
3.321e-02 | -3.40 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 50 |
NFIA |
3.342e-02 | -3.40 | EV release from cardiac cells and their functional effects | WikiPathways | WP3297 | 9 | 1 | 5310 | 20 |
ERBB4 |
3.351e-02 | -3.40 | cell fate commitment | biological process | GO:0045165 | 257 | 3 | 18204 | 50 |
ERBB4,SOX5,NFIA |
3.363e-02 | -3.39 | TSC22D4 (TSC22 domain family member 4) | protein interactions | 81628 | 112 | 2 | 19454 | 50 |
ABLIM1,CLU |
3.363e-02 | -3.39 | EDA (ectodysplasin A) | protein interactions | 1896 | 112 | 2 | 19454 | 50 |
GPM6A,ERBB4 |
3.363e-02 | -3.39 | CEP170P1 (centrosomal protein 170 pseudogene 1) | protein interactions | 645455 | 112 | 2 | 19454 | 50 |
MACF1,TRPS1 |
3.377e-02 | -3.39 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 37 |
SPARCL1 |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.395e-02 | -3.38 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 48 |
BMPR1B |
3.395e-02 | -3.38 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 48 |
ATP1A2 |
3.395e-02 | -3.38 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 48 |
SLC4A4 |
3.405e-02 | -3.38 | NR3C1 (nuclear receptor subfamily 3 group C member 1) | protein interactions | 2908 | 950 | 6 | 19454 | 50 |
ATP13A4,SLC1A3,NFIA,ZBTB20,CTNND2,TRPS1 |
3.418e-02 | -3.38 | YWHAG (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma) | protein interactions | 7532 | 1211 | 7 | 19454 | 50 |
PARD3,MACF1,SORBS1,ABLIM1,PITPNC1,PARD3B,NHSL1 |
3.418e-02 | -3.38 | GFI1B (growth factor independent 1B transcriptional repressor) | protein interactions | 8328 | 113 | 2 | 19454 | 50 |
DTNA,ZNRF3 |
3.427e-02 | -3.37 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 13 | 16828 | 49 |
NHSL1,ATP1A2,FGFR3,RFX4,SOX5,CTNND2,TRPM3,ZNRF3,ZBTB20,PTPRZ1,SLC1A2,LRIG1,MAML2 |
3.432e-02 | -3.37 | organ growth | biological process | GO:0035265 | 106 | 2 | 18204 | 50 |
PRKG1,FGFR3 |
3.439e-02 | -3.37 | ear | COSMIC cancer mutations | ear | 624 | 5 | 16828 | 49 |
PRKG1,ZBTB20,SPARCL1,FGFR3,NPAS3 |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.440e-02 | -3.37 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.455e-02 | -3.37 | phosphotransferase activity, alcohol group as acceptor | molecular function | GO:0016773 | 686 | 5 | 18094 | 48 |
ERBB4,BMPR1B,PRKG1,TNIK,FGFR3 |
3.459e-02 | -3.36 | plasma membrane raft | cellular component | GO:0044853 | 114 | 2 | 19108 | 49 |
ATP1A2,SORBS1 |
3.459e-02 | -3.36 | small molecule binding | molecular function | GO:0036094 | 6197 | 23 | 18094 | 48 |
ATP1A2,FGFR3,TRPS1,GLIS3,PITPNC1,MACF1,DTNA,SLC1A2,PTGDS,ATP13A4,ZNRF3,ZBTB20,PARD3,ACSS1,RORA,PRKG1,SLC1A3,ABLIM1,SPARCL1,TNIK,BMPR1B,ERBB4,RYR3 |
3.474e-02 | -3.36 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 2 | 19454 | 50 |
ZBTB20,MACF1 |
3.474e-02 | -3.36 | MIR | prosite domains | PS50919 | 10 | 1 | 12186 | 43 |
RYR3 |
3.487e-02 | -3.36 | RNA polymerase II cis-regulatory region sequence-specific DNA binding | molecular function | GO:0000978 | 1180 | 7 | 18094 | 48 |
HIF3A,RFX4,ZBTB20,GLIS3,SOX5,RORA,NFIA |
3.500e-02 | -3.35 | Ion_trans_dom | interpro domains | IPR005821 | 109 | 2 | 18521 | 50 |
TRPM3,RYR3 |
3.510e-02 | -3.35 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 43 |
CTNNA2 |
3.514e-02 | -3.35 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 50 |
RORA |
3.514e-02 | -3.35 | negative regulation of homotypic cell-cell adhesion | biological process | GO:0034111 | 13 | 1 | 18204 | 50 |
PRKG1 |
3.514e-02 | -3.35 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 50 |
CTNNA2 |
3.514e-02 | -3.35 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 50 |
RORA |
3.514e-02 | -3.35 | olfactory bulb interneuron differentiation | biological process | GO:0021889 | 13 | 1 | 18204 | 50 |
ERBB4 |
3.514e-02 | -3.35 | negative regulation of amyloid fibril formation | biological process | GO:1905907 | 13 | 1 | 18204 | 50 |
CLU |
3.514e-02 | -3.35 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 50 |
NFIA |
3.527e-02 | -3.34 | ACTB (actin beta) | protein interactions | 60 | 958 | 6 | 19454 | 50 |
SORBS1,SFXN5,MACF1,DTNA,NHSL1,ABLIM1 |
3.530e-02 | -3.34 | TBXT (T-box transcription factor T) | protein interactions | 6862 | 115 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.530e-02 | -3.34 | CDH2 (cadherin 2) | protein interactions | 1000 | 115 | 2 | 19454 | 50 |
CTNND2,PARD3 |
3.532e-02 | -3.34 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 49 |
CLU |
3.532e-02 | -3.34 | Ethanol Degradation | SMPDB pathways | SMP0000449 | 7 | 1 | 1369 | 7 |
ACSS1 |
3.532e-02 | -3.34 | g-Secretase Mediated ErbB4 Signalling Pathway | SMPDB pathways | SMP0089975 | 7 | 1 | 1369 | 7 |
ERBB4 |
3.538e-02 | -3.34 | DNA-binding transcription repressor activity | molecular function | GO:0001217 | 272 | 3 | 18094 | 48 |
TRPS1,ZBTB20,GLIS3 |
3.540e-02 | -3.34 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 50 |
BMPR1B |
3.540e-02 | -3.34 | MB (myoglobin) | protein interactions | 4151 | 14 | 1 | 19454 | 50 |
MAML2 |
3.540e-02 | -3.34 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 50 |
FGFR3 |
3.540e-02 | -3.34 | GAGE1 (G antigen 1) | protein interactions | 2543 | 14 | 1 | 19454 | 50 |
PRKG1 |
3.540e-02 | -3.34 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 1 | 19454 | 50 |
ZBTB20 |
3.540e-02 | -3.34 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 1 | 19454 | 50 |
CST3 |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
MACF1 |
3.540e-02 | -3.34 | Stag2 (STAG2 cohesin complex component) | protein interactions | 20843 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 50 |
GLIS3 |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | RSPO1 (R-spondin 1) | protein interactions | 284654 | 14 | 1 | 19454 | 50 |
ZNRF3 |
3.540e-02 | -3.34 | Aifm1 (apoptosis-inducing factor, mitochondrion-associated 1) | protein interactions | 26926 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | C9 (complement C9) | protein interactions | 735 | 14 | 1 | 19454 | 50 |
CLU |
3.553e-02 | -3.34 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 48 | 16828 | 49 |
ERBB4,PTPRZ1,TNIK,GLIS3,RORA,LRIG1,GPC5,SLC1A3,NHSL1,NKAIN3,FGFR3,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,NPAS3,PARD3,ZBTB20,DTNA,ABLIM1,NTM,HIF3A,LSAMP,PITPNC1,PTGDS,MAML2,SFXN5,TRPS1,PREX2,BMPR1B,ZNRF3,SORBS1,SLC1A2,CLU,FBXL7,SLC4A4,TRPM3,RYR3,MSI2,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,MACF1,CDH20,NFIA |
3.559e-02 | -3.34 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 31 |
GPC5 |
3.559e-02 | -3.34 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 31 |
GPC5 |
3.559e-02 | -3.34 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 31 |
FGFR3 |
3.559e-02 | -3.34 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 31 |
FGFR3 |
3.559e-02 | -3.34 | Ethanol oxidation | REACTOME pathways | R-HSA-71384 | 12 | 1 | 10285 | 31 |
ACSS1 |
3.559e-02 | -3.34 | Regulation of gene expression by Hypoxia-inducible Factor | REACTOME pathways | R-HSA-1234158 | 12 | 1 | 10285 | 31 |
HIF3A |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.579e-02 | -3.33 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 19 |
SLC4A4 |
3.586e-02 | -3.33 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 2 | 19454 | 50 |
SPARCL1,MACF1 |
3.586e-02 | -3.33 | RBBP8 (RB binding protein 8, endonuclease) | protein interactions | 5932 | 116 | 2 | 19454 | 50 |
CTNNA2,CLU |
3.610e-02 | -3.32 | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | 3507 | 16 | 16828 | 49 |
ATP1A2,PARD3B,PRKG1,PREX2,CTNND2,TRPM3,MACF1,SLC4A4,PTPRZ1,PARD3,NPAS3,ERBB4,ZBTB20,GPC5,RYR3,LRIG1 |
3.612e-02 | -3.32 | positive regulation of tumor necrosis factor production | biological process | GO:0032760 | 109 | 2 | 18204 | 50 |
CLU,ZBTB20 |
3.620e-02 | -3.32 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 3 | 18204 | 50 |
ZNRF3,CTNND2,GPC5 |
3.642e-02 | -3.31 | ELK3 (ETS transcription factor ELK3) | protein interactions | 2004 | 117 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.652e-02 | -3.31 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 48 |
MACF1 |
3.668e-02 | -3.31 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 5 | 19454 | 50 |
DTNA,TNIK,SLC1A3,PARD3,MACF1 |
3.670e-02 | -3.31 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 3 | 18094 | 48 |
PARD3,PARD3B,PITPNC1 |
3.678e-02 | -3.30 | bHLH_dom | interpro domains | IPR011598 | 112 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.678e-02 | -3.30 | HLH_DNA-bd_sf | interpro domains | IPR036638 | 112 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.702e-02 | -3.30 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 37 |
ERBB4,FGFR3 |
3.717e-02 | -3.29 | regulation of phosphate metabolic process | biological process | GO:0019220 | 1154 | 7 | 18204 | 50 |
TNIK,SLC4A4,PARD3,FGFR3,ERBB4,PRKG1,ZBTB20 |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.732e-02 | -3.29 | regulation of phosphorus metabolic process | biological process | GO:0051174 | 1155 | 7 | 18204 | 50 |
ZBTB20,PRKG1,TNIK,SLC4A4,ERBB4,PARD3,FGFR3 |
3.745e-02 | -3.28 | MIR | smart domains | SM00472 | 10 | 1 | 9717 | 37 |
RYR3 |
3.754e-02 | -3.28 | basal plasma membrane | cellular component | GO:0009925 | 288 | 3 | 19108 | 49 |
SLC1A3,ERBB4,SLC4A4 |
3.759e-02 | -3.28 | human chr8p21.1 | chromosome location | human chr8p21.1 | 20 | 1 | 26134 | 50 |
CLU |
3.762e-02 | -3.28 | phosphate-containing compound metabolic process | biological process | GO:0006796 | 1681 | 9 | 18204 | 50 |
ACSS1,ERBB4,BMPR1B,FGFR3,TNIK,PRKG1,RORA,ATP1A2,PTPRZ1 |
3.764e-02 | -3.28 | Ion_trans | pfam domains | PF00520 | 109 | 2 | 17795 | 50 |
TRPM3,RYR3 |
3.768e-02 | -3.28 | ATP binding | molecular function | GO:0005524 | 1467 | 8 | 18094 | 48 |
FGFR3,ATP13A4,ATP1A2,ACSS1,TNIK,PRKG1,ERBB4,BMPR1B |
3.771e-02 | -3.28 | protein localization to membrane | biological process | GO:0072657 | 462 | 4 | 18204 | 50 |
TNIK,MACF1,ERBB4,PARD3 |
3.779e-02 | -3.28 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.779e-02 | -3.28 | neurotransmitter receptor localization to postsynaptic specialization membrane | biological process | GO:0099645 | 14 | 1 | 18204 | 50 |
ERBB4 |
3.779e-02 | -3.28 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 50 |
SLC1A2 |
3.779e-02 | -3.28 | protein localization to postsynaptic specialization membrane | biological process | GO:0099633 | 14 | 1 | 18204 | 50 |
ERBB4 |
3.779e-02 | -3.28 | acetyl-CoA biosynthetic process | biological process | GO:0006085 | 14 | 1 | 18204 | 50 |
ACSS1 |
3.779e-02 | -3.28 | mechanosensory behavior | biological process | GO:0007638 | 14 | 1 | 18204 | 50 |
SLC1A3 |
3.779e-02 | -3.28 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 50 |
RYR3 |
3.779e-02 | -3.28 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.788e-02 | -3.27 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 50 |
BMPR1B |
3.788e-02 | -3.27 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 50 |
FGFR3 |
3.788e-02 | -3.27 | NPR1 (natriuretic peptide receptor 1) | protein interactions | 4881 | 15 | 1 | 19454 | 50 |
PRKG1 |
3.788e-02 | -3.27 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 1 | 19454 | 50 |
CLU |
3.814e-02 | -3.27 | cis-regulatory region sequence-specific DNA binding | molecular function | GO:0000987 | 1203 | 7 | 18094 | 48 |
SOX5,GLIS3,RFX4,HIF3A,ZBTB20,NFIA,RORA |
3.815e-02 | -3.27 | LIPOCALIN | prosite domains | PS00213 | 11 | 1 | 12186 | 43 |
PTGDS |
3.815e-02 | -3.27 | GATA_ZN_FINGER_2 | prosite domains | PS50114 | 11 | 1 | 12186 | 43 |
TRPS1 |
3.819e-02 | -3.27 | membrane raft | cellular component | GO:0045121 | 290 | 3 | 19108 | 49 |
SLC1A2,SORBS1,ATP1A2 |
3.829e-02 | -3.26 | carboxylic acid biosynthetic process | biological process | GO:0046394 | 271 | 3 | 18204 | 50 |
PTGDS,SLC1A3,ACSS1 |
3.850e-02 | -3.26 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.850e-02 | -3.26 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.850e-02 | -3.26 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.850e-02 | -3.26 | Notch-HLH transcription pathway | REACTOME pathways | R-HSA-350054 | 13 | 1 | 10285 | 31 |
MAML2 |
3.850e-02 | -3.26 | ERBB2 Activates PTK6 Signaling | REACTOME pathways | R-HSA-8847993 | 13 | 1 | 10285 | 31 |
ERBB4 |
3.850e-02 | -3.26 | NOTCH2 intracellular domain regulates transcription | REACTOME pathways | R-HSA-2197563 | 13 | 1 | 10285 | 31 |
MAML2 |
3.856e-02 | -3.26 | metencephalon development | biological process | GO:0022037 | 113 | 2 | 18204 | 50 |
RORA,PRKG1 |
3.856e-02 | -3.26 | positive regulation of tumor necrosis factor superfamily cytokine production | biological process | GO:1903557 | 113 | 2 | 18204 | 50 |
ZBTB20,CLU |
3.864e-02 | -3.25 | GATA | pfam domains | PF00320 | 14 | 1 | 17795 | 50 |
TRPS1 |
3.881e-02 | -3.25 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 49 |
PARD3B,HIF3A |
3.881e-02 | -3.25 | Endocytosis | KEGG pathways | ko04144 | 260 | 3 | 7161 | 21 |
ERBB4,FGFR3,PARD3 |
3.881e-02 | -3.25 | Endocytosis | KEGG pathways | hsa04144 | 260 | 3 | 7161 | 21 |
ERBB4,FGFR3,PARD3 |
3.885e-02 | -3.25 | membrane microdomain | cellular component | GO:0098857 | 292 | 3 | 19108 | 49 |
SLC1A2,SORBS1,ATP1A2 |
3.893e-02 | -3.25 | Stimuli-sensing channels | REACTOME pathways | R-HSA-2672351 | 104 | 2 | 10285 | 31 |
TRPM3,RYR3 |
3.908e-02 | -3.24 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 48 |
PITPNC1 |
3.908e-02 | -3.24 | AMP binding | molecular function | GO:0016208 | 15 | 1 | 18094 | 48 |
ACSS1 |
3.914e-02 | -3.24 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 3 | 16828 | 49 |
PTPRZ1,SLC4A4,ATP13A4 |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
DTNA,NHSL1 |
3.936e-02 | -3.24 | organic acid biosynthetic process | biological process | GO:0016053 | 274 | 3 | 18204 | 50 |
ACSS1,SLC1A3,PTGDS |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.943e-02 | -3.23 | cell migration | biological process | GO:0016477 | 921 | 6 | 18204 | 50 |
PRKG1,ERBB4,CTNNA2,CDH20,GPC5,GPM6A |
3.967e-02 | -3.23 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 46 | 16828 | 49 |
NKAIN3,FGFR3,ATP13A4,RFX4,PRKG1,SOX5,CTNND2,SLC1A3,NHSL1,TNIK,GLIS3,LRIG1,RORA,GPC5,ERBB4,PTPRZ1,PREX2,TRPS1,LSAMP,PITPNC1,MAML2,SFXN5,NPAS3,PARD3,ZBTB20,DTNA,ABLIM1,NTM,HIF3A,SLC4A4,TRPM3,FBXL7,SLC1A2,CLU,BMPR1B,ZNRF3,SORBS1,MACF1,CDH20,NFIA,PARD3B,SPARCL1,ACSS1,GPM6A,ATP1A2,RYR3 |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | Znf_GATA | interpro domains | IPR000679 | 15 | 1 | 18521 | 50 |
TRPS1 |
3.981e-02 | -3.22 | fatty acid biosynthetic process | biological process | GO:0006633 | 115 | 2 | 18204 | 50 |
PTGDS,ACSS1 |
3.988e-02 | -3.22 | EF_HAND_2 | prosite domains | PS50222 | 215 | 3 | 12186 | 43 |
SPARCL1,RYR3,MACF1 |
3.988e-02 | -3.22 | PAX7 (paired box 7) | protein interactions | 5081 | 123 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.002e-02 | -3.22 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.027e-02 | -3.21 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 49 |
TNIK |
4.028e-02 | -3.21 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 7 |
FGFR3 |
4.035e-02 | -3.21 | GABRR1 (gamma-aminobutyric acid type A receptor subunit rho1) | protein interactions | 2569 | 16 | 1 | 19454 | 50 |
PRKG1 |
4.035e-02 | -3.21 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | FZD4 (frizzled class receptor 4) | protein interactions | 8322 | 16 | 1 | 19454 | 50 |
ZNRF3 |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.035e-02 | -3.21 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 50 |
ZBTB20 |
4.035e-02 | -3.21 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 1 | 19454 | 50 |
MACF1 |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.035e-02 | -3.21 | TMEM134 (transmembrane protein 134) | protein interactions | 80194 | 16 | 1 | 19454 | 50 |
ERBB4 |
4.035e-02 | -3.21 | NBL1 (NBL1, DAN family BMP antagonist) | protein interactions | 4681 | 16 | 1 | 19454 | 50 |
LRIG1 |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 50 |
MACF1 |
4.043e-02 | -3.21 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 50 |
SLC1A2 |
4.043e-02 | -3.21 | collateral sprouting | biological process | GO:0048668 | 15 | 1 | 18204 | 50 |
PRKG1 |
4.043e-02 | -3.21 | positive regulation of glycogen biosynthetic process | biological process | GO:0045725 | 15 | 1 | 18204 | 50 |
SORBS1 |
4.043e-02 | -3.21 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 50 |
NFIA |
4.043e-02 | -3.21 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 50 |
FGFR3 |
4.043e-02 | -3.21 | regulation of circadian sleep/wake cycle, sleep | biological process | GO:0045187 | 15 | 1 | 18204 | 50 |
PTGDS |
4.043e-02 | -3.21 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | regulation of inositol phosphate biosynthetic process | biological process | GO:0010919 | 15 | 1 | 18204 | 50 |
PRKG1 |
4.043e-02 | -3.21 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 50 |
RORA |
4.043e-02 | -3.21 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 50 |
MACF1 |
4.043e-02 | -3.21 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | negative regulation of amino acid transport | biological process | GO:0051956 | 15 | 1 | 18204 | 50 |
PRKG1 |
4.043e-02 | -3.21 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 50 |
SOX5 |
4.043e-02 | -3.21 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 50 |
NFIA |
4.079e-02 | -3.20 | SP7 (Sp7 transcription factor) | protein interactions | 121340 | 297 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
4.081e-02 | -3.20 | Circadian rythm related genes | WikiPathways | WP3594 | 207 | 3 | 5310 | 20 |
PTGDS,RORA,CST3 |
4.092e-02 | -3.20 | phosphorus metabolic process | biological process | GO:0006793 | 1707 | 9 | 18204 | 50 |
PRKG1,TNIK,ACSS1,BMPR1B,FGFR3,ERBB4,ATP1A2,PTPRZ1,RORA |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
LRIG1,LSAMP,FGFR3,NTM |
4.106e-02 | -3.19 | SOCS6 (suppressor of cytokine signaling 6) | protein interactions | 9306 | 125 | 2 | 19454 | 50 |
BMPR1B,ERBB4 |
4.117e-02 | -3.19 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC4A4 |
4.118e-02 | -3.19 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 10 | 16828 | 49 |
PARD3,ERBB4,FBXL7,ACSS1,PTPRZ1,ATP13A4,CDH20,RYR3,PREX2,PITPNC1 |
4.128e-02 | -3.19 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 22 | 18204 | 50 |
RORA,GPC5,GPM6A,GLIS3,SORBS1,ZBTB20,SLC1A2,RFX4,FGFR3,MACF1,NFIA,PTPRZ1,SLC1A3,CLU,MAML2,BMPR1B,ERBB4,SOX5,PARD3,SLC4A4,TNIK,NPAS3 |
4.134e-02 | -3.19 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 50 |
ATP1A2 |
4.134e-02 | -3.19 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 50 |
TNIK |
4.141e-02 | -3.18 | SHC1 events in ERBB4 signaling | REACTOME pathways | R-HSA-1250347 | 14 | 1 | 10285 | 31 |
ERBB4 |
4.141e-02 | -3.18 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 31 |
ABLIM1 |
4.148e-02 | -3.18 | bicellular tight junction | cellular component | GO:0005923 | 126 | 2 | 19108 | 49 |
PARD3,PARD3B |
4.155e-02 | -3.18 | CNMP_BINDING_2 | prosite domains | PS00889 | 12 | 1 | 12186 | 43 |
PRKG1 |
4.163e-02 | -3.18 | cGMP binding | molecular function | GO:0030553 | 16 | 1 | 18094 | 48 |
PRKG1 |
4.163e-02 | -3.18 | misfolded protein binding | molecular function | GO:0051787 | 16 | 1 | 18094 | 48 |
CLU |
4.163e-02 | -3.18 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 48 |
RORA |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
PITPNC1,GPM6A |
4.168e-02 | -3.18 | positive regulation of phosphorus metabolic process | biological process | GO:0010562 | 697 | 5 | 18204 | 50 |
ZBTB20,TNIK,SLC4A4,FGFR3,ERBB4 |
4.168e-02 | -3.18 | positive regulation of phosphate metabolic process | biological process | GO:0045937 | 697 | 5 | 18204 | 50 |
ZBTB20,ERBB4,FGFR3,SLC4A4,TNIK |
4.170e-02 | -3.18 | synapse assembly | biological process | GO:0007416 | 118 | 2 | 18204 | 50 |
GPM6A,ERBB4 |
4.193e-02 | -3.17 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 10 | 18204 | 50 |
SORBS1,ZNRF3,CTNND2,MAML2,NFIA,BMPR1B,FGFR3,ERBB4,MACF1,TNIK |
4.193e-02 | -3.17 | response to stimulus | biological process | GO:0050896 | 7803 | 28 | 18204 | 50 |
DTNA,SLC1A2,SORBS1,ZBTB20,PITPNC1,GPM6A,RYR3,CTNNA2,MACF1,MAML2,CLU,TNIK,BMPR1B,CTNND2,ZNRF3,ATP1A2,RORA,PTGDS,NFIA,SPARCL1,FGFR3,PREX2,SLC1A3,PRKG1,CST3,PARD3,ERBB4,SOX5 |
4.195e-02 | -3.17 | positive regulation of cellular metabolic process | biological process | GO:0031325 | 3164 | 14 | 18204 | 50 |
CLU,SORBS1,ZBTB20,RFX4,MAML2,RORA,GLIS3,NFIA,NPAS3,SLC4A4,BMPR1B,FGFR3,ERBB4,TNIK |
4.223e-02 | -3.16 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 3 | 16828 | 49 |
RYR3,CDH20,SOX5 |
4.226e-02 | -3.16 | PAX9 (paired box 9) | protein interactions | 5083 | 127 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.235e-02 | -3.16 | cNMP-bd_CS | interpro domains | IPR018488 | 16 | 1 | 18521 | 50 |
PRKG1 |
4.250e-02 | -3.16 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 8 | 16828 | 49 |
CTNND2,TRPM3,RYR3,ATP13A4,MACF1,ATP1A2,ERBB4,PARD3B |
4.273e-02 | -3.15 | apical dendrite | cellular component | GO:0097440 | 17 | 1 | 19108 | 49 |
CLU |
4.282e-02 | -3.15 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 49 |
FGFR3 |
4.282e-02 | -3.15 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 50 |
SOX5 |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.282e-02 | -3.15 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 50 |
ABLIM1 |
4.282e-02 | -3.15 | NOTCH4 (notch receptor 4) | protein interactions | 4855 | 17 | 1 | 19454 | 50 |
MAML2 |
4.282e-02 | -3.15 | SHD (Src homology 2 domain containing transforming protein D) | protein interactions | 56961 | 17 | 1 | 19454 | 50 |
ERBB4 |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.282e-02 | -3.15 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.286e-02 | -3.15 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 2 | 19454 | 50 |
SOX5,MACF1 |
4.286e-02 | -3.15 | TEAD2 (TEA domain transcription factor 2) | protein interactions | 8463 | 128 | 2 | 19454 | 50 |
TRPS1,ZBTB20 |
4.286e-02 | -3.15 | MYB (MYB proto-oncogene, transcription factor) | protein interactions | 4602 | 128 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.294e-02 | -3.15 | Helix-loop-helix DNA-binding domain | gene3d domains | 4.10.280.10 | 111 | 2 | 14470 | 43 |
NPAS3,HIF3A |
4.307e-02 | -3.14 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | short-chain fatty acid metabolic process | biological process | GO:0046459 | 16 | 1 | 18204 | 50 |
ACSS1 |
4.307e-02 | -3.14 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 50 |
SLC1A2 |
4.307e-02 | -3.14 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 50 |
SLC1A3 |
4.307e-02 | -3.14 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000095 | 16 | 1 | 18204 | 50 |
ZNRF3 |
4.311e-02 | -3.14 | human chr2q34 | chromosome location | human chr2q34 | 23 | 1 | 26134 | 50 |
ERBB4 |
4.333e-02 | -3.14 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 2 | 7161 | 21 |
SLC1A3,SLC1A2 |
4.333e-02 | -3.14 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 2 | 7161 | 21 |
SLC1A2,SLC1A3 |
4.333e-02 | -3.14 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 43 |
FGFR3,ERBB4 |
4.346e-02 | -3.14 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 2 | 19454 | 50 |
ZBTB20,ABLIM1 |
4.346e-02 | -3.14 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 50 |
SOX5,ZBTB20 |
4.352e-02 | -3.13 | skin-chest-malignant_melanoma | COSMIC cancer mutations | skin-chest-malignant_melanoma | 114 | 2 | 16828 | 49 |
ERBB4,PREX2 |
4.368e-02 | -3.13 | pleura-mesothelioma | COSMIC cancer mutations | pleura-mesothelioma | 4189 | 18 | 16828 | 49 |
PTPRZ1,HIF3A,BMPR1B,ERBB4,CLU,PITPNC1,MAML2,TNIK,MSI2,LRIG1,RORA,FBXL7,TRPS1,PRKG1,PREX2,CTNND2,SOX5,FGFR3 |
4.389e-02 | -3.13 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 4 | 19108 | 49 |
MACF1,ABLIM1,SORBS1,CTNNA2 |
4.400e-02 | -3.12 | basal part of cell | cellular component | GO:0045178 | 307 | 3 | 19108 | 49 |
SLC4A4,ERBB4,SLC1A3 |
4.407e-02 | -3.12 | DVL1 (dishevelled segment polarity protein 1) | protein interactions | 1855 | 130 | 2 | 19454 | 50 |
PARD3,ZNRF3 |
4.417e-02 | -3.12 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.417e-02 | -3.12 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.424e-02 | -3.12 | Ig-like_fold | interpro domains | IPR013783 | 721 | 5 | 18521 | 50 |
NTM,FGFR3,LRIG1,PTPRZ1,LSAMP |
4.430e-02 | -3.12 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | REACTOME pathways | R-HSA-2162123 | 15 | 1 | 10285 | 31 |
PTGDS |
4.430e-02 | -3.12 | ERBB2 Regulates Cell Motility | REACTOME pathways | R-HSA-6785631 | 15 | 1 | 10285 | 31 |
ERBB4 |
4.432e-02 | -3.12 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 20 |
RYR3 |
4.432e-02 | -3.12 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 20 |
BMPR1B |
4.449e-02 | -3.11 | tight junction | cellular component | GO:0070160 | 131 | 2 | 19108 | 49 |
PARD3B,PARD3 |
4.468e-02 | -3.11 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 50 |
RORA,NFIA |
4.468e-02 | -3.11 | TRPS1 (transcriptional repressor GATA binding 1) | protein interactions | 7227 | 131 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.468e-02 | -3.11 | ZNF609 (zinc finger protein 609) | protein interactions | 23060 | 131 | 2 | 19454 | 50 |
SOX5,NFIA |
4.477e-02 | -3.11 | ZnF_GATA | smart domains | SM00401 | 12 | 1 | 9717 | 37 |
TRPS1 |
4.477e-02 | -3.11 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 37 |
NFIA |
4.493e-02 | -3.10 | AMP-bd_C | interpro domains | IPR025110 | 17 | 1 | 18521 | 50 |
ACSS1 |
4.493e-02 | -3.10 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 50 |
CST3 |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | PAC | interpro domains | IPR001610 | 17 | 1 | 18521 | 50 |
HIF3A |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.499e-02 | -3.10 | ITCH (itchy E3 ubiquitin protein ligase) | protein interactions | 83737 | 309 | 3 | 19454 | 50 |
ERBB4,RORA,GLIS3 |
4.507e-02 | -3.10 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 49 | 16828 | 49 |
ACSS1,ATP1A2,GPM6A,SPARCL1,PARD3B,NFIA,MACF1,CDH20,RYR3,MSI2,FBXL7,TRPM3,SLC4A4,SORBS1,ZNRF3,BMPR1B,CLU,SLC1A2,TRPS1,PREX2,DTNA,HIF3A,NTM,ABLIM1,NPAS3,PARD3,ZBTB20,PTGDS,PITPNC1,SFXN5,MAML2,LSAMP,NHSL1,SLC1A3,PRKG1,RFX4,CTNND2,SOX5,FGFR3,NKAIN3,ATP13A4,PTPRZ1,CST3,ERBB4,GPC5,GLIS3,TNIK,RORA,LRIG1 |
4.525e-02 | -3.10 | kinase activity | molecular function | GO:0016301 | 739 | 5 | 18094 | 48 |
ERBB4,BMPR1B,FGFR3,TNIK,PRKG1 |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.529e-02 | -3.09 | PTGFR (prostaglandin F receptor) | protein interactions | 5737 | 18 | 1 | 19454 | 50 |
PTGDS |
4.529e-02 | -3.09 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | CYP2E1 (cytochrome P450 family 2 subfamily E member 1) | protein interactions | 1571 | 18 | 1 | 19454 | 50 |
CLU |
4.529e-02 | -3.09 | SELL (selectin L) | protein interactions | 6402 | 18 | 1 | 19454 | 50 |
PRKG1 |
4.529e-02 | -3.09 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.558e-02 | -3.09 | cellular process | biological process | GO:0009987 | 14996 | 46 | 18204 | 50 |
CTNND2,ABLIM1,ZNRF3,GLIS3,LSAMP,RORA,GPC5,ATP13A4,PTGDS,MSI2,SLC1A3,PREX2,NTM,PARD3,SLC4A4,NHSL1,DTNA,PITPNC1,GPM6A,RYR3,FBXL7,CTNNA2,SFXN5,MAML2,PTPRZ1,TRPM3,BMPR1B,RFX4,ATP1A2,NFIA,SPARCL1,FGFR3,PARD3B,CDH20,CST3,PRKG1,SOX5,ERBB4,ACSS1,ZBTB20,SORBS1,SLC1A2,MACF1,CLU,HIF3A,TNIK |
4.560e-02 | -3.09 | positive regulation of lipid metabolic process | biological process | GO:0045834 | 124 | 2 | 18204 | 50 |
SORBS1,ZBTB20 |
4.561e-02 | -3.09 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 49 |
FGFR3 |
4.570e-02 | -3.09 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 50 |
SLC1A2 |
4.570e-02 | -3.09 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 50 |
NFIA |
4.570e-02 | -3.09 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 1 | 18204 | 50 |
CLU |
4.570e-02 | -3.09 | mammary gland epithelial cell differentiation | biological process | GO:0060644 | 17 | 1 | 18204 | 50 |
ERBB4 |
4.570e-02 | -3.09 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 50 |
RYR3 |
4.570e-02 | -3.09 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 50 |
CTNNA2 |
4.570e-02 | -3.09 | positive regulation of glycogen metabolic process | biological process | GO:0070875 | 17 | 1 | 18204 | 50 |
SORBS1 |
4.570e-02 | -3.09 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 50 |
NFIA |
4.570e-02 | -3.09 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 50 |
RORA |
4.570e-02 | -3.09 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 50 |
TNIK |
4.570e-02 | -3.09 | regulation of inclusion body assembly | biological process | GO:0090083 | 17 | 1 | 18204 | 50 |
CLU |
4.570e-02 | -3.09 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 50 |
RORA |
4.570e-02 | -3.09 | regulation of amyloid fibril formation | biological process | GO:1905906 | 17 | 1 | 18204 | 50 |
CLU |
4.579e-02 | -3.08 | endoplasmic reticulum lumen | cellular component | GO:0005788 | 312 | 3 | 19108 | 49 |
CST3,SPARCL1,CLU |
4.621e-02 | -3.07 | adenyl ribonucleotide binding | molecular function | GO:0032559 | 1528 | 8 | 18094 | 48 |
ERBB4,BMPR1B,TNIK,PRKG1,ACSS1,FGFR3,ATP13A4,ATP1A2 |
4.653e-02 | -3.07 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 2 | 19454 | 50 |
GPM6A,NTM |
4.671e-02 | -3.06 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 1 | 18094 | 48 |
RYR3 |
4.671e-02 | -3.06 | GABA receptor binding | molecular function | GO:0050811 | 18 | 1 | 18094 | 48 |
ERBB4 |
4.671e-02 | -3.06 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 48 |
PITPNC1 |
4.673e-02 | -3.06 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 50 |
PTPRZ1 |
4.673e-02 | -3.06 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 50 |
DTNA |
4.673e-02 | -3.06 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 50 |
CST3 |
4.673e-02 | -3.06 | AMP-binding_C | pfam domains | PF13193 | 17 | 1 | 17795 | 50 |
ACSS1 |
4.674e-02 | -3.06 | GRB2 (growth factor receptor bound protein 2) | protein interactions | 2885 | 769 | 5 | 19454 | 50 |
ERBB4,FGFR3,MSI2,SLC1A2,CLU |
4.716e-02 | -3.05 | FOXP1 (forkhead box P1) | protein interactions | 27086 | 135 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.716e-02 | -3.05 | BMP4 (bone morphogenetic protein 4) | protein interactions | 652 | 135 | 2 | 19454 | 50 |
BMPR1B,CLU |
4.716e-02 | -3.05 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 2 | 19454 | 50 |
TRPS1,ABLIM1 |
4.716e-02 | -3.05 | SOX15 (SRY-box transcription factor 15) | protein interactions | 6665 | 135 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.718e-02 | -3.05 | GRB2 events in ERBB2 signaling | REACTOME pathways | R-HSA-1963640 | 16 | 1 | 10285 | 31 |
ERBB4 |
4.718e-02 | -3.05 | PI3K events in ERBB2 signaling | REACTOME pathways | R-HSA-1963642 | 16 | 1 | 10285 | 31 |
ERBB4 |
4.718e-02 | -3.05 | Rap1 signalling | REACTOME pathways | R-HSA-392517 | 16 | 1 | 10285 | 31 |
PRKG1 |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
SORBS1,BMPR1B,ZNRF3,CLU,SLC1A2,FBXL7,TRPM3,SLC4A4,MSI2,RYR3,GPM6A,ATP1A2,ACSS1,PARD3B,SPARCL1,NFIA,CDH20,MACF1,CST3,PTPRZ1,ERBB4,GPC5,RORA,LRIG1,TNIK,GLIS3,NHSL1,SLC1A3,SOX5,CTNND2,RFX4,PRKG1,ATP13A4,NKAIN3,FGFR3,NTM,ABLIM1,HIF3A,DTNA,ZBTB20,PARD3,NPAS3,SFXN5,MAML2,PTGDS,PITPNC1,LSAMP,TRPS1,PREX2 |
4.752e-02 | -3.05 | Leu-rich_rpt_4 | interpro domains | IPR025875 | 18 | 1 | 18521 | 50 |
LRIG1 |
4.752e-02 | -3.05 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 50 |
FBXL7 |
4.752e-02 | -3.05 | Furin_repeat | interpro domains | IPR006212 | 18 | 1 | 18521 | 50 |
ERBB4 |
4.754e-02 | -3.05 | ZYX (zyxin) | protein interactions | 7791 | 316 | 3 | 19454 | 50 |
MACF1,ABLIM1,SORBS1 |
4.760e-02 | -3.05 | cell-cell junction assembly | biological process | GO:0007043 | 127 | 2 | 18204 | 50 |
PARD3,CDH20 |
4.761e-02 | -3.04 | postsynaptic density | cellular component | GO:0014069 | 317 | 3 | 19108 | 49 |
ERBB4,CTNND2,TNIK |
4.764e-02 | -3.04 | astrocyte projection | cellular component | GO:0097449 | 19 | 1 | 19108 | 49 |
SLC1A2 |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.764e-02 | -3.04 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 49 |
TNIK |
4.774e-02 | -3.04 | OSM (oncostatin M) | protein interactions | 5008 | 19 | 1 | 19454 | 50 |
TRPM3 |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
PTPRZ1 |
4.774e-02 | -3.04 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 50 |
ZBTB20 |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | FBXO27 (F-box protein 27) | protein interactions | 126433 | 19 | 1 | 19454 | 50 |
CLU |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.774e-02 | -3.04 | ZNF532 (zinc finger protein 532) | protein interactions | 55205 | 19 | 1 | 19454 | 50 |
ERBB4 |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.774e-02 | -3.04 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 50 |
MACF1 |
4.774e-02 | -3.04 | HBEGF (heparin binding EGF like growth factor) | protein interactions | 1839 | 19 | 1 | 19454 | 50 |
ERBB4 |
4.793e-02 | -3.04 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 1 | 5310 | 20 |
RYR3 |
4.804e-02 | -3.04 | carboxylic acid transport | biological process | GO:0046942 | 297 | 3 | 18204 | 50 |
SLC1A3,SFXN5,SLC1A2 |
4.827e-02 | -3.03 | myelination | biological process | GO:0042552 | 128 | 2 | 18204 | 50 |
CLU,PARD3 |
4.827e-02 | -3.03 | glial cell development | biological process | GO:0021782 | 128 | 2 | 18204 | 50 |
PARD3,CLU |
4.832e-02 | -3.03 | response to misfolded protein | biological process | GO:0051788 | 18 | 1 | 18204 | 50 |
CLU |
4.832e-02 | -3.03 | receptor catabolic process | biological process | GO:0032801 | 18 | 1 | 18204 | 50 |
ZNRF3 |
4.832e-02 | -3.03 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 50 |
CST3 |
4.832e-02 | -3.03 | myelin maintenance | biological process | GO:0043217 | 18 | 1 | 18204 | 50 |
CLU |
4.832e-02 | -3.03 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 1 | 18204 | 50 |
PRKG1 |
4.832e-02 | -3.03 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 50 |
ATP1A2 |
4.832e-02 | -3.03 | positive regulation of myelination | biological process | GO:0031643 | 18 | 1 | 18204 | 50 |
PARD3 |
4.832e-02 | -3.03 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 50 |
CTNND2 |
4.838e-02 | -3.03 | TYRKINASE | prints domains | PR00109 | 98 | 2 | 5227 | 19 |
ERBB4,FGFR3 |
4.839e-02 | -3.03 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 49 |
FGFR3 |
4.842e-02 | -3.03 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.843e-02 | -3.03 | organic acid transport | biological process | GO:0015849 | 298 | 3 | 18204 | 50 |
SLC1A2,SFXN5,SLC1A3 |
4.856e-02 | -3.02 | protein-folding chaperone binding | molecular function | GO:0051087 | 133 | 2 | 18094 | 48 |
CLU,ATP1A2 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.892e-02 | -3.02 | protein phosphorylation | biological process | GO:0006468 | 503 | 4 | 18204 | 50 |
BMPR1B,ERBB4,TNIK,PRKG1 |
4.893e-02 | -3.02 | phosphorylation | biological process | GO:0016310 | 729 | 5 | 18204 | 50 |
BMPR1B,FGFR3,ERBB4,TNIK,PRKG1 |
4.893e-02 | -3.02 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 37 | 16828 | 49 |
ZBTB20,PARD3,NPAS3,ABLIM1,DTNA,RYR3,LSAMP,SFXN5,MAML2,TRPS1,SPARCL1,ATP1A2,GPM6A,ACSS1,CDH20,MACF1,PREX2,ERBB4,SORBS1,PTPRZ1,RORA,SLC1A2,LRIG1,TNIK,GPC5,CLU,SLC1A3,FBXL7,NHSL1,ATP13A4,FGFR3,NKAIN3,TRPM3,CTNND2,SOX5,PRKG1,RFX4 |
4.924e-02 | -3.01 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 48 |
ATP1A2 |
4.924e-02 | -3.01 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 48 |
BMPR1B |
4.936e-02 | -3.01 | Alpha carbonic anhydrase | gene3d domains | 3.10.200.10 | 17 | 1 | 14470 | 43 |
PTPRZ1 |
4.940e-02 | -3.01 | ACTA1 (actin alpha 1, skeletal muscle) | protein interactions | 58 | 321 | 3 | 19454 | 50 |
MACF1,DTNA,SORBS1 |
4.941e-02 | -3.01 | LRR_4 | pfam domains | PF12799 | 18 | 1 | 17795 | 50 |
LRIG1 |
4.951e-02 | -3.01 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 50 |
SLC1A2,SORBS1,RYR3,SLC1A3 |
4.962e-02 | -3.00 | ensheathment of neurons | biological process | GO:0007272 | 130 | 2 | 18204 | 50 |
CLU,PARD3 |
4.962e-02 | -3.00 | axon ensheathment | biological process | GO:0008366 | 130 | 2 | 18204 | 50 |
PARD3,CLU |